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This thesis explores three broad areas of interest in the pathophysiology of type 2 diabetes 
(T2D). The first part of the thesis examines the relative contributions of body fat 
measurements on T2D and related morbidities in a large cohort of twins. A proxy measure of 
visceral fat was constructed from anthropometric and dual-energy X-ray absorptiometry, its 
heritability was estimated at 58% using the classical twin model and its influence on 
morbidity was compared to total abdominal fat and the body mass index. The findings from 
this work show that intra-abdominal adiposity confers the greatest independent risk on 
morbidity and appears to almost entirely mediate the observed association between morbidity 
and all the other measures of adiposity investigated. 
 
The second part of this thesis is a candidate gene study of the PARL/ABCC5 gene region 
motivated by prior evidence suggesting a role for PARL in T2D susceptibility. Using a single 
marker test of association, SNPs in and around the PARL gene showed no evidence of 
association with T2D. However, analysis based upon SNPs in the entire gene region 
(184,743-185,548Kb, build 36) using a multi-marker test of association, provided strong 
evidence that the neighbouring gene (ABCC5) is associated with T2D in both European and 
African American samples. In addition, ABCC5 expression in subcutaneous adipose tissue 
was strongly associated with fasting insulin and glucose serum levels, visceral fat 
accumulation, and T2D with evidence that the disease susceptibility variant(s) is a regulatory 
element (an expression quantitative trait locus) located at intron 26 in ABCC5. 
 
The third component of this thesis is a comprehensive investigation into the potential role of 
nuclear-encoded mitochondrial (NEM) genes in the aetiology of T2D. A pathway analysis 
approach is used to test for enrichment of T2D association signals across the genome in 
defined NEM gene sets. From this analysis, the biological pathways of glycolysis, the 
tricarboxylic acid cycle, and mitochondrial translation all show evidence of pathway 
enrichment. These findings demonstrate for the first time, potential associations between 
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This chapter provides the necessary background information to the research topics discussed 
in this thesis. I begin by defining type 2 diabetes (T2D) and describing how this disease is 
diagnosed and its prevalence both worldwide and in the United Kingdom. In the second half 
of the introduction, I review the supporting evidence for a mitochondrial contribution to T2D 
susceptibility and end with an outline of the research aims of this thesis. 
 
Type 2 Diabetes 
It is a condition of chronic hyperglycaemia as a result of insulin resistance and pancreatic 
beta cell dysfunction - insulin resistance describes the biological lack of sensitivity to the 
peptide hormone insulin secreted by the pancreatic beta cells. When beta cells are not able to 
secrete sufficient quantities of insulin in order to reduce glucose level, this is termed beta cell 
dysfunction. Either extreme insulin resistance or beta cell dysfunction is sufficient to cause 
diabetes – the depletion of pancreatic beta cells in type 1 diabetes (T1D) can be considered an 
extreme from of pancreatic beta cell dysfunction. Moreover, rare and severe forms of insulin 
resistance are known (Mantzoros et al., 1998, Semple et al., 2011). With the development of 
T2D, the increasing lack of tissue sensitivity to insulin and compensatory increase in insulin 
secretion is not adequate to decrease the blood glucose levels, which if left unchecked, is 
toxic and ultimately results in irreversible nerve damage and organ failure. 
 
Himsworth (1936) first recognised diabetic individuals could be classified into insulin 
sensitive and resistant phenotypes. The first report by the World Health Organisation (WHO) 
on diabetes in 1964 initially classified diabetes by age of onset; this was later changed in their 
1980 report by distinguishing the two major types of diabetes by insulin sensitivity. As more 
was learnt about diabetes, new diagnostic methods were introduced along with re-evaluation 
of the diagnostic criteria, the latter being reclassified on many occasions, which has an impact 
on historical epidemiological comparisons of prevalence and incidence. It was thought that 
insulin resistance was the primary pathogenic trigger in T2D, requiring tissues to demand 
ever-increasing amounts of insulin. It is now recognised that predisposition to beta cell 
dysfunction is likely to be a pre-existing condition within individuals that go on to develop 
T2D - insulin secretion is ostensibly adequate in the context of high insulin sensitivity and the 
inability for compensatory insulin secretion is hidden at this stage. Only as peripheral 




This current view has been is supported by a recent study from Tabak et al. (2009), in which 
they investigated the relationship between insulin resistance and pancreatic beta cell function 
prior to T2D onset using longitudinal data collected for approximately a decade on more than 
6,500 British civil servants. The study confirmed the known inverse relationship between age 
and insulin sensitivity – as age increases, insulin sensitivity decreases in both non-diabetics 
and those who developed diabetes during the course of the study (incident diabetes). In the 
non-diabetics, beta cell function remained essentially constant with increasing age. However, 
as shown in Figure 1.1, those individuals that go on to develop T2D have higher beta cell 
function than the non-diabetic group for almost the entire length of the study. This is 
combined with poorer insulin sensitivity for the same period and a brief compensatory 
increase followed by an abrupt decline in beta cell function shortly (~3 years) prior to T2D 
diagnosis. This study supports the concept of a primary pancreatic beta cell defect, which 
when confronted with decreasing insulin sensitivity, temporarily increases insulin output 







Figure 1.1. Insulin sensitivity (A) and beta cell function (B) time course to T2D 
diagnosis or end of follow up for non-diabetics (Tabak et al., 2009). 
Graphs A and B show a 13-year prospective time course comparison of beta cell function and 
insulin sensitivity in those that become diabetic (blue line) and those that do not (green line). 






Insulin and Glucose Action 
In normal physiology, increased blood glucose causes an array of metabolic responses, one of 
which is an increase in the rate of insulin secretion from pancreatic beta cells. Notable targets 
of insulin action include the liver, muscle, and adipose tissue, where insulin stimulates 
glucose uptake (Leney and Tavare, 2009), while suppressing endogenous glucose production 
in the hepatocytes (Postic et al., 2004). The cumulative effect of insulin in the presence of 
hyperglycaemia therefore acts to lower the concentration of circulating glucose, returning to a 
state of normoglycaemia. Whilst beta cells are able to increase insulin secretion in response 
to glucose, they eventually reach a plateau in which insulin output is not able to restore 
normoglycaemia.  
 
Insulin secretion by the pancreatic beta cell is largely driven by the ATP to ADP ratio within 
the cell. Known as the triggering pathway – an increase in the ATP:ADP ratio causes ATP-
sensitive potassium channels to close, depolarising the cell membrane, which opens the 
calcium channels and the influx of calcium into the cell triggers the exocytosis of insulin-
containing vesicles. An additional, potassium-channel-independent amplifying pathway has 
been described (Henquin, 2011), in which glucose-mediated insulin secretion occurs when 
ATP-sensitive potassium channels are prevented from either opening or closing, through the 
use of diazoxide and sulfonylurea. Other studies (Nenquin et al., 2004, Ravier et al., 2009) 
have also shown insulin secretion occurs in beta cells lacking components of the ATP-
sensitive potassium channel. 
 
As the major producer of ATP, mitochondria can be considered central to the triggering 
pathway of insulin secretion. Anaplerotic products from mitochondrial metabolic activities, 
such as glutamate and malonyl-CoA are also implicated in the amplifying pathway (Maechler 
et al., 2006). Defects in mitochondrial processes that are involved in ATP production leading 
to failure to attain a sufficient ATP:ADP ratio have the potential to contribute to beta cell 
dysfunction in T2D. One of the most effective oral agents for T2D (Halimi, 2006) is 
metformin, (1,1-dimethylbiguanide). Pertinently, its primary mechanism of action is 
inhibition of the mitochondrial protein complex 1 (Owen et al., 2000), which as a result, 







Figure 1.2. Molecular pathways controlling glucose-stimulated insulin secretion in 
pancreatic beta cells (Muoio and Newgard, 2008). 
Products of glucose metabolism, in addition to the adenosine triphosphate (ATP) to 
adenosine biphosphate (ADP) ratio, trigger mitochondrially-derived signals and promote the 





Measures of Insulin Resistance and Beta Cell Function 
An important measure in describing insulin sensitivity is the ability to model the 
physiological relationship between glucose and insulin, assessing the combined contributions 
of both beta cell function and insulin resistance. For this purpose, the homeostasis model 
assessment (HOMA) was described by Matthews et al. (1985), the model uses fasting plasma 
insulin and glucose concentrations to estimate the degree of beta cell function and insulin 
resistance as shown by two formulae: 
 
HOMA1-%B = (20 x fasting plasma insulin) / (fasting plasma glucose - 3.5) 
HOMA1-IR = (fasting plasma insulin x fasting plasma glucose) / 22.5 
 
Where, HOMA1-%B and HOMA1-IR refer to beta cell function and insulin resistance 
respectively; a third measure, HOMA1-%S is an estimate of insulin sensitivity and equal to 
100 / HOMA1-IR. The units of measure used for this model are milliunits per litre (mU/l) for 
fasting plasma insulin and millimoles per litre (mmol/l) for glucose concentration. For 
insulin, 1 mU/l is equal to 6.945 pmol/l. 
 
The original HOMA was later updated by Levy et al. (1998) to incorporate a more accurate 
representation of the relationship over a range of insulin and glucose values. The updated 
version (HOMA2) differs from the original HOMA in two key areas; the first accounts for 
hyperglycaemic suppression of hepatic glucose production, and the second allows a variable 
insulin secretion response to glucose concentrations (Wallace et al., 2004). Thus, HOMA2 is 
the recommended model for use (Levy et al., 1998). For both HOMA versions, beta cell 
function and insulin resistance cannot be reported in isolation as it may lead to erroneous 







Figure 1. 3. Original (A; HOMA) and the updated (B; HOMA2) versions of the 
homeostasis model assessment (Wallace et al., 2004). 
Graphs illustrate the relationship between beta cell function (%B) and insulin sensitivity (%S) 
plotted over a range of fasting plasma glucose (x axis) and insulin (y axis) values. The 
original model (A) is linear, whilst the updated model (B) is curvilinear representing the 





Both HOMA1 and HOMA2 estimates for beta cell function and insulin resistance have 
shown to be correlated with the same measures obtained through the euglycaemic and 
hyperglycaemic clamp tests. This is noteworthy because the HOMA estimates beta cell 
function and insulin resistance under normal physiological conditions for insulin and glucose, 
whereas, the euglycaemic and hyperglycaemic clamp tests specifically alter these parameters 
way and measure the response. To appreciate the difference, it is important to briefly outline 
the principles behind the clamp-based methods.  
 
The insulin and glucose clamp techniques was first described over 30 years ago by DeFronzo 
et al. (1979), the hyperglycaemic clamp involves raising the plasma glucose concentration 
intravenously to reach a hyperglycaemic equilibrium of 125 mg/dl (6.9 mmol/l) above basal 
glucose level, once equilibrium is obtained, it maintained for 2 hours through infusion of 
glucose "maintenance doses". Under such conditions, glucose infusion is a measure of insulin 
secretion. In the euglycaemic clamp, the plasma insulin concentration is raised to 100 μU/ml 
(694.5 pmol/l) above basal insulin level and maintained at this level by the infusion of a fixed 
dose of insulin. Shortly after, the plasma glucose concentration is held at a basal level by 
variable glucose infusion. In this state, the rate of glucose infusion is an indicator of insulin 
clearance, thus sensitivity.  
 
Wallace et al. (2004) have argued that HOMA should be used where possible instead of other 
indices such as the fasting insulin to glucose ratio (IGR) or the quantitative insulin sensitivity 
check index (QUICKI; 1/[log (fasting plasma insulin x fasting plasma glucose)]). QUICKI is 
effectively the log of HOMA1-IR. Discriminatory power of these indices to identify insulin 
resistance is usually determined from receiver operator curve (ROC) analysis; individuals 
that are truly insulin resistant are classified by direct tests such as the hyperinsulinemic-
euglycaemic clamp. For a thorough review of current methods to assess insulin resistance and 
their indices please see Muniyappa et al. (2008). 
 
In the “Uses Abuses of HOMA Modeling” paper, Wallace et al. (2004) note an important 
caveat about how estimates from HOMA should be interpreted in relation to the clamp-based 
methods, in that the two techniques “give information about different aspects of beta cell 
function or insulin resistance”. For epidemiological purposes, this point is pertinent as 
invasive clamp methods are unfeasible for large studies and so insulin-glucose indices are 




physiological range of insulin and glucose. In fact, studies incorporating these clamp-based 
methods cannot be compared if infusion rates differ (Natali et al., 2000). Moreover, no one 
metric combining insulin and glucose that outperforms another in terms of correlation with 
euglycaemic clamp-measured insulin resistance (Ruige et al., 2006, Lorenzo et al., 2010). 
These results suggest that surrogate measures of insulin resistance provide the same or very 
similar information on insulin resistance; therefore, with careful interpretation, the choice 
between them might not be too important for research purposes. 
 
In addition, Samaras et al. (2006) have rightly pointed out that attention should instead be 
focused on how diabetes risk factors influence insulin resistance (McLaughlin et al., 2007). 
Cut-off values to identify insulin resistance, where they exist, are arbitrary, population and 
assay specific; furthermore, insulin resistance is a continuous scale – every individual has 
some level of insulin resistance. It is unnecessary to dichotomise a measure of insulin 
resistance where there is no evidence to suggest that individuals that sit immediately adjacent 
to the cut-off point differ substantially in future risk of morbidity. However, if the entire 
distribution of insulin resistance is considered, meaningful comparisons can be made between 
the tails of the distribution in the context of risk factors. 
 
An exception to this argument is made for disease diagnosis based on a quantitative trait such 
as glucose concentration for T2D, body mass index (BMI) for obesity, or blood pressure for 
hypertension. Cut-off values for these disorders are somewhat misleading in that they should 
identify individuals with a substantially increased risk of future mortality and complications, 
one such example is the steep increase in retinopathy prevalence for individuals above the 
diagnostic criteria for T2D (Figure 1.4). There is no dispute that individuals with extremely 
high values will experience poor future health, but for those individuals that flank the 
threshold, the difference in future morbidity is less clear, reflecting the attempt of 
extrapolating a single continuous measure to future organ or system-level dysfunction. 
Diagnosis for T2D differs from that of obesity and hypertension because the measurement, 
i.e. glucose level, is of that of the perpetrator; a high glucose concentration has a direct 





Diagnostic Test Criteria for T2D 
Many people with T2D are often unaware due to its asymptomatic nature in the early phase 
of the disorder; symptoms such as thirst, frequent urination, and weight loss can go 
unnoticed. Diagnosis of T2D is based on a variety of tests that measure glucose 
concentration. I will briefly outline the most common measures and comment on their 
qualities, as these measures are available for some of our study sample. 
 
One method to identify hyperglycaemic individuals is to measure the amount of glucose in 
blood plasma after eight or more hours of fasting. This was the most popular method of 
diagnosing T2D due to its simplicity and low cost relative to other methods. The fasting 
plasma glucose (FPG) test measures the product of two opposing actions – endogenous 
glucose production, which replenishes glucose level during a period of fasting, and the 
response by insulin to lower elevations in glucose level. Despite its popularity, the FPG test 
suffers from major limitations: the individual must fast for the preceding eight hours before 
the test, two tests are required to confirm a positive diagnosis, and FPG is influenced by 
many behavioural and biological factors resulting in within- and -between day variability. 
Lastly, it has been noted (Schrot et al., 2007) that glucose measurement in blood plasma is 
usually higher than the same measure in whole blood. 
 
Another method to measure blood glucose level is by glycosylated haemoglobin (HbA1c). 
The current guidelines on HbA1c as a diagnostic test are presented in the 2011 WHO 
diabetes report (http://www.who.int/diabetes/publications/report-hba1c_2011.pdf). The report 
made the recommendation that a HbA1c level greater than 6.5% (47.5 mmol/mol) can be 
used to diagnose T2D and that values less than this do not exclude diabetes diagnosis from 
glucose tests. HbA1c is the preferred method of T2D diagnosis as it captures the average 
plasma glucose over the preceding 3 months, does not require the individual to be in the 
fasting state and has less day-to-day variability than FPG. The HbA1c and FPG diagnostic 
criteria for T2D are comparable for prevalence of microvascular complication, such as 





Measure Diagnostic criteria 
Glycosylated haemoglobin (HbA1c) >6.5% 
Fasting plasma glucose (FPG) >7.0 mmol/l 
2-h plasma glucose >11.1 mmol/l 
Random plasma glucose >11.1 mmol/l 
 
Table 1.1. The American Diabetes Association diagnostic criteria for T2D (American 
Diabetes, 2011)  
This table lists four diagnostic criteria for T2D; repeated tests that exceed any of these criteria 
confirm T2D diagnosis. Fasting plasma glucose is measured after the individual has fasted for 
at least eight hours; the non-fasted alternative measures random plasma glucose and has the 







Figure 1.4. Prevalence of moderate non-proliferative retinopathy (NPDR) by vigintiles 
of fasting plasma glucose (FPG), 2-hour plasma glucose (2-h PG), and glycosylated 
haemoglobin (HbA1c). 
The prevalence of NPDR increases rapidly above glycaemic diagnostic thresholds (indicated 
by the vertical hashed line) for T2D. Adapted from the WHO Use of Glycated Haemoglobin 





Prevalence and Incidence 
The prevalence of T2D is estimated by the diagnostic measure of glycaemia used for 
diagnosis. Diagnostic criteria (Table 1.1) have fluctuated throughout history reflecting 




It is estimated that 336 million people are affected by T2D (Ashcroft and Rorsman, 2012, 
Danaei et al., 2011), the most common form of diabetes, accounting for 90-95% of all cases. 
Other types of diabetes included T1D, which is predominantly caused by immune-mediated 
destruction of beta cells, and gestational diabetes, which occurs during pregnancy. 
 
England 
Diabetes statistics in England and Wales is publically available by The National Diabetes 
Audit (NDA) and Diabetes UK for the National Health Service (NHS). Table 1.2. shows 
year-on-year increases in the prevalence of diabetes in England from 2004 to 2011. The most 
recent report by the NDA is the 2010-2011 report, which for England, combined diabetes 
patient data from 152 Primary Care Trusts (2.15 million individuals of an estimated 2.46 
million diagnosed with diabetes). The NDA report from the previous year (2009-2010) 
provided a gender and ethnicity breakdown of T2D prevalence; diagnosis of T2D in males 
was higher than females (4.35% vs. 3.41%) and individuals that describe themselves as white 
made up 77.7% of the 1.9 million T2D cases in this report. The most recent report (2013) by 
Diabetes UK (http://www.diabetes.org.uk) estimates the number of individuals diagnosed 
with T2D at 2.56 million and a diabetes prevalence of 5.5% in England, and if the ratio of 
T2D to T1D is 1:10 as stated in the report; the 2011 prevalence of T2D in England estimated 















2004 - 1.48 2.95 (2.66) Diabetes UK 2004 
2005 - 2.10 3.50 (3.15) Diabetes UK 2005 
2006 - 2.20 3.73 (3.35) QOF/Diabetes UK 
2007-2008 1.41 2.09 3.91 (3.52) 
Extrapolated from NDA  
2008-2009 
2008-2009 1.70 2.20 4.13 (3.65) NDA 2008-2009 
2009-2010 1.9 2.34 4.35 (3.87) NDA 2009-2010 
2010-2011 2.15 2.46 4.57 (4.07) NDA 2010-2011 
 
Table 1.2. Diabetes prevalence in England between 2004-2011. 
Summary statistics from the National Diabetes Audit for adults. Total diagnosed from 
Quality and Outcomes Framework (QOF; http://www.qof.ic.nhs.uk). Where there is 
discrepancy between QOF/Diabetes UK and the National Diabetes Audit (NDA), NDA 
values are presented as these are better documented. Note that pre-2007, prevalence estimates 






Mitochondrial Function and T2D 
In order to investigate mitochondrial function in relation to insulin resistance and T2D, it is 
important to look at the appropriate tissue, i.e. tissues that are major sites of insulin-
stimulated glucose production, uptake, and/or disposal. The major tissues in this category are 
the pancreas, the liver, skeletal muscle, and adipose tissue. Dysfunctional mitochondria or 
low mitochondrial content in the cells of these tissues may have a direct consequences on 
insulin secretion or glucose management that depend on mitochondrial processes. I will 
outline evidence for and against this hypothesis in the following sections. 
 
Adipocytes are the main storage site for free fatty acids (FFA) in the human body. 
Subcutaneous adipose tissue is responsible for much of the FFA in circulation (Karpe et al., 
2011) while visceral adipose tissue seems to be the prominent source of hepatic FFA delivery 
(Nielsen et al., 2004). Any comparisons in mitochondrial content between subcutaneous and 
visceral adipose tissues or subcutaneous/visceral adipose tissue between normoglycaemic and 
T2D individuals, is complicated by the fact that adipose tissue contains adipocytes of 
different sizes and thus a given tissue mass may contain an unequal number of adipocytes.  
 
In rats, it is known that accumulation of visceral adiposity follows stages of hypertrophy, an 
increase in adipose cell count, and reduction in cell size (Strissel et al., 2007, Leney and 
Tavare, 2009). There is little reason why this time course should not also be true for humans, 
but without estimates of the proportions of adipocyte size, it is difficult to reach consensus 
over mitochondrial content and activity between studies. 
 
Laye et al. (2009) tracked changes in mitochondrial content in visceral adipose tissue from 
normoglycaemic to T2D showing mitochondrial content decreases in obese T2D rats 
compared to non-obese normoglycaemic rats. This finding is consistent with earlier work 
(Choo et al., 2006), which showed in both T2D (leptin receptor deficient, db/db) and obesity 
(leptin deficient, ob/ob) mouse models have fewer and smaller mitochondria in adipocytes 
than their heterozygous or wild-type counterparts. 
 
Increased circulating FFA have been shown to increase the mitochondrial content of muscle 
cells along with the rate of fatty acid oxidation and development of insulin resistance 




response by mitochondria to oxidise fatty acids, which is known to impair insulin signalling 
transduction pathways (Dresner et al., 1999, Virkamaki et al., 2001, Yu et al., 2002). 
However, this does not contradict the observations that oxidative phosphorylation activity in 
muscle cells from T2D individuals is reduced compared to controls (Phielix et al., 2008), 
mitochondria are smaller in muscles obtained from T2D individuals (Kelley et al., 2002), and 
insulin resistance correlates with mitochondrial content within muscle fibres (Chomentowski 





Genetics of T2D 
Genetic Architecture of Common Disease 
T2D has a multifactorial aetiology; both genetic and environmental factors contribute to the 
trait. A critical factor in unravelling the genetic component and successfully identifying 
susceptibility variants is the mode of inheritance or the genetic architecture of the trait; that is 
the number of gene loci involved, their allele frequency and penetrance. The hope for gene 
mapping studies of complex traits is that the mode of inheritance includes at least some 
genetic loci (oligogenic) of moderate effect which are detectable, in addition to the many loci 
(polygenic) with small effect. 
 
Genome-Wide Association Studies 
The common disease common variant (CDCV) hypothesis posits that disease-predisposing 
alleles with relatively high frequency in the population underlie genetic susceptibility to 
common diseases (Reich and Lander, 2001). The same idea can be applied to any quantitative 
trait, such as height or BMI. The CDCV assumption underpins the study design of genome-
wide association (GWA) studies; common alleles that confer susceptibility to the trait are 
expected to be present at a higher frequency in the affected/disease group compared to the 
unaffected/control group. 
 
GWA studies as a method of genetic analysis have empirically confirmed that most complex 
traits appear to have a polygenic mode of inheritance (Yang et al., 2010, Clayton, 2009). 
Using T2D and related glycaemic traits as an example, over 60 loci (Morris et al., 2012) have 
been identified as conferring susceptibility to these traits. Lack of statistical power due to 
small effect sizes and lack of linkage disequilibrium (Chapter 2: Linkage Disequilibrium) 
between the causal and genotyped single nucleotide polymorphism (SNP), combined with 
stringent significance threshold incurred for testing hundreds of thousands to millions of 
SNPs may hide many more loci (Spencer et al., 2009). Conventional GWA studies use a 
significance threshold of 10-8, which is based on an estimate for the effective number of tests 
performed in a GWA scan (Tanaka, 2005, Dudbridge and Gusnanto, 2008). This figure is 
similar to a standard Bonferroni correction, in which the desired nominal significance for a 
single test is divided by the total number of tests performed. For example, if the desired alpha 
value for a single test is 0.05, the significance threshold for testing 500,000 SNPs is a p-value 





Eight years after the first GWA study (Klein et al., 2005) over 2000 SNPs have been 
associated with complex traits (Visscher et al., 2012), yet for any particular trait, the 
implicated genetic variants explain a smaller fraction of the genetic component of the trait, as 
estimated from twin or family studies (Table 1.3). This situation has been termed as "missing 
[narrow-sense] heritability" and explanations have been extensively discussed (Manolio et 
al., 2009, Eichler et al., 2010). As of 2009, the 18 loci identified for T2D explained just 6% 
of its narrow-sense heritability, approximately the same figure was found for height with 
more than double the number of loci, in comparison, some 50% of the narrow-sense 
heritability for age-related macular degeneration is explained by just 5 loci (Manolio et al., 
2009). Potential sources of “missing heritability” include rare variants with large effects 
(CDRV hypothesis) and/or the effect of structural variants; however, it is not due epigenetics 
(Slatkin, 2009), nor gene-gene interactions or gene-environment interactions as these do not 
contribute to additive genetic variance (Chapter 2: Variance). 
 
Peter Visscher and colleagues provide a compelling argument in this discussion. In the first 
of two studies by the group, Yang et al. (2010) explore an alternative method to test for SNP-
trait associations, whereby instead of testing each SNP individually, they fit a linear model to 
estimate how much phenotypic variance is explain by considering all genomic SNPs 
simultaneously using REsticted Maximum Likelihood (REML) regression models. Using this 
approach, genomic SNPs collectively accounted for 45% of the phenotypic variance; this 
estimate of the phenotypic variance explained by empirical SNP data falls short of the 
frequently reported narrow-sense heritability of 80% for height.  
 
One reason for this discrepancy is that LD between genotyped SNPs and causal variants is 
incomplete; for example, if LD between genotyped common and genotyped rarer SNPs is 
comparable to LD between (non-genotyped) causal variants and genotyped rarer SNPs, then 
the empirical SNP-based narrow-sense heritability increases to 54%. However, if the minor 
allele frequency (MAF) of the causal variants are much lower than the genotyped SNPs (e.g. 
an allele spectrum of intermediate and rare allele frequencies), LD would be substantially 
reduced between the two and the proportion of variance explained by genotyped SNPs would 
rise to 80%, thereby accounting for the entire narrow-sense heritability of height. Hence the 
“missing heritability” for height can be completely accounted for by a spectrum of common 




The second study (Yang et al., 2011) related to the subject of "missing heritability" in 
relation to four traits, including height and BMI to examine how the phenotypic variance is 
captured by common genotyped SNPs distributed throughout the genome. Across these traits, 
the amount of phenotypic variance explained by genotyped SNPs is (1) much higher than 
previously thought and (2) positively associated with the number of genes and physical 
length of the chromosome. This latter point is relevant because, as the authors comment, if 
genetic variation is spatially correlated with genic regions, then these regions are prime 
candidates for harbouring causal variants, and depending upon the trait, provides justification 
for using exome capture as opposed to whole-genome sequencing in the search for causal 
variants. 
 
Figure 1.5 conceptually illustrates the wide range of allelic spectra underpinning multi-
factorial and monogenic disease; much of the attention to genetic variants in this introduction 
and this thesis is towards common variants, which are present at frequencies greater than 5% 
in the population. Low frequency (>0.5% and <5%) and rare (<0.5%) genetic variants are 
now being explored in the hope that they will reveal more susceptibility loci for complex 
traits and with larger effects than have been witnessed for common variants. The 1000 
genome project (http://www.1000genomes.org) is currently underway with the aim of 
cataloguing genetic variants down to a MAF of 1%; to date it has identified 22 million novel 
SNPs, bringing the total number of catalogued SNPs in the human genome to 38 million 
(Buchanan et al., 2012). 
 
It is unknown how many susceptibility loci remain to be found and to what extent do they 
influence the complex traits. To date, many of the loci identified for T2D have low effect size 
and penetrance – carrying any single risk allele or even all known risk alleles does not 






Figure 1.5. Spectrum of allele frequencies and effect sizes from (Manolio et al., 2009). 
In this graph various combinations exist for the frequency of a genetic variant (x-axis) and its 
effect size expressed as an odds ratio (OR, y-axis). Common variants with modest effect sizes 
are considered the low-hanging fruits in the search for genetic variants underlying complex 
traits. The stringent significance threshold at a genome-wide level, which can involve 






Trait or Disease h2 Pedigree Studies h2 GWAS Hits h2 All GWAS SNPs 
Type 1 diabetes 0.90 0.60* 0.30 
Type 2 diabetes 0.30 – 0.61 0.05 – 0.10 – 
Obesity (BMI) 0.4 – 0.6 0.01 – 0.02 0.20 
Crohn’s disease 0.60 – 0.80 0.10 0.40 
Ulcerative colitis 0.50 0.05 – 
Multiple sclerosis 0.30 – 0.80 0.10 – 
Ankylosing spondylitis >0.90 0.20 – 
Rheumatoid arthritis 0.60 – – 
Schizophrenia 0.70 – 0.80 0.01 0.30 
Bipolar disorder 0.6 – 0.7 0.02 0.40 
Breast cancer 0.30 0.08  
Von Willebrand factor 0.66 – 0.75 0.13 0.25 
Height 0.80 0.10 0.50 
Bone mineral density 0.60 – 0.80 0.05 – 
QT interval 0.37– 0.60 0.07 0.20 
HDL cholesterol 0.50 0.10 – 
Platelet count 0.80 0.05 – 0.1 – 
 
Table 1.3. Narrow-sense heritability and proportion of variance explained by SNPs 
(Visscher et al., 2012). 
The first column of the table shows the narrow-sense heritability (h2) estimate from family 
studies, the second and third columns shows the proportion of trait variance explained by 
SNPs that reach genome-wide significance and all genotyped SNPs on the array respectively. 






Monogenic Forms of Insulin Resistance 
Severe monogenic forms of insulin resistance have been described, some affecting the whole 
body (George et al., 2004, Savage et al., 2002), whilst others are tissue specific. The original 
nomenclature used to describe the different forms of insulin resistance (Kahn et al., 1976) 
discriminated two forms, type A and type B, where the primary defect in type A was insulin 
receptor binding, and the presence of anti-insulin receptor antibodies in type B. These 
subphenotypes of severe insulin resistance are now recognised to include all disorders of 
insulin signal transduction or defects in adipose tissue development or function 
(lipodystrophies), which may or may not have an immune-mediated component. A new 
classification system for diagnosis of severe insulin resistance has been proposed (Semple et 
al., 2011), which delineates the aetiology between the two main forms as primary insulin-
signalling defects or because of adipose tissue abnormalities. 
 
Novel Biological Insights of Insulin Secretion/Resistance From GWA Studies 
To date, approximately 60 (Morris et al., 2012) T2D susceptibility loci have been identified. 
Table 1.4 demonstrates the impact of GWA studies on number of loci identified for T2D and 
related traits (NB. does not include the 10 additional loci identified by Morris et al. (2012) for 
T2D). Many of the reported genes for T2D encode proteins implicated in beta cell function, 
while disproportionally few genes are implicated in insulin resistance (Table 1.5). Potential 
reasons for the lack of identified insulin resistance genes have been discussed (Petrie et al., 
2011) and the main arguments are listed below: 
 
1. Susceptibility variants in insulin resistance genes may have small effect sizes 
requiring very large samples. 
2. Insulin secretion is limited to a single tissue with a single cascade of protein 
interactions; insulin resistance can affect any of the major sites of insulin action: the 
liver, skeletal muscle, or adipose tissue. The mechanism(s) by which these tissues 
become resistant to insulin may be numerous each with small individual effects, 
making them difficult to identify. 
3. The case-control study design in GWA studies for T2D may inadvertently include 
individuals with high levels of insulin resistance in the control group, decreasing the 




4. GWA studies for quantitative T2D-related phenotypes such as fasting insulin, 
glucose, or indices based upon them, maybe biased to the discovery of genes involved 

















NOTCH2, PROX1, GCKR, THADA, BCL11A, RBMS1, IRS1, ADAMTS9, ADCY5, IGF2BP2, WFS1, 
ZBED3, CDKAL1, DGKB, JAZF1, GCK, KLF14, TP53INP1, SLC30A8, PTPRD, CDKN2A, 
CHCHD9, CDC123, HHEX, DUSP8, KCNQ1, CENTD2, MTNR1B, HMGA2, TSPAN8, HNF1A, 
ZFAND6, PRC1, FTO, SRR, HNF1B, DUSP9, CDCD4A, UBE2E2, GRB14, ST6GAL1, VPS26A, 
HMG20A, AP3S2, HNF4A, SPRY2  
BMI 1 MC4R 30 
NEGR1, TNNI3K, PTBP2, TMEM18, POMC, FANCL, LRP1B, CADM2, ETV5, GNPDA2, 
SLC39A8, HMGCR, PCSK1, ZNF608, NCR3, HMGA1, LRRN6C, TUB, BDNF, MTCH2, FAIM3, 
MTIF3, PRKD1, MAP2K5, FTO, SH2B1, GPRC5B, KCTD15, GIPR, TMEM160  
Glucose / 
Insulin 
1 GCK 15 
GCKR, G6PC2, IGF1, ADCY5, MADD, ADRA2A, CRY2, FADS1 (MIM 606148), GLIS3, SLC2A2, 
PROX1, C2CD4B, DGKB, GIPR, VPS13C 
Fat 
distribution 
0  20 
TBX15, LYPLAL1, IRS1, SPRY2, GRB14, STAB1, ADAMTS9, CPEB4, VEGFA, TFAP2B, LY86, 
RSPO3, NFE2L3, MSRA, ITPR2, HOXC13, NRXN3, ZNRF3, PIGC 
Total 5  107  
 
Table 1.4. Genes implicated for metabolic traits before and after the main wave of GWA studies (Visscher et al., 2012). 
This table illustrates the impact GWA studies have had on complex traits. Using metabolic traits as an example, the number of susceptibility loci 
identified has increased by over 2000% in just 4 years, these loci inherently implicate the biological pathways they act within, which has 






Chr SNP Nearest Gene Beta cell function Insulin Action 
1 rs10923931 NOTCH2 – – 
1 rs340874 PROX1 – – 
2 rs780094 GCKR – Yes 
2 rs11899863 THADA Yes – 
2 rs243021 BCL11A – – 
2 rs7578426 IRS1 – Yes 
3 rs13081389 PPARG – Yes 
3 rs6795735 ADAMTS9 Yes – 
3 rs11708067 ADCY5 Yes – 
3 rs1470579 IGF2BP2 Yes – 
4 rs1801214 WFS1 Yes – 
5 rs4457053 ZBED3  – 
6 rs10440833 CDKAL1 Yes – 
7 rs2191349 DGKB-TMEM195 Yes – 
7 rs849134 JAZF1 Yes – 
7 rs4607517 GCK Yes – 
7 rs972283 KLF14 – Yes 
8 rs896854 TP53INP1 – – 
8 rs3802177 SLC30A8 Yes – 
9 rs10965250 CDKN2A/B Yes – 
9 rs13292136 CHCHD9 – – 
10 rs12779790 CAMK1D Yes  
10 rs5015480 HHEX/IDE Yes – 
10 rs7903146 TCF7L2 Yes – 
11 rs2334499 Imprinted region –  
11 rs231362/rs163184 KCNQ1 Yes – 
11 rs5215 KCNJ11 Yes – 
11 rs1552224 CENTD2 Yes – 
11 rs1387153 MTNR1B Yes – 
12 rs1531343 HMGA2 – Possible 
12 rs4760790 TSPAN8 Yes – 
12 rs7957197 HNF1A – – 
15 rs11634397 ZFAND6 – – 
15 rs8042680 PRC1 – – 
16 rs11642841 FTO – Yes 
17 rs4430796 HNF1B Yes – 
19 rs10423928 GIPR Yes – 
X rs5945326 DUSP9 – Possible 
 
Table 1.5. Validated T2D-implicated genes that are involved in insulin secretion 
or resistance (Petrie et al., 2011). 
The vast majority of these genes implicated in T2D susceptibility have functions that 





Mitochondria and Diabetes 
All eukaryotic cells contain mitochondria that are responsible for most of the ATP-
generation within the cell. In evolutionary terms, mitochondria are aerobic bacteria 
that formed a symbiotic relationship with primordial eukaryotic cells. Over time, the 
mitochondrial DNA (mtDNA) of these once free living prokaryotes have made their 
way into the nucleus of the eukaryotic host cell via endosymbiotic gene transfer 
(Timmis et al., 2004). There is not much evidence for the transfer of nuclear DNA 
into mitochondria, presumably due to the added complexity of transcribing intron-
containing eukaryotic genes and lack of ability to process the mRNA transcript within 
the mitochondrion. The mitochondrial genome is just 16, 571 bp in size and contains 
37 genes – 22 of which are transfer RNA (tRNA) genes, 13 are protein-coding genes, 
and two are ribosomal RNA (rRNA) genes (Figure 1.6). The current estimate of the 
number of nuclear-encoded mitochondrial (NEM) genes in the human genome is 
1,098 (Pagliarini et al., 2008). Each mitochondrion has 2-10 copies of mtDNA and 
depending upon cell-type and each cell is estimated to contain 1,000 – 2,000 
mitochondria. In contrast to nuclear DNA, mDNA is virtually devoid of intronic, 







Figure 1.6. The human mitochondrial genome (Mercer et al., 2011). 
The human mitochondrial genome contains 37 genes, the abbreviated gene names are 






How do Mutations in the Mitochondrial Genome Cause Diabetes? 
Maternally inherited diabetes-deafness (MIDD) syndrome (OMIM #520000) is a 
condition characterised by various neurological, endocrinological, and sensory 
features caused by mutations in one of three mitochondrial tRNA genes. Studies of 
patients with MIDD have shown the diabetes component of this condition resembles 
T1D more closely than T2D in that affected individuals have low levels of circulating 
insulin. A well-studied mtDNA polymorphism that causes MIDD is the A3243G 
mutation – an A to G transition at position 3243 in the mitochondrially-encoded 
tRNA (Leu, UUR) gene MTTL1 (van den Ouweland et al., 1992). This mutation 
causes a dimerisation in the D loop of the tRNA molecule, which destabilises the 
molecule and ultimately hinders mitochondrial protein synthesis and the rate of 
oxidative phosphorylation (Wittenhagen and Kelley, 2002). It is thought this inability 
to synthesise sufficient ATP via oxidative phosphorylation lowers the ATP/ADP ratio 
and consequently insulin is not secreted in response to glucose (Maassen et al., 2004). 
 
Contribution of Mitochondrial and Nuclear Genome Variants to T2D 
The identification of a form of diabetes caused by a polymorphism in mitochondrial 
DNA raises the possibility that mitochondrial variants may also contribute to the 
common form of T2D. A recent meta-GWA scan of T2D (Voight et al., 2010), 
revealed novel susceptibility loci for T2D were previously known to cause monogenic 
forms of diabetes. This overlap of loci implicated between monogenic and common 
T2D confirms the notion that careful genetic studies of all types of diabetes can aid 
our understanding of the aetiology of this clinically heterogeneous condition. 
 
Examples of highly penetrant mutations in genes identified for monogenic and 
syndromic forms of diabetes that are also implicated in the common polygenic form 
of diabetes are presented in Table 1.6 reproduced from Vaxillaire and Froguel (2008). 
Some variants in these genes with minor effects on T2D susceptibly have not been 
detected through GWA studies, e.g. TCF1, TCF2, and ABCC8. This serves as a 
reminder that although GWA studies have shown both novel and previously-known 
genes to be associated with T2D, many more may be missed either due to their rarer 
frequency (MAF < 0.10) or small effect size (for common variants) and the high 












Variants at the P2 promoter (MAF  0.15). OR = 1.15 [1.00 –1.30] 
in Europeans 
(Love-Gregory et al., 2004, Silander et 




Variant –30G/A (-cell promoter). OR = 1.22 [1.13–1.32] in 
Europeans 
(Sladek et al., 2007, Diabetes Genetics 






G319S, OR = 2.0 in Oji-Cree (heterozygous carriers). OR = 1.17 
[1.06–1.30] in Europeans (other variants, MAF  0.10) 






Intronic variants (MAF  0.10). OR = 1.12 [1.07–1.17] in 
Europeans. 










E23K (MAF  0.30). OR = 1.14 [1.10 –1.19] in Europeans 
(Hani et al., 1999, Gloyn et al., 2003, 





A1369S (MAF  0.30). OR = 1.14 [1.02–1.28] in Caucasians 





R611H (MAF ~ 0.60), other intronic variants. OR = 1.11 [1.08 –
1.16] in Europeans. 
(Sandhu et al., 2007, Frayling, 2007) 
 
Table 1.6. Type 2 diabetes genes identified in both monogenic and polygenic forms of the disease (Vaxillaire and Froguel, 2008). 
Genes that underlie monogenic and syndromic forms of diabetes also contain variants that contribute to the polygenic form of the disease. 





Why Might NEM Genes be Important in T2D? 
Moving from the mitochondrial genome to the nuclear genome, there is some 
evidence that NEM genes may play a role in T2D – for example, a nonsynonymous 
SNP (rs71645922, H324Q) in LARS2 gene has been associated with T2D in 4 
population samples from the Netherlands and Denmark (Hart et al., 2005). LARS2 is 
an interesting nuclear candidate gene as it is involved in the same pathway as the 
mitochondrially-encoded tRNA gene MTTL1, described above. A follow-up study 
(Reiling et al., 2010) with the Diagram consortium (Zeggini et al., 2008) and 
individuals from several European samples found no significant association despite 
the large sample size (n = 35,712). 
 
A search of the National Human Genome Research Institute (NHGRI) catalogue of 
published GWA Studies (Hindorff et al., 2009) for T2D and related traits show six 
NEM genes (Pagliarini et al., 2008) to be associated with these traits. These six genes 
are MRPL33, FITM2, TRIAP1, C6orf57, HK1, and IDE, with mitochondrial functions 
that range from ribosome components to degradation of mitochondrial targeting 
sequences. 
 
Rather than taking a hypothesis-free approach to identifying T2D susceptibly variants 
in NEM genes, some studies have looked specifically at NEM genes that encode the 
proteins of the oxidative phosphorylation (OXPHOS) pathway. This pathway is 
central to T2D as the production of ATP is one of the key signals in the pancreatic 
beta cell for glucose-stimulated insulin secretion (Henquin, 2009) and avoidance of 
hyperglycaemia hinges on insulin secretion overcoming insulin resistance. Moreover, 
by only looking at variants in genes in the OXPHOS pathway and not the entire 
genome, it lessens the penalty incurred by multiple testing. 
 
Another study (Reiling et al., 2009) has looked at the role of 13 “essential” NEM 
genes involved in mitochondrial transcription, translation or replication in order to 
test for association with T2D. In their two-stage study design, they first analysed 58 
SNPs, which tagged nearly all common SNPs in 13 genes, for association with T2D. 
The second stage took the top SNPs (minimum p-value = 0.005) from stage one, 




for replication. None of the nominally associated SNPs in the initial stage were 
replicated. 
 
The majority of proteins in the OXPHOS pathway are encoded by nuclear genes 
(Baughman et al., 2009). A study (Olsson et al., 2011a) attempted to identify any 
common SNPs in or near OXPHOS genes using clinical phenotypic data from the 
Diabetes Genetics Initiative (DGI) GWA scan for T2D. Nine SNPs from six genes 
showed nominal association with T2D with p-values less than 1 x 10-2 in the initial 
DGI GWA scan, of these, the two SNPs with lowest p-values (rs606164, p-value = 
9x10-4; rs1323070, p-value = 3x10-3) were selected to be followed up with in vivo 
studies. Both SNPs were nominally associated (p-value < 0.05) with an insulinogenic 
index (following an oral glucose tolerance test: [[insulin at 30 minutes – insulin at 0 
minutes] / [glucose at 30 minutes – glucose at 0 minutes]]). 
 
In a similar study design, Snogdal et al. (2012) investigated 10 variants in six 
OXPHOS genes that showed nominal association (p-value < 1x10-2) in a T2D GWAS 
meta-analysis (Zeggini et al., 2008) by attempting to replicate their associations in an 
independent Danish cohort. Only one of the ten SNPs reached a nominal association 
with T2D (rs9915302, odds ratio, OR = 1.14 [1.02 – 1.28], p-value = 0.02) in the 
Danish cohort. Combining their Danish cohort with a second T2D meta-GWAS 
(Voight et al., 2010), improved the number of nominal associations to six. The 
authors also looked at associations with diabetes-related phenotypes, again only 
nominal associations (p-value  0.05) were found. None of the original 10 SNPs were 
significantly associated with any phenotype after correction for multiple testing in the 
three analyses in the study (Snogdal et al., 2012). 
 
A problem with these studies (Olsson et al., 2011a, Snogdal et al., 2012) is that they 
lack any examination of the extent of LD surrounding the selected SNPs, limiting 
themselves to the initial GWA scan results. It is known the causal variant(s) is rarely, 
if at all, identified via a GWA scan. The hope in performing a GWA scan is that the 
casual variant(s) lies within a haplotype block that also harbours a genotyped SNP. 
The goal of GWA scan is to elucidate the genetic pathways underlying phenotypic 




the loci identified by the GWA scan that contribute to phenotypic variation. Therefore 
to focus on purely on SNPs, that did not even reach genome-wide significance, then 
to show inconsistent or weak association in separate, albeit large samples, the findings 
(Olsson et al., 2011a, Snogdal et al., 2012) are not convincing and naïve to conclude 
that NEM genes to do not contribute to T2D. 
 
Reasoning that as previous studies looking at candidate NEM genes failed to detect 
any robust associations with T2D or related phenotypes, it has been suggested (Segre 
et al., 2010) that the effect of an individual NEM gene variant is too small to be 
detected and that gene-set based pathway analyses may be more fruitful. To that end, 
a modified Gene Set Enrichment Analysis, GSEA (Subramanian et al., 2005) 
approach called Meta-Analysis Gene-set Enrichment of variaNT Associations 
(MAGENTA) has been developed by Segre et al. (2010). While GSEA was 
developed to analyse gene expression data, MAGENTA was developed to analyse 
SNP p-values from a GWA scan. Briefly, the MAGENTA pipeline involves mapping 
SNPs to genes, assigning the minimum SNP p-value to the gene, adjusting for gene 
size, number of SNPs, LD per kilobase (Kb), and calculating an association 
enrichment score for each gene set over and above that expected under the null 
hypothesis. The enrichment score is determined as the fraction of genes in a gene set 
with a p-value less than a predetermined threshold and the gene set p-value (or 
evidence of enrichment) is obtained by comparing this fraction with a fraction 
obtained from a random gene set of identical size. 
 
This MAGENTA method was applied to T2D GWA data to test for enrichment of 
NEM gene regulators of mitochondrial gene transcription, NEM genes pertinent to 
OXPHOS, and all known NEM genes. No enrichment was found for T2D or related 
phenotypes, which failed to support the original application of GSEA (Mootha et al., 
2003) that found enrichment for the down regulation of a subset of OXPHOS genes in 
skeletal muscle from individuals with IGT or T2D. A likely reason for why Segre et 
al. (2010) did not observe results similar to Mootha et al. (2003) is that gene 
expression data lends itself better to gene-centred analyses than SNP data does. 
 
It is common in GSEA-type analyses of GWA data to use the minimum SNP p-value 




a poor measure of the importance of each gene in a pathway. This form of 
reductionism disregards the presence of multiple independent signals with a gene and 
fails to adequately control for gene size or degree of linkage disequilibria. It would be 
more desirable to incorporate all SNP p-values such as methods described by Purcell 
et al. (2007), which takes the mean association value for all SNPs within a gene, or 
O'Dushlaine et al. (2011), which computes a ratio of significant and non-significant 





Research Aims of this Thesis 
The three main research aims of this thesis are: 
 
1a. The validation and estimation of an accurate proxy measure for visceral fat 
accumulation using DXA and simple anthropometrical measures. 
 
1b. Investigate whether visceral fat mediates the observed association between 
different measures of body adiposity and common cardiovascular and 
metabolic morbidities, including T2D. 
 
2. Determine if the locus encompassing two genes encoding the presenilin-
associated, rhomboid-like (PARL) and the ATP-binding cassette, sub-family C 
(CFTR/MRP), member 5 (ABCC5) proteins is a novel disease susceptibility 
locus for T2D. 
 













Subjects used for the studies in this thesis include adult twin volunteers from the 
Department of Twin Research and Genetic Epidemiology (DTR), which is based at 
St. Thomas' Hospital in London, United Kingdom (Spector and Williams, 2006, 
Moayyeri et al., 2013, Moayyeri et al., 2012). Recruitment to the registry (TwinsUK) 
is largely through campaigns in the national press, TV, radio, through their own 
website (www.twinresearch.ac.uk) and recently social networking websites. The 
registry currently consists of 12,000 same-sexed twins - approximately 80% are 
female and the ratio of monozygotic (MZ) and dizygotic (DZ) twins is roughly 1:1. 
Twins have participated in a variety of studies over the last two decades; there have 
been three major phases of TwinsUK (Figure 2.1): the baseline phase ran from the 
registry’s inception in 1992 until 2004, the first follow-up phase took place between 
2004-2007, whilst the second follow-up, known as the Healthy Ageing Twin Study 
(HATS), ran between 2007-2010. The aim of the HATS was to provide longitudinal 
data for female twins over 40 years old and had previously visited the hospital. 
 
During these phases, many types of studies were conducted; these included 
questionnaire-based, posted collection kits and clinical visits at the hospital. At the 
clinical visit, in addition to extensive health questionnaires, routine biological samples 
were collected and clinical assessments were performed during the visit to the 
hospital. For specialised studies, such as those focused on eye-related phenotypes, 
additional study-specific phenotypes were collected, therefore the number of 
phenotypes differs among twins. A comprehensive list of phenotypes collected can be 
downloaded from http://www.twinsuk.ac.uk/data-access/phenotypes. 
 
Upon joining the registry all twins provided informed written consent for proposed 
usage and storage of their information and biological specimen(s). Each individual is 
assigned a unique study number identifier to ensure anonymity. For each subsequent 
round of study participation, twins are re-consented, which ensures the individual 
understands the purpose of the study and is given the opportunity to withdraw from 
the study. St. Thomas’ Hospital Research Ethics Committee approved all studies 




Data used in this study were originally collected and managed by staff and PhD 
students of the DTR, including myself for the first two years of my PhD. However, I 
did not collect the genotypic, DXA and glycaemic data that are central to some of the 
questions addressed in this thesis. 
 
 
Figure 2.1. Schematic of the major TwinsUK recruitment phases (Moayyeri et 
al., 2012). 
Participation levels for the TwinsUK volunteers from 1992-2010; data analysis in this 






As the focus of the thesis is T2D and related glycaemic traits, the main biological 
phenotypes used are fasting plasma insulin and glucose. Twins were asked to fast for 
at least 8 hours preceding their visit to St Thomas’ Hospital. Visits took place both in 
the morning and afternoon; unfortunately the time of visit had only recently (post-
2007) been recorded. Insulin and glucose measurements by the DTR since its 
formation are listed in Table 2.1. The nurses and research assistants of the DTR 
performed collection of blood. 
 
Dual-Energy X-ray Absorptiometry 
Research assistants at the Department of Twin Research performed whole body dual-
energy X-ray absorptiometry (DXA) scans in the supine position, using a fan beam X-
ray bone densitometer (QDR-4500W, Hologic, Massachusetts) and analysed with 
QDR System Software Version 12.6 (Hologic, Inc., Massachusetts). The DXA 
scanner was calibrated daily with a spine phantom and weekly using the step phantom 
as instructed by the manufacturer’s guidelines. 
 
Computed Tomography 
Computed tomography (CT) scans used in this thesis were provided by Dr Marina 
Cecelja. Scan details are as follows: subjects were placed in the supine position and a 
truncal CT scan was performed using a CT helical scanner (Brilliance CT component 
of the Philips Precedence SPECT/CT system, Philips, Eindhoven, Netherlands) with 
slice thickness set at 5 mm. The total cross sectional area (CSA) was intersected at the 
level of the intervertebral disc between lumbar vertebrae four and five (L4:L5). CT 
scans were analysed using Osirix X imaging software, version 3.7.1 (Pixmeo, 
Switzerland) to provide X-ray attenuation data at the pixel level. 
 
MuTHER Fat Expression 
During the clinical visits to St Thomas’ Hospital, approximately 850 twins had 
abdominal skin punch biopsies performed to extract skin and subcutaneous fat, as 
well as a blood sample to generate lymphoblastoid cell lines (LCLs). Details of the 
biopsy method can be found elsewhere (Nica et al., 2011). Genome-wide messenger 
RNA expression (~48,000 probes) was measured in these three tissues by the Multiple 
Tissue Human Expression Resource (MuTHER) project (http://www.muther.ac.uk/) 




Comprehensive details of the data normalisation process are described in the original 
reports (Nica et al., 2011, Stranger et al., 2007); in summary data generated for each 
tissue was first transformed on the log2 scale, then quantile normalised across 
individual replicates then across all individuals. The normalised fat expression data 







Table 2.1. Assay and instrument details for measuring insulin and glucose from 1992-2012 at St Thomas’ Hospital, London, UK. 
Various instruments were used to measure insulin and glucose in the TwinsUK sample. The duration each assay was in use for was useful in 
handling potential batch effects, as was the manufacturers’ reference range. 
 












Enzymatic rate / Colorimetric assay 
Kodak Ektachem dry chemistry 
analysers (Johnson and Johnson 
Vitros Ektachem machine) 
3.5 - 5.5 mmol/L 
August 2000-
March 2006 
Time rate / Conductivity  
Glucose concentration is determined by the oxygen rate 
method employing a Beckman Oxygen electrode. 
Electronic circuits determine the rate of oxygen 
consumption, which is directly proportional to the 
concentration. 
Beckman LX20 analysers 3.5 - 5.5 mmol/L 
April 2006 - 
present 






1992 - 2000 
Microparticle Enzyme Immunoassay (Abbott Laboratories 
Diagnostics Division, Maidenhead, U.K.) 
Abbot IMX Analyser 0 - 15.6 µU /ml 
1996 - May 2007 Solid-phase two-site chemiluminescent assay Immulite 100 analyzer (DCP Ltd) 8.9 - 28.4 µU /ml 




Wellcome Trust Case Control Consortium 
Established in 2005, the Wellcome Trust Case Control Consortium (WTCCC; 
http://www.wtccc.org.uk) comprises of more than 50 British research groups with the 
aim of investigating the genetics of disease susceptibility. Phase one of the project 
(WTCCC1) looked at seven diseases (T1D, T2D, coronary heart disease, 
hypertension, bipolar disorder, rheumatoid arthritis and Crohn's disease) in 
comparison with an ostensibly healthy shared control group selected from the 1958 
Birth Cohort and the UK Blood Services Controls (UKBS).  
 
Sample recruitment and phenotype definition for each of the seven diseases is fully 
described in their original report (Wellcome Trust Case Control, 2007). T2D cases 
were identified from the Diabetes UK Warren 2 repository, diagnosis was determined 
if the individual has been prescribed treatment with hypoglycaemic agents and/or 
previous evidence of hyperglycaemia. T1D, MODY, and mitochondrial diabetes cases 
were excluded based on personal and family history; current or previous gestational 
diabetes was not reported in the exclusion criteria. In the T2D GWA scan, three SNPs 
(rs9465871, rs4506565, rs9939609) were associated with T2D, all of which were in or 
near genes that had previously been implicated by other GWA studies. 
 
National Institute for Diabetes and Digestive and Kidney diseases (NIDDK) 
The NIDDK focuses on diabetes (all types) and common complications arising from it 
(Fradkin and Rodgers, 2013). It was formed in 1950 in Maryland (USA) and is funded 
by the National Institutes of Health (NIH). At the beginning of 2012, members of the 
NIDDK reported a GWA study of T2D in African Americans (Palmer et al., 2012); 
cases were adults over 25 years of age with T2D and end stage renal disease (ESRD, 
discovery cohort) and T2D without ESRD for the replication phase, recruited from 
health centres in North Carolina and neighbouring states. Controls were individuals 






Genotype data used throughout this thesis originate from a number of different 
platforms, including fine map genotyping undertaken specifically for studies 
presented in this thesis. Here I outline the key attributes of each starting with the 
TwinsUK, then the publically available WTCCC1 and the NIDDK African American 
GWA resources obtained from dbGAP. 
 
TwinsUK 
TwinsUK have genome-wide SNP data for 5, 701 individuals split across the Illumina 
HumanHap 300K and the Illumina HumanHap 610 Quad platforms. Staff from the 
DTR took blood from the twins and genotyping was performed on DNA extracted 
from whole blood at the Wellcome Trust Sanger Institute (Cambridgeshire, United 
Kingdom) and the Center for Inherited Disease Research (CIDR; Maryland, United 
States of America). 
 
The Illumina HumanHap300 interrogates approximately 317,000 SNPs, estimated to 
capture around 80% of SNPs with MAF > 5% in HapMap (European ancestry; CEU) 
phases 1 and 2 (Illumina HumanHap300 data sheet). Markers are evenly distributed 
throughout on a physical map scale with an average of one SNP per nine Kb. The 
Illumina Human610-Quad platform has around 620,00 SNPs, with coverage of the 
HapMap (CEU) release 23 data (four million SNPs) by this platform estimated to 
89% and the mean physical spacing between markers on the platform is one SNP per 
five Kb (Illumina HD analysis data sheet). 
 
For the HumanHap300, 2,226 samples were genotyped, including 27 duplicates, thus 
2,199 unique individuals; for the Human610-Quad platform, 3,512 samples were 
genotyped, 10 of which duplicate samples. In terms of zygosity, the 2,199 individuals 
on the HumanHap300 platform comprised of 1,416 DZ, 780 MZ, and three with 
unknown zygosity at the time of genotyping; the 3,502 individuals on the Human610-
Quad platform comprised of 1,977 DZ, 1,485 MZ, and 40 with unknown zygosity at 





The SNP data from both platforms were checked for quality control (QC) by the staff 
of the DTR, also described in Richards et al. (2008); in summary this involved 
filtering out genotype calls based on the following: a genotype calling posterior 
probability less than 95%, a call rate less than 90%, deviation from Hardy-Weinberg 
equilibrium (p value < 1.0x10-4), or minor allele frequency (MAF) less than 1%. The 
sample genotyped on the HumanHap300 platform has previously been subjected to 
population stratification analysis implemented in Structure (Pritchard et al., 2000) and 
showed the TwinsUK sample to be homogenous. 
 
For the work presented in Chapter 4, the HumanHap300 and Human610-Quad 
samples were initially analysed separately due to different marker coverage and also 
to check for potential phenotypic heterogeneity with respect to fasting plasma insulin 
and glucose. Imputation was not used to increase marker coverage in the thesis 
because some of the analyses in Chapters 4 and 5 require empirical modelling of all 
marker pair-wise relationships. 
 
WTCCC1 
In total, 17,000 samples were genotyped on the Affymetrix 500K platform for 
WTCCC1; individual level genotype data can be downloaded from the European 
Genotype Archive (http://www.ebi.ac.uk/ega). The genotyping assay protocol is 
described in the WTCCC1 initial report (2007); coverage is substantially less than the 
TwinsUK 610-Quad platform with 392,575 SNPs passing QC and MAF > 1%. The 
coverage on the Affymetrix 500K is more evenly distributed than the HumanHap 
300K, with the latter being more targeted towards SNPs within exons (Table 2.2). 
 
 HumanHap 300K Affymetrix 500K 
Intragenic (between Tx start and stop) 123,373 (0.39) 184,912 (0.37) 
Exonic 12,023 8,513 
Intronic 111,350 176,399 
Within 10Kb of Tx start or stop 35,290 (0.11) 52,208 (0.10) 
Intergenic 158,839 (0.50) 236,706 (0.53) 
 
Table 2.2. Comparison of SNP coverage between the HumanHap 300K and 
Affymetrix 500K (DeWan et al., 2007). 
Number of SNPs given in table with proportion of total SNPs given in parentheses. 






Phenotype and genotype data for the NIDDK African American sample were obtained 
from the National Center for Biotechnology Information (NCBI) database of 
genotypes and phenotypes, dbGaP (http://www.ncbi.nlm.nih.gov/gap). The original 
genotyping and QC details can be found in Palmer et al. (2012); here I only note that 
post-QC coverage on the Affymetrix Genome-wide Human SNP array 6.0 platform 
exceeds 800K SNPs, which is greater than both the TwinsUK Human610-Quad 
(583K post-QC SNPs) and the WTCCC1 Affymetrix 500K (393K post-QC SNPs) 
platforms. 
 
One major difference between TwinsUK (Illumina) and the publically available data 
sets (Affymetrix) is the genotyping method. The Illumina HumanHap300 and the 610-
platforms utilise the single-base extension genotyping method (Steemers et al., 2006). 
In short, an oligonucleotide 50 bp in length is hybridised adjacent to the SNP, labelled 
dideoxynucleotides are incorporated at the SNP locus, which identifies the allele at 
the locus. The Affymetrix genotyping system was used for the WTCCC1 (Affymetrix 
500K) and the NIDDK African American (Affymetrix 6.0) GWA studies; the 
Affymetrix system requires a complex reduction stage prior to differential 
hybridisation of labelled DNA to the quartet of perfect and mismatched pairs of 25-





Quantitative Genetic Theory  
Biometrical genetics is the study of the inheritance of a continuous phenotype. A 
phenotypic measurement is the outcome of latent genetic and environmental 
contributions: 
 
P = G + E 
 
Where P is the phenotypic mean value, G is the genotypic value, and E is the 
environmental deviation. The focus of the following section is the partitioning of 
genotypic contribution into additive and dominance components: 
 
Gtotal = Gadditive + Gdominance 
 
Genotypic values can be assigned to specify the phenotypic value for each genotype. 
If one initially assumes that there is no intra-locus dominance effect at an autosomal 
biallelic locus with alleles A1 and A2, whereby A1 increases the phenotypic value, the 
genotypic effect of the homozygote A2A2 and A1A1 genotypes are -a and +a, 
respectively. In this example the alleles act additively in that the genotypic effect of 
heterozygote, A1A2, is exactly midway between -a and +a. 
 
Any deviation from this additivity is termed the degree of dominance (d), which can 
range from none to complete. If allele A1 is dominant over A2, d is greater than zero, 
and conversely, if allele A2 is dominant over A1, d is less than zero (Figure 2.2). For 









As genotypes are not passed from parents to offspring, the allelic effect must be 
considered instead of the genotypic effect. This new measurement, the average effect 
() of an allele, combines allele frequencies with the genotypic effect at a locus:  = a 
+ d(q – p), where p and q represent the allele frequencies for A1 and A2 respectively.  
 
The sum of the average effect of the alleles at each locus an individual possess is its 
breeding value, also known as the additive genetic value. For example, for a single 
locus (A) the breeding value of an A1A1 homozygote is twice A1, for an A1A2 
heterozygote it is the sum of A1and A2, and lastly for the A2A2 homozygote, the 
breeding value is twice A2. This the mean genotypic value at the A locus in the 
offspring as it is the sum of the breeding values of its parents and thus individual 
breeding values is important in designing breeding programmes for a trait. 
 
In the derivation of the additive genetic value of an individual, the effects of 
dominance and interaction between alleles at different loci (epistasis) are initially 
ignored. As noted earlier, the genotypic value of a locus is attributable to additive 
genetic effects, while deviations from additivity can be attributed in part to dominant 
and epistasis genetic effects. For two or more loci, we take the sum of the additive 
genetic and dominance values at the loci and include a term for the any interaction 
between loci. 
 





Figure 2.3. The relationship between genotypic value, genotype frequency, and 
additive genetic values (Falconer, 1989). 
The genotypic value (open circles, y1-axis) is plotted against genotype frequency (x-
axis) and the additive genetic value (closed circles, y2-axis). The A1 allele is 
dominant over the A2 allele to the extent that the genotypic value for the A1A2 
heterozygote is almost equal to the genotypic value of the A1A1 homozygote. The 
average effect () is indicated between the A2A2 homozygote and the A1A2 
heterozygote, but is identical in magnitude to the value between the A1A1 homozygote 







The focus of the previous section was the derivation of the breeding mean value of an 
individual; here I will describe the second order moment of the breeding value, the 
variance. The partitioning of breeding value variance is central to estimating 
heritability. 
 
Total phenotypic variance (VP) comprises of genetic (VG) and environmental (VE) 
components of variance:  
 
VP = VG + VE 
 
The biometric model tells us that the genetic component is a culmination of additive 
genetic effects, with deviations from additivity in the form of dominance and 
interaction terms between alleles at different loci (epistatsis). Therefore, the total 
phenotypic variance in the can be expressed as: 
 
VP = VA + VD + VI + VE 
 
The ratio of genetic variance to observed phenotypic variance is the broad sense 
heritability (H2) of that phenotype. Replacing the total genetic variance with just the 
additive genetic variance, i.e. what is transmitted from parents to their offspring, in 
the ratio gives the narrow-sense heritability (h2).  
 
Having described how the genetic component of phenotypic variance can be further 
decomposed into additive and dominance component, it is important to note that a 
relationship may exist between the genotype and the environment. For example a 
genotype maybe correlated with an environment – i.e. if nutrition of an animal was 
determined by its phenotype e.g. weight, there is a correlation between phenotype and 
environment. As a portion of the individual’s phenotype is determined by the sum of 






In human genetics these considerations of correlation and interaction between 
genotypes and the environment are often assumed to be absent. The reason for 
assuming an absence of genotype-environment correlation is that testing for such 
correlation requires study designs that are difficult to implement such as inbreeding 
and/or complete environmental control. Genotype-environment interactions are also 
ignored because the prerequisite for testing this relationship is that the environmental 
factor contributing to the interaction is known and accurately measured. 
 
Genetic Model Specification 
The true underlying genetic model of a risk allele is seldom known. There are a few 
key models that describe the effect of the risk genotype on the phenotype – additive, 
multiplicative, codominant, dominant, and recessive. A starting point in genetic tests 
of association in case-control data is a count of observed genotypes at a SNP in the 
case and control groups (the full data box in Figure 2.4), the test is Pearson's 2, 
which is described in a following section (Allelic and Genotypic Tests of 
Association). This is the safest type of analysis to perform as it does not assume a 
genetic model, thereby avoiding specifying the wrong genetic model, which leads to a 
reduction in statistical power (Lettre et al., 2007), Figure 2.5. It might be attractive to 
test all genetic models to determine the model that produces the largest test statistic. 
However this would incur both a multiple testing penalty and increase the 
computational burden by four, which is substantial on a genome-wide scale with 
approximately a million SNPs to be tested. 
 
Where there is prior evidence to suggest a particular genetic model (for example, 
Leu262Val in Chapter 4) it is best to fit a genetic model rather than the generic 
Pearson's 2 test. The models vary slightly in their interpretation depending on the 
data type, i.e. quantitative trait or case-control status. An additive model is one where 
the disease risk increases with increasing number of risk alleles, so that heterozygotes 
will have a phenotypic value or risk of case status approximately midway between the 
values for the two homozygotes. This trend can be tested using the Cochran-Armitage 
test for trend. A multiplicative model tests allele rather than genotype counts and the 
presumed risk of disease increases by a risk factor “r” with number of risk alleles, e.g. 




r2. Note the comparison between the risk genotype in additive and multiplicative 
models, which are 2r and r2, respectively. If the disease risk conferred by the 
heterozygous genotype lies between the two homozygous genotypes but not 
approximately midway (additive model), then the model is said to be codominant. 
 
The dominant and recessive models work by collapsing the three observable 
genotypes at a biallelic SNP into just two groups; this example is illustrated in Figure 
2.4 (Lewis and Knight, 2012). In the dominant model, assuming the “T” allele is the 
dominant allele, the phenotypic value for GT heterozygotes will be the same as the 
TT homozygotes. Similarly, in the recessive model, the GG homozygotes and GT 








Figure 2.4. Genetic models to test for SNP association in case-control data (Lewis 
and Knight, 2012). 







Figure 2.5. Effect of specifying inappropriate genetic models on statistical power 
(Lettre et al., 2007). 
Plots show the effect on power by fitting additive, dominant, recessive and 
codominant statistical models to additive, dominant, and recessive loci. 





Ordinary Least Squares Regression 
If the relationship between a quantitative trait and SNP is linear, a simple ordinary 
least squares (OLS) linear regression can be used to test for association. For example, 
if one assumes a biallelic SNP with three genotypes – AA, Aa, and aa, each genotype 
is considered by the number of minor alleles it possess. The minor allele of a SNP, as 
the name suggests, refers to the less frequent allele at that SNP, thus if the “A” allele 
is more common than the “a” allele in a sample, the genotype allele counts are as 
follows: AA – 0, Aa – 1, and aa – 2. The OLS regression model is described as:  
 
y = c + SNP + e 
 
Where, 
 y is the estimated quantitative phenotype 
 c is the intercept term, i.e. the fitted value of the phenotype for the 
homozygous common genotype (0). 
 SNP represents the beta coefficient of the SNP, which is the slope of the 
regression line (Figure 2.6) 
 e is the residual error term and represents the difference between the actual 
values of the quantitative trait and the fitted values based on the regression 
model. 
 
Such a model is also known as a linear dose response model, for each additional copy 
of the "a" allele, the estimated trait value will increase by the value of SNP. The 
intercept term, a, is interpreted as the trait estimated trait value for individuals with no 





Figure 2.6. Ordinary least squares regression of quantitative trait and SNP 
minor allele count. 
 
Covariates can also be added to the model that account for confounders or additional 
explanatory variables, for example if we assume age is associated with fasting insulin 
level and want to test if a SNP was also associated, the model would become: 
 
y = c + SNP + age + e 
 
SNP + age are partial coefficients – the partial coefficient for the SNP is the effect 
increasing the SNP variable by one whilst adjusting for the influence of age on the 
phenotype. 
 
Statistical software will often report descriptive statistics of the model such as the 
standard error, a test statistic, the p-value of that test statistic for each beta coefficient. 
The standard error of the beta coefficient (SEβ) is an estimate of the extent to which 
the sample beta coefficient varies about the true population mean. The test statistic, t, 
is simply the beta coefficient divided by its standard error and follows a t distribution, 
which is asymptomatically normal for large sample sizes. The significance of the t 




significance threshold (e.g. 0.05, 0.01, 0.001, etc) and degrees of freedom. If the p-
value for the test statistic is below a significance threshold, then there is evidence to 
reject the null hypothesis (H0) that SNP is equal to 0 and the result favours the 
alternative hypothesis (H1) that SNP is not equal to 0. 
 
An explanatory variable might be statistically significant and therefore associated 
with the response variable, but still might not explain much of the variation in the 
response. The proportion of variance of the response variable explained by the model 
is given by coefficient of determination (R2). For a multiple regression, R2 can be 
adjusted by the number of explanatory variables included in the model. 
 
Logistic Regression 
If the phenotype is binary, such as disease status, which can be presented as 
unaffected (0) or affected (1), association between the binary phenotype and SNP (or 
any continuous phenotype) can be tested using logistic regression or contingency 
tables. In comparison to OLS linear regression described above, a logit transformation 
is applied to the outcome variable to convert the binary variable into a continuous 
variable. 
 
Logit(p) = ln (p / 1-p) = c + SNP 
 
Where, 
 ln is the natural logarithm 
 p is the affected proportion 
 1-p is the unaffected proportion 
 
If the explanatory variable is a SNP coded as 0, 1, or 2 with increasing count of the 
minor allele as above, the interpretation of the beta coefficient from this regression is 
the increase in risk for each additional minor allele. The beta coefficient can also be 





Many statistical software packages calculate a pseudo-R2 model-fit statistic that is 
analogous (but not directly comparable) to the OLS regression R2. While R2 can be 
interpreted as the proportion of variance explained by the model, pseudo-R2 is loosely 
interpreted as the proportion of variation in risk liability explained by the model 
(StatCorp, Texas). 
 
Allelic and Genotypic Tests of Association  
Tests of association can be performed on allele or genotype counts. For a biallelic test 
(Table 2.3), the two alleles of the SNP are summed across the affected and unaffected 
groups, compared to their expected counts and a Pearson's 2 statistic is calculated. 
The null hypothesis being tested is no association between the alleles and the 
affection status, it is a one degree of freedom test as degrees of freedom = (number of 
rows−1)(number of colums−1) = (2-1)(2-1) = 1. 
 
The alternative test is a genotypic association (Table 2.4), which works on the same 
principle, the difference being that, rather than alleles, the number of genotypes at a 
single locus are counted for the affected and unaffected groups. As three genotypes 
are possible at a biallelic locus, the degrees of freedom for this test can be two 
(equivalent to testing for additive and dominant terms) or one (equivalent to an 






 B b Total 
Cases Bcases bcases Bcases + bcases 
Controls Bcontrols bcontrols Bcontrols+ bcontrols 
Total Bcases + Bcontrols bcases + bcontrols N 
 
Table 2.3. Allele contingency table. 
 
 bb Bb BB Total 
Cases bbcases Bbcases BBcases bbcases + Bbcases +BBcases 










Table 2.4. Genotype contingency table 
 
The effect of an allele or genotype on a trait is frequently reported as an odds ratio 
(OR); the odds ratio for an allele or genotype can be estimated by the following: 
 
Allele “b” from Table 2.3 for example, 
 
ORb = (bcases x Bcontrols)/(Bcases x bcontrols) 
 
Similarly, the OR for the bb genotype compared to the BB genotype (Table 2.4) is 
 





Classical Twin Modelling 
The first reported epidemiological study of multiple births was by James Matthews 
Duncan. In his book (Duncan, 1865) he discusses amongst other things, the influence 
of maternal age on the frequency of multiple births. The following is a quote from his 
book: 
 
“… twinning to be the result of the act of conception taking place on the rupture of a 
Graafian vesicle fortuitously containing a double ovum or two ova, or on the rupture 
of two Graafian vesicles accidently matured simultaneously” 
 
Two types of twins are usually distinguished – those that arose from a single fertilised 
egg are monozygotic MZ twins and are genetically identical, while those that arose 
from two separately fertilised eggs are DZ twins and share on average half of their 
genetic material. 
 
The classical twin study design compares phenotypic similarity between MZ and DZ 
twins. For phenotypes influenced by genetic factors it is expected that MZ twins will 
show a greater resemblance than DZ twins. Curtis Merriman first described the 
classical twin study design in 1924 with a study of mental abilities in twins (Rende et 
al., 1990). Twin studies, like other family based study designs, aim to demonstrate 
familial clustering of a phenotype, which could be a result of their shared genes 
and/or familial environment. Where twin studies differ from a family design is that, 
with care, they allow the estimation of the genetic and shared environmental 
components that contribute to the observed phenotype. 
 
Assumptions and Limitations 
In order for a twin study to be valid, some key assumptions must be met. The most 
important and perhaps contentious being that to the extent that twins have a shared 
familial environment, MZ and DZ twins, on average, share their environments to the 
same degree. This is known as the equal environments assumption (EEA). This can be 
interpreted as both MZ and DZ twins are exposed to the same (often unknown) 
environmental factors that may contribute to the phenotypic variance. If MZ interact 




that DZ twins experience, then any estimate of the genetic effect on the phenotype 
being studied is likely to be inflated. Conversely, where the opposite is true, i.e. DZ 
twins systematically experience more similar environmental influences than MZ twins 
with respect to a specific phenotype, the genetic contribution will be underestimated. 
 
Violation of the EEA can occur at pre- and post-term – in utero monochorionic, 
monoamniotic MZ twins share the same placenta and amniotic sac. One argument is 
that the co-localisation of both MZ foetuses confers a more similar intrauterine 
environment than the majority of DZ twins, which do not share a placenta. 
Conversely, competition between monochorionic, monoamniotic MZ foetuses for 
resources may drive intrauterine differences such as those experienced in twin–twin 
transfusion syndrome (Fisk et al., 2009). 
 
Differences in environmental interaction between MZ and DZ twin pairs may 
continue from childhood into adulthood, where perceived zygosity may influence 
behaviour and preferences. MZ and DZ twins may have identical or opposite, for 
example, dietary habits and physical activity levels as they or their parents 
(unconsciously) augment or lessen, similarity between them. Another assumption of 
the classical twin study is that the total observed phenotypic variance must be the 
same for MZ and DZ twins. Equal variances for MZ and DZ twins indicates the two 
groups represent a single homogenous group. 
 
Twins are assumed to be representative of the population from which they are 
sampled from, so that inferences made about the relative contributions to the 
phenotype can be generalised. In practical terms, this means for continuous 
phenotypes, such as height or weight, twins and randomly selected individuals from 
the population should have the same means and variances if the sample size collected 
is sufficiently large. Similarly, to make claims about a genetic contribution to a 
disease, the disease prevalence in the twin sample must be the same as in the 
population from which the twins are drawn from. Twin registries must ensure they do 
not have a bias in their recruitment such as advertising solely in hospitals, which 





Based upon the assumptions outlined above, twin studies allow empirical estimation 
of the genetic contribution to a phenotype by comparing concordance between MZ 
and DZ twins. As stated previously, MZ twins are formed by the cleavage of a single 
fertilised zygote into two separate zygotes, therefore are genetically identical, sharing 
additive and dominance variances completely. Whilst DZ twins result from the 
independent fertilisation of two eggs and share, on average, 50% of the alleles at all 




The proportion of dominance variance shared between DZ twins is 0.25, which is the 
conditional probability that both siblings inherit the same maternal and paternal 
alleles at a single locus. If subscripts 1 & 2 represent the observed phenotypic value 
for twin 1 & 2 respectively, the difference in genetic covariance between MZ and DZ 
pairs can be shown as: 
 
CovMZ = (MZ1, MZ2) = VA + VD + VE 
 
CovDZ = (DZ1, DZ2) = 0.5VA + 0.25VD + VE 
 
One way of empirically determining heritability is by structural equation modelling 
(SEM) that estimates variance components to identify a model that best describes the 
observed data. These equations take the general form of phenotypic variance 
decomposition for each twin in a pair: 
 
VP1 = a1VA1 + d1VD1 + c1VC1 + e1VE1 
 
VP2 = a2VA2 + d2VD2 + c2VC2 + e1VE2 
 
These equations show the path coefficients (in lower case) for each variance 
component, the magnitude of these coefficients is not expected to be different 




a1 = a2 = a 
d1 = d2 = d 
c1 = c2 = c 
e1 = e2 = e 
 
With twin data we want to estimate the relative contributions of the latent genetic and 
environmental factors, i.e. a variance components model, not the path coefficients per 
se, so all path coefficients are fixed to 1. The variance components are freely 
estimated with one expected variance-covariance matrix for each model. The variance 
component parameters that generate the best correspondence between the specified 
model and the observed variance-covariance matrix represent the best estimate of the 
true variance component parameters. A SEM equation can be illustrated in the form of 







Figure 2.7. Univariate twin path diagram (Maes et al., 1997). 
Illustrating the partitioning of phenotypic variance into additive genetic (A), dominant 






In the Figure 2.7 path diagram of twin data, latent genetic and environmental factors 
with path coefficients point toward the observed phenotype represented by the 
squared boxes. The unidirectional arrows point causality in that the observed 
standardised phenotype is caused by unobserved genetic and environmental 
components. The double-headed arrows represent the covariance of the latent variance 
components with themselves (thus, the variance of each latent component). 
 
Using tracing rules described by Wright (1934), the total path distance between latent 






  A1 
 
V A    A2 

1




  D1 
 
VD   D2 

1




  C1 
 
VC    C2 

1
  P2 
 
Expected CovMZ = VA + VD + VC 
 




  A1 

0.5VA   A2 

1




  D1 

0.25VD   D2 

1




  C1 
 
VC    C2 

1
  P2 
 
Expected CovDZ = 0.5VA + 0.25VD + VC 
 
The observed covariance matrices are compared to covariance matrices expected from 
the path diagram model. The expected covariance matrices for MZ and DZ twins are: 
 
For MZ twins: 
VP1
MZ (VA1 + VD1 + VC1 + VE1)  
Cov12
MZ (VA12 + VD12 + VC12) VP2







For DZ twins: 
VP1
DZ (0.5VA + 0.25VD + VC2 + VE1)  
Cov12
DZ (0.5VA12 + 0.25VD12 + VC12) VP2
DZ (0.5VA2 + 0.25VD2 + VC2 + VE2) 
 
For twins that are raised together the effects of genetic dominance (VD) and a shared 
environment (VC) and genetic dominance (VD) are confounded and cannot be 
estimated simultaneously (Maes et al., 1997). 
 
When two or more phenotypes are measured for each individual, a multivariate model 
fitting approach can be performed by extending the univariate model to include the 
cross-trait, cross twin and cross-trait within individual covariance terms. The path 
diagram for the model-fitting approach illustrated in Figure 2.8 appears more 







Figure 2.8. A bivariate biometric path diagram. 
This pathway diagram shows all latent sources of phenotypic variance (additive 
genetic [A], common shared environmental [C], and unique environmental [E]) for 
insulin and glucose values measured for pairs of twins (subscripts 1 and 2). Lower 








Linkage disequilibrium (LD) refers to the non-random association of alleles at 
different loci. For example, consider a pair of biallelic loci A and B with alleles A1 
and A2 at locus A and B1 and B2 at locus B. If the product of the individual allele 
frequencies of A1 and B2 is equal to the observed frequency of the co-occurrence of 
the alleles at these loci (X12), i.e. X12 - A1B2 = 0, then the alleles are independent and 
in as state of linkage equilibrium.  
 
Accordingly, when the observed frequency of the co-occurrence of alleles at a pair of 
biallelic loci is not equal to their expected frequency given by the product of 
individual allele frequencies, alleles at the two loci are not independent and this 
disequilibrium is represented by: 
 
D12 = X12 - A1B2 
 
Where, D12 is the difference between the observed frequency co-occurrence of these 
alleles and the product of allele frequencies at both loci. Changes in D reflect changes 
in the non-random association between alleles and/or changes in allele frequencies, 
which is not desirable when comparing different samples. As a solution to this 
problem, Lewontin (1964) suggested adjusting D by observed allele frequencies to 
give a relative measure of D, D’: 
 
D’12 = D12 / Dmax 
 
Where the dominator of this ratio, Dmax, can take one of two values depending on the 
value of D. When D12 is less than 0, Dmax is the minimum value between A1B2 and the 
product of (1-A1)(1-B2): min[A1B2, (1-A1)(1-B2)].  
 
When D12 is greater than 0, Dmax is the minimum value between A1(1-B2) and B2(1-
A1): min[A1(1-B2), B2(1-A1)] 
 
Like D, D’ remains dependent on allele frequencies but is scaled to allow meaningful 




of 1 is interpreted as complete LD, while a value of -1 for D’ indicates the presence of 
a very rare allele for the pair of markers being investigated. 
 
D can also be scaled by the observed allele frequencies at both loci (Hill and 
Robertson, 1968) and the resulting quantity equivalent to the Pearson product-
moment correlation coefficient, r: 
 
r12 = D12 / (A1A2B1B2) 
 
The correlation coefficient inherits the sign of D, which can be removed by replacing 
D with D2,  
 
r2 = D2 / (A1A2B1B2) 
 
The product of the squared correlation coefficient (r2) and the sample size (n) is equal 
to Chi-squared (2) test statistic with one degree of freedom: 2 = r2n for independent 
loci (Hill and Robertson, 1968). In addition, a 2 goodness of fit test could be used to 
test for equilibrium between markers. The expected allele frequencies (p) assuming 
independence can be represented by: 
 
 Locus 1  
A A 
Locus 2 
B pApB pB(1- pA) pB 
b pA(1- pB) (1- pA)(1- pB) 1- pB 
 pA 1- pA  
 
And in the presence of disequilibrium between loci: 
 
 Locus 1  
A A 
Locus 2 B pApB + D pB(1- pA) – D pB 
b pA(1- pB) - D (1- pA)(1- pB) + D 1- pB 







The Pearson’s 2 test is: 
 
2 = (Oi - Ei)2 / Ei2 
 
Where, Oi and Ei are the observed and expected cell counts in the above 2 by 2 
contingency tables. The calculated 2 value is compared to the critical 2 value with 1 
degree of freedom for a given level of significance. 
 
Ultimately recombination between loci is the main driver of breakdown in LD (figure 
1), the frequency of recombination between loci that are in close proximity is low, 
consequently it is expected that the greater the distance between loci the greater the 
frequency of recombination. The recombination fraction () represents the proportion 
of recombination events between two loci, and so defines genetic distances whereby a 
1% recombination frequency between loci equals 1 centiMorgan (cM) on a genetic 
map, which unlike physical distances, are not additive. 
 
The rate of LD decay over t generations depends on the recombination frequency 
(Figure 2.10) and its magnitude is diminished by a factor of (1 - )t in each generation 
(Hedrick, 1987). After t generations the LD that remains is: 
 
Dt = (1 - )t D0 
 
Where, Dt is the LD after t generations,  is the recombination fraction, D0 is the LD 






Figure 2.9. Decay of LD with increasing genetic and physical distance (Palmer 










  = D / Q(1-R) 
 
Where, D is the difference between observed frequency for a pair of loci and that 
frequency expected from the product of their individual frequencies. Q and R are the 
frequencies of the common and rarest alleles for a pair of biallelic loci respectively, 
which can be illustrated by a 2 by 2 table (Table 2.5). 
 
 
Table 2.5. Frequencies of a pair of biallelic loci (Kuo et al., 2007). 
Cells a-d are haplotype frequencies for all combinations for a pair of biallelic SNPs. 
The table is rearranged so the Q is less than (1-Q, R, 1-R) and the product of 
haplotype frequency of a+d is greater than b+c. 
 




SNP 1 1 a b a + b Q 
2 c d c + d 1-Q 
Column Total a + c b + d 
 




Collins and Morton (1998) use the Malécot model of isolation by distance (Malécot, 
1970) to obtain the expected association (

ˆ ) between loci: 
 

ˆ = (1 –L)M exp( - i di) 
 
Where, 
L reflects residual LD at large distance not due to linkage,  
M is the proportion for which the youngest haplotype is monophyletic,  
 is the exponential decline with distance d between a pair of loci.  
 
The parameter, , is calculated by considering all pair-wise SNP associations in a 
region of ordered SNPs. The association between the first and second SNPs is the 
most informative and so has the largest weighting, the association between the first 
and third SNPs will have the second largest weighting (Tapper, 2007). The term i di 
give an additive measure of LD for each SNP, and used for the construction of LD 
maps (Maniatis et al., 2002). Parameters ε, M, and L are not known but are estimated 
by maximising the composite likelihood based on the observed association probability 





Chapter 3: The Relationship Between DXA-based and 






Excess accumulation of visceral fat is a prominent risk factor for cardiovascular and 
metabolic morbidity. While CT is the gold standard to measure visceral adiposity, this 
is often not possible for epidemiological studies - thus proxy measures of visceral fat 
are required. Study aims were to a) identify a valid proxy measure of VAT area, b) 
estimate VAT heritability and c) assess visceral fat association with morbidity in 
comparison to body fat distribution. A validation sample of 54 females measured for 
detailed body fat composition - assessed using CT, DXA, and anthropometry – was 
used to evaluate previously published predictive models of CT-measured visceral fat. 
Based upon a validated model, we realised an estimate of abdominal VAT area for a 
population-based sample of 3,457 female volunteer twins and estimated VAT area 
heritability using a classical twin study design. Regression and residuals analyses 
were used to assess the relationship between adiposity and morbidity. 
 
Published models applied to the validation sample explained >80% of the variance in 
CT-measured visceral fat. Narrow sense VAT area heritability was estimated to be 
58% (95% CI: 51-66%) with a shared familial component of 24% (17-30%). VAT 
area is strongly associated with T2D, hypertension (HT), subclinical atherosclerosis 
and liver function tests. In particular, VAT area is associated with T2D, HT and 
alanine aminotransaminase liver function, conditional upon association with DXA 
total abdominal fat and BMI. DXA and anthropometry measures can be used to derive 
reliable estimates of visceral fat. Visceral fat is heritable and appears to mediate 
association between adiposity and morbidity. This observation is consistent with 
hypotheses that suggest excess visceral adiposity is causally related to cardiovascular 






For the purpose of work presented in the subsequent chapter, it is important to 
identify the measure of adiposity that bears the strongest relationship with T2D. 
Mitochondrial dysfunction and their loss in adipocytes through lipid overload may 
drive excess lipid storage toward insulin resistance (Kusminski and Scherer, 2012), 
however, the focus of this Chapter is to identify a measure of adiposity to act as an 
intermediate phenotype for T2D. 
 
Body fat distribution, particularly abdominal adiposity, is strongly associated with a 
range of chronic metabolic and cardiovascular morbidities. The abdomen includes 
depots of both subcutaneous and visceral adipose tissue, which are distinct tissues that 
exhibit different gene expression (Palou et al., 2009), endocrinological profiles 
(Bastard et al., 2008) and pathogenicity (Kim et al., 2007). The detrimental effect of 
excess fat accumulation is contingent on body fat distribution. It has been shown that 
the diabetic phenotype of the leptin knock out obese mice can be rescued by shifting 
fat storage away from the viscera and into the subcutaneous depot (Kim et al., 2007). 
The high ratio of subcutaneous to visceral fat in this mouse model is in contrast to the 
familial partial forms of lipodystrophy observed in humans, a pathology characterised 
by a redistribution of adipose tissue to the intra-abdominal region, giving rise to 
severe metabolic abnormalities. These extreme cases illustrate the potent effect that 
adipose distribution can have upon health (Mantzoros et al., 2011, Savage et al., 
2010) and the role of visceral fat accumulation in the aetiology of cardiovascular and 
metabolic disease. 
 
Adiposity can be measured with a variety of techniques such as DXA, CT, and 
magnetic resonance imaging (MRI). In whole body composition analysis, CT is 
regarded as the gold standard and as such has been used extensively as a benchmark 
for the quantitative assessment of subcutaneous and visceral adiposity. There is a 
continued effort to identify informative adiposity measures that are easily acquired 
and show robust correlation with CT-measured visceral fat content (Bertin et al., 





Family and twin studies can be used to estimate the heritability (the proportion of trait 
variance explained by genetic factors) and the relative importance of genetic and 
shared environmental factors in influencing phenotypic variance, by contrasting trait 
covariance between relatives with degree of relatedness. Establishing the heritable 
basis of a trait is also an important consideration prior to gene mapping studies 
(Andrew et al., 2006). 
 
The aims of this study are to 1) identify and estimate a valid DXA and/or 
anthropometric based measure of visceral fat, 2) to estimate the heritability of visceral 
fat accumulation and 3) to assess whether association between body composition 
measures of adiposity and morbidities can be fully explained by the mediation 
through visceral fat. We hypothesise that if visceral fat is casually related to 
morbidity, we would expect visceral fat to remain associated with morbidity 





Materials and Methods 
Subjects and Data Collection 
Background information for the subjects used in this study is presented in Chapter 2 
(TwinsUK sample). While the twins are largely representative of the age-matched UK 
female population (Andrew et al., 2001), our findings relating to adiposity are 
restricted to Caucasian women over 40 years old. The validation sample comprised 54 
female individuals over the age of 40 years with both CT and DXA data, but was 
otherwise unselected. Previously reported linear regression models (Treuth et al., 
1995, Snijder et al., 2002, Hill et al., 2007) and adiposity indices (Bertin et al., 2000) 
were assessed for this sample to identify the most predictive combination of DXA 
abdominal fat and anthropometry measures required to estimate visceral fat. A 
validated best-fit model was used to estimate abdominal visceral fat for a study 
sample of 3,457 individuals (533 MZ twin pairs, 1,102 DZ twin pairs, 187 




Full details of the CT scans are described in Chapter 2 (TwinsUK sample). The body 
cavity CSA was obtained by tracing the outer contour of the abdominal wall and 
adipose tissue within this area was identified as having an attenuation value between -
190 and -30 Hounsfield units (Yoshizumi et al., 1999). For the 54 subjects with CT 
and DXA scan data (referred to as the “validation sample”), visceral fat was directly 
measured as a pixel count using CT single slice area (VAT area). VAT area was 
defined as (visceral pixel count / total body cavity pixel count) x CSA. Single slice 




Full details for DXA scan are described in Chapter 2 (TwinsUK sample). A total of 
3,457 DXA scans were available for this study (referred to as the “study sample”). 
The region of interest for body composition analysis was manually defined in a 




upper horizontal border located at the lowest rib and a lower border determined by the 
external end of iliac crests, but the lateral borders were delineated by the inner body 
wall rather than the body wall. DXA fat mass from this abdominal region was 
recorded and abdominal transverse internal and external diameters were measured as 
described by Bertin et al. (2000). 
 
Anthropometry 
Anthropometric measurements for both the validation and study samples were height, 
weight, and BMI. Where anthropometric measurements were unavailable for the 
validation sample they were measured directly from the CT scans and are regarded as 
anthropometric. Sagittal depth, body cavity, subcutaneous fat and total abdominal fat 
cross sectional areas, transverse internal and external diameters (TID and TED 
respectively), subcutaneous fat width (SFW), and waist circumference were measured 
using CT scans. Skin fold was estimated using the formula SFW = (TED – TID)/2 
(Bertin et al., 2000) as calliper skin fold measure was not taken for this study. The 
validation sample were also measured for TED and TID (with SFW derived) using 
DXA software to draw a horizontal line on the DXA image at the upper most point of 
the iliac crest, which was converted from pixel to mm length by multiplying by a 
constant of 2.048 (DXA software support, Vertec Scientific Limited). 
 
T2D 
Subjects were identified as type 2 diabetic if they were classified as hyperglycaemic 
for one or more of the following diagnostics: fasting glucose serum concentration > 7 
mmol/L, fasting oral glucose tolerance test > 11.1 mmol/L or glycosylated 
haemoglobin > 6.5% (48 mmol/mol). Questionnaire data on physician diagnosis and 
medication was also used to identify self-reported cases of T2D. Fasting plasma 
glucose was measured by enzymatic colorimetric slide assay (Johnson and Johnson 
Clinical Diagnostic Systems, Amersham UK). 
 
Hypertension 
Blood pressure was measured twice using an automatic blood pressure monitor 




hypertension (HT), if currently receiving anti-hypertensive medication and/or the 
repeated systolic/diastolic blood pressure was greater than 140/90 mm Hg. 
 
Carotid Intima-Media Thickness 
Carotid intima-media thickness (cIMT) was measured as previously described by 
Cecelja et al. (2010) and the quantitative trait was dichotomised at the 75th percentile 
as a surrogate for subclinical atherosclerosis (Stein et al., 2008, Benzaquen and 
Nguyen-Thanh, 2009). In brief, the left and right carotid and femoral arteries were 
visualized with B-mode ultrasound (Siemens CV70, Siemens, Erlangen, Germany, 
with 13-MHz vascular probe). Common cIMT was measured in the near and far 
walls, 1 to 2 cm proximal to the carotid bifurcation with automated wall-tracking 
software (Medical Imaging Applications, Coralville, Iowa) during diastole in an area 
free of overt plaque. Mean values of cIMT in the near and far walls of both arteries 
were used for analysis. 
 
Liver Function Tests 
Data on liver function test (LFT) proteins were available for a sub-sample of subjects 
(Rahmioglu et al., 2009). Abnormal liver function as assessed by LFTs can be used to 
assist diagnosis of non-alcoholic fatty liver disease (Armstrong et al., 2012). Serum 
concentrations of alanine aminotransaminase (ALT), alkaline phosphatase (ALK), 
total bilirubin (BIL) and gamma glutamyl transpeptidase (GGT) were used in this 
study as markers of liver function. Of the four tests, ALT is the most sensitive marker 
for liver cell damage (as a consequence of disease or drug use), while ALK and GGT 
are more indicative of cholestatic injury and BIL, haem catabolism (Aragon and 
Younossi, 2010, Burke, 2002). The upper limit of normal threshold used for each 
protein were: ALT: 39.4 IU/L (Kariv et al., 2006), ALK: 81 IU/L (taken as the 75% 
(Lazo et al., 2008), GGT: 33 
IU/L (Sabanayagam et al., 2009).  
 
Model Validation 
Multiple regression analyses (Treuth et al., 1995, Snijder et al., 2002, Hill et al., 
2007) and indices of adiposity were assessed (Bertin et al., 2000) to address two 




adiposity and a range of anthropometric measures: 1) which of these predictive 
models for the “gold standard” CT measure of visceral fat, best fit our validation 
sample of 54 females; and 2) in relation to previous discussions (Bertin et al., 2000), 
can visceral fat be reliably estimated based upon anthropometry alone. CT and DXA 
scans for the same individuals were date-matched to between 0.23 - 2.5 years of one 
another. The difference in scan date for the validation sample was included in all 
visceral fat regression models as a nuisance factor. A Bland-Altman analysis was 
conducted to assess if the predicted VAT error term was constant or varied across the 
range of CT-measured VAT area. 
 
Heritability Analysis 
The classical twin model was used to estimate the relative influence of genetic and 
environmental factors upon individual variation about the visceral fat sample mean 
(Martin et al., 1997). Using variance components analysis, the total phenotypic 
variance was partitioned into estimates of the additive (A), dominant (D) genetic and 
shared familial (common; C) and unique to the individual (E) environmental (and 
measurement error) components using genetically informative data. The model 
assumes no epistasis, gene-environment correlation or interactions and that shared 
environmental factors are not confounded by zygosity (the equal environments 
assumption). Provided these assumptions hold, on the basis that MZ twins share 
identical genes and DZ twins share, on average, half their segregating genes, twin data 
can be used to infer heritability and shared familial estimates. Mx (Neale et al., 1992) 
was used for all heritability analyses. 
 
In addition to the univariate heritability analysis, we also conducted a bivariate 
variance components analysis between the realised estimate of VAT area and total 
abdominal fat as an indirect means to further validate the proxy measure of VAT area. 
Bivariate analysis facilitates a test of genetic correlation between two variables, but 
also whether each variable has a specific genetic component that is not shared by the 
two traits. We used the specific test to assess if there was evidence for a genetic 
component that is unique to VAT area and not shared with DXA total abdominal fat 





Morbidity Association with Adiposity  
T2D, hypertension and liver function were associated with the different measures of 
adiposity, age and other confounding variables using logistic regression. Incident 
subclinical atherosclerosis (cIMT) was modelled using Cox regression and baseline 
measures of visceral fat taken on average 10 years (range 5 - 16 years) previously. 
Since there was no baseline examination of cIMT, we could not exclude the small 
proportion of individuals who may have already developed pre-clinical 
atherosclerosis at baseline. To the extent this was true, the study design for these 
individuals would have been cross-sectional rather prospective.  
 
LFTs were performed using blood samples collected at the same visit as the DXA 
scan. The mean, standard deviation and median were all examined to identify 
potential batch effects across years, but no obvious trend was identified. Therefore the 
year of visit was categorised as quintiles and included in all analyses as a categorical 
confounding variable. 
 
Co-linearity between the explanatory measures of VAT area, DXA total abdominal 
fat, BMI and age was assessed using pair-wise correlations and residuals analysis 
(David Clayton, 1993, O'Brien, 2007). A variance inflation factor (VIF) was 
calculated for these data, with a score of > 10 sometimes used as a (conservative) 
threshold indicator for potentially problematic co-linearity between model 
explanatory variables (O'Brien, 2007). To assess consistency of results, the multiple 
regression analyses were repeated using random subgroups of data and using 
quantitative traits for all subjects, where morbidity had been defined using a 
quantitative trait threshold (i.e. systolic and diastolic blood pressure and LFTs). 
 
Parsimonious best-fit multiple regression models for morbidity were identified by a) 
using a likelihood ratio test (LRT) to assess the contribution of each explanatory 
variable to the full model; b) assessing model fit using pseudo-R2 for T2D, HT and 
LFTs and the Wald statistic for incident cIMT, and c) the implementation of a linear 
residuals analyses (David Clayton, 1993) to assess whether adiposity measures are 
independent of morbidity when conditioned upon on visceral fat. For example, to 
assess if VAT completely mediates the association between BMI and T2D, secondary 




ordinary least squares residuals for BMI, both with respect to VAT area and age. 
Ordinary least squares (OLS) residuals for DXA total abdominal fat were also taken 
with respect to VAT area and age. The secondary residuals analysis then involved the 
linear OLS regression of T2D upon BMI residuals and DXA residuals. No evidence 
of association between residuals would imply that BMI/DXA association with 
morbidity is primarily mediated via VAT area, while a significant residual association 
demonstrates either that BMI/DXA are associated with morbidity through a path not 
mediated by VAT area, or that the parametric assumptions of the association models 
are false. 
 
Unadjusted and adjusted OR results are presented in the results for VAT area (cm2), 
DXA total abdominal fat (kg) and BMI (kg/m2). To facilitate comparison between the 
different adiposity units, all adiposities were standardised for the regression analyses. 
Robust standard errors were estimated by grouping twin pairs using the cluster option 
in Stata to account for intra-family relatedness. All statistical analyses were performed 
using Stata version 11.1 (StatCorp, Texas). The VIF and residuals analyses were 
performed by Dr Toby Andrew, full analyses are presented for T2D (Supplementary 






Estimation of Visceral Fat (Validation Sample) 
Descriptive statistics for anthropometric and body composition for the validation and 
study samples are presented in Table 3.1. All subjects were female and over 40 years 
old at examination. The mean height, weight, BMI and DXA abdominal fat do not 
statistically differ between the two samples, although the mean age for the validation 
sample was six years older (p-value = 6.5x10-11) with a larger waist circumference (p-
value = 2.05x10-6) than the study sample. The study sample prevalence and 95% 
confidence interval for morbidity related to the quantitative traits presented in Table 
3.1 were as follows: T2D 0.046 (0.04-0.05), HT 0.08 (0.07-0.09), cIMT 0.27 (0.24-






  Validation sample (n = 54) Study sample (n = 3457) 
  Mean SD Min. Max. Mean SD Min. Max. 
Age (years) 60.4 6.1 49.3 72.8 54.2 8.3 40.0 79.5 
Weight (kg) 65.7 9.4 48.4 87.4 66.6 11.8 35.6 139.5 




88.0 9.9 66.6 111.2 81.0 11.0 55.0 134.0 
Sagittal depth 
(cm) 
21.8 3.2 15.9 31.1 - - - - 
Scan difference 
(years) 
1.3 0.8 0.2 2.5 - - - - 
BMI (kg/m2) 25.1 3.8 19.2 33.8 25.6 4.5 15.1 51.7 
Total abdominal 
fat (kg) 
1.4 0.62 0.24 3.08 1.44 0.61 0.14 3.94 
VAT area (cm2) 127.8 52.1 37.7 279.5 144.6 49.6 37.7 347.4 
Diastolic BP 
(mmHG) 
77.3 8.3 61.0 95.5 75.9 8.9 47.5 108.0 
Systolic BP 
(mmHG) 
122.0 11.5 92.0 151.0 123.1 14.7 86.5 189.0 
cIMT 0.68 0.08 0.53 0.82 0.67 0.11 0.30 1.11 
ALT 23.9 11.8 3.0 68.0 26.7 11.4 2.5 217.3 
ALK 64.8 19.0 26.0 114.0 71.2 18.2 23.5 218.9 
BIL 9.5 3.7 5.7 23.5 8.7 3.0 1.0 30.5 
GGT 30.3 17.4 12.0 65.3 27.9 21.7 3.0 359.0 
 
Table 3.1. Validation and study sample characteristics. 
Age, weight, height, body fat distribution and intermediate quantitative traits used to 
define clinical morbidity. Waist circumference for the validation sample is based upon 
the transverse circumference of CT body scan image at the waist, while the study 
sample is a tape measurement taken at the same time as the DXA scan. Abbreviations: 
ALT – alanine aminotransaminase, ALK - alkaline phosphatase, BIL – bilirubin, BP – 
blood pressure, cIMT – carotid intima-media thickness, GGT - gamma glutamyl 






The Pearson product moment correlation coefficients (r) between the different 
adiposity measures and CT-measured VAT area for the validation sample are 
presented in Table 3.2. CT-measured VAT area was most strongly correlated with 
CT-measured body cavity cross sectional area (r = 0.85), sagittal depth (r = 0.84) and 
tape-measured waist circumference (r = 0.86) and DXA total abdominal fat (r = 0.79). 
Consistent with these data, is the observation that reported models of visceral fat in 
the literature, whether linear regressions or derived anthropometric indices, all attempt 
to capture information about the body cavity volume (or area) in relation to the 
subcutaneous volume (Treuth et al., 1995, Bertin et al., 2000, Snijder et al., 2002, Hill 
et al., 2007). This insight was used to guide the choice of linear regression to estimate 













SD WC TID TED SFW DXA BMI 
BC 0.85           
Sub. 
CSA 
0.58 0.44          
Total 
CSA 
0.81 0.80 0.90         
SD 0.84 0.80 0.84 0.96        
WC 0.86 0.77 0.83 0.94 0.94       
TID 0.66 0.72 0.46 0.67 0.61 0.65      
TED 0.66 0.56 0.89 0.87 0.82 0.85 0.62     
SFW 0.43 0.26 0.83 0.69 0.66 0.67 0.17 0.88    
DXA 0.79 0.56 0.68 0.74 0.76 0.77 0.56 0.75 0.60   
BMI 0.71 0.60 0.80 0.84 0.83 0.82 0.57 0.85 0.72 0.79  
Weight 0.67 0.64 0.77 0.84 0.76 0.81 0.69 0.88 0.68 0.69 0.86 
 
Table 3.2. Validation sample (n = 54) correlation coefficients between computed 
tomography visceral adipose tissue (VAT) area, anthropometric and abdominal 
fat measures. 
All measures presented here are based upon CT scan images apart from DXA total 
abdominal fat, BMI and weight. Abbreviations and units: BC - body cavity area 
(cm2), BMI - body mass index (kg/m2), CSA – body cross-sectional area (cm2) at 
L4:L5, DXA – DXA-measured total abdominal fat (kg), SD - sagittal depth (cm), 
Sub.CSA – subcutaneous cross sectional area, SFW - subcutaneous fat width (cm), 
TED - transverse external diameter (cm), TID - transverse internal diameter (cm), 
VAT area - visceral adipose tissue area (cm2), WC – waist circumference (cm) 





Table 3.3 presents the results for three previously reported DXA-based regression 
models and anthropometric indices for estimating visceral fat, applied to the 
TwinsUK CT validation sample. The best-replicated regression models included 
DXA trunk fat and sagittal depth (R2 ≈ 0.8), while a combination of DXA and skin 
fold was less predictive of visceral fat. The best individual indices were functions of 
sagittal depth (SD), SFW, TID and TED (r > 0.85 or r2 > 0.72). Moreover, the most 
reproducible indices of visceral fat all relate to body cavity CSA. By assuming body 
cavity CSA takes the form of an ellipse, this was calculated as BC CSA = π x (SD – 











Snijder et al. 
(2002) 
DXA trunk fat + sagittal depth 0.74 0.80 
DXA trunk fat + abdominal 
circumference 
0.71 0.78 
    
Treuth et al. 
(1995) 
Sagittal depth + age + waist 
circumference + % DXA trunk fat 
0.81 0.79 
    
Hill et al. 
(2007) 
DXA + skin fold 0.68 0.65 




















Abdominal fat mass (kg) 0.57 0.79 
Thigh fat mas (kg) 0.06* - 
Abdominal fat mass / thigh fat mass 0.75 - 
Abdominal fat mass / SFW 0.83 0.58 
TED (cm) 0.54 0.61 
TID (cm) 0.9 0.61 
SFW (cm) -0.23* 0.28 
(SD)(TID) 0.89 0.87 
(SD)(TID) / height 0.91 0.86 
(SD)(TID) / BMI 0.66 0.49 
(SD-SFW) 0.86 0.89 
(SD-SFW)(TID) 0.92 0.79 
(SD-SFW)(TID) / height 0.94 0.87 
 
Table 3.3. Visceral adipose tissue (VAT) area linear model estimates and 
correlational indices. 
Previously reported models in the literature were applied to the TwinsUK validation 
sample of CT-measured VAT area (n=54) and the coefficient of determination (R2) is 
presented for each study as an indication of the proportion of VAT variance explained 
by the model (A). The Pearson product-moment correlation coefficients between CT-
measured VAT area and adiposity indices described in Bertin et al. (2000) were also 
calculated for the TwinsUK validation sample (B). Asterisks in B indicate the 
reported correlation coefficient does not differ significantly from zero (at significance 
threshold = 0.05). Abbreviations: DXA - dual-energy X-ray absorptiometry, SD - 
sagittal depth, SFW - subcutaneous fat width, TED - transverse external diameter, 





In modelling CT-measured VAT area, the best fit and most interpretable model 
included a combination of measures for DXA abdominal fat, body cavity cross 
sectional area (estimated using the ellipse formula above) and waist circumference 
(Table 3.4, Model 0), which together explained 91% of the variance in CT-measured 
VAT area (R2 = 0.91). However, since sagittal depth was not available for the study 
sample for which we wished to estimate VAT area, we also assessed a model 
including only DXA total abdominal fat, tape-measured waist circumference and age. 
This model obtained an R2 of 0.83 (Table 3.4, Model 1) and is described by the 
following linear regression equation using standardised explanatory variables and no 
intercept term:  
 
VAT area = 10.1(DXA abdominal fat mass, kg) + 40.8(waist circumference, cm) + 
1.4(age, years) 
 
For this estimate, a Bland-Altman analysis showed no evidence of heteroscedascity 
across the full range of CT-measured VAT area, with only 2 out of 54 (3.7%) values 
outside the 95% limits of agreement (the mean difference ± twice the standard 
deviation of the difference between the two measures). Model 1 was selected for 












(A) Model 0  0.91 
Combination of DXA & 
anthropometric measures 
DXA abdominal fat 20.07 3.39 5.9 2x10-9 13.2 27.0  
BC CSA 32.44 4.52 7.2 4x10-13 23.2 41.6  
WC 11.07 5.57 2.0 2x10-2 -0.3 22.4  
 
(B) Model 1 0.83 
Combination of DXA & 
anthropometric measures 
DXA abdominal fat 10.1 4.82 2.1 0.04 0.31 19.9  
WC 40.8 5.68 7.2 3x10-13 29.2 52.3  
Age 1.4 0.52 2.6 0.01 0.32 2.44  
 
(C) Model 2  0.86 
Anthropometric measures only 
BC CSA 25.5 5.58 4.57 2x10-6 14.1 36.8  
WC 30.5 5.46 5.59 1x10-8 19.4 41.6  
 
 
Table 3.4. Linear regression models for computed tomography (CT) visceral adipose tissue (VAT) area using the validation sample (n = 
54). 
(A) Model 0: combination of DXA and anthropometric measures guided by previously published models presented in Table 3.3A. (B) Model 1: 
combination of DXA and anthropometric measures restricted to DXA total abdominal fat, WC and age that were also available for the study 
sample. (C) Model 2: using anthropometric measures only. BC CSA was estimated using BC = (π x [SD–2SFW] x TID) from the CT images at 
intervertebral disc L4:L5 as described in Chapter 2 (TwinsUK sample). Note that for Model 2, using these explanatory variables instead of BC 
CSA, yields equally good or better prediction of VAT area (R2 = 0.89), but the model is less interpretable with a negative beta coefficient for 
SFW. Abbreviations: BC - body cavity, CSA - cross sectional area, DXA - dual-energy X-ray absorptiometry, SD - sagittal depth, SFW - 






In relation to efforts attempting to estimate visceral fat using only anthropometric 
measures (Bertin et al., 2000, Karelis et al., 2012), we also obtained a highly 
explanatory model (R2 = 0.86) with a linear equation using only two CT measures of 
body cavity CSA (estimated as an ellipse) and waist circumference (Table 3.4, Model 
2). This figure rose to R2 = 0.89 using body cavity components SD, SFW and WC as 
explanatory variables for CT VAT area (data not shown). Body cavity CSA results 
are presented, as this model is more interpretable, while the model including SD, 
SFW and WC yields a negative beta coefficient for SFW due to co-linearity. Again, 
these simple anthropometric models could not be used for the study sample because 
SD was not recorded. 
 
In addition to these validation models, we indirectly assessed the validity of our study 
sample estimates of visceral fat by making two observations: 
 
1. Realised estimates of VAT area (VATModel1 and VATModel2) for the validation 
sample were equally or more strongly correlated with VATCT (r = 0.89 and r = 
0.93) than DXA total abdominal fat (r = 0.88 and r = 0.70); 
 
2. Bivariate variance component analysis between VATModel1 and DXA total 
abdominal fat provided strong statistical evidence (∆χ21= 43.7, p = 4x10-11) for 
a specific heritable component that was unique to VATModel1 and not shared 
with DXA total abdominal (data not shown). 
 
Heritability 
The data provided a narrow sense heritability estimate (A) of 0.58 (95% CI: 0.51-
0.66) and a familial environmental effect of 0.24 (95% CI: 0.17-0.30) for VAT area 
(Table 3.5), with the best fit to the data being the ACE model, including additive 





Model -2 LL df AIC Δdf Δχ2 p - value Component h2 95% CI 
ACE 51399.9 4737 41925.9 - - - 
A 0.58 (0.51-0.66) 
C 0.24 (0.17-0.30) 
E 0.18 (0.16-0.20) 
 
AE 51438.7 4738 41962.7 1 39 4.7x10-10 
A 0.83 (0.81-0.84) 
C - - 
E 0.18 (0.16-0.19) 
 
CE 51608.4 4738 42132.4 1 209 2.9x10-47 
A - - 
C 0.62 (0.59-0.64) 
E 0.38 (0.36-0.41) 
 
Table 3.5. Visceral adipose tissue (VAT) area estimate of heritability (h2) and model fit statistics (n = 3,457). 
Full (ACE) and nested (AE and CE) model estimates are presented. Nested models test the hypothesis that the estimated additive polygenic 
genetic variance component (model CE) and the shared familial environmental component (model AE) do not contribute to the observed 
phenotypic variance. The full ACE model is highlighted as best-fit, since the more parsimonious nested models do not fit the data as well (p ≤ 
0.05). The model with the lowest AIC fit statistic also indicates best model fit. Abbreviations: -2 LL: minus twice the log-likelihood; AIC: 
Akaike’s Information Criterion; ∆χ2: likelihood ratio χ square statistic; A – additive polygenic variance component, C – common familial 






Visceral Fat as a Risk Factor of Morbidity (Study Sample) 
The correlation between study sample explanatory variables is presented in 
Supplementary Table 3.1. As a function of these variables, VAT area is most strongly 
correlated with waist circumference and DXA total abdominal fat. While the 
univariate odd ratios for VAT area, DXA abdominal fat and BMI were all 
significantly associated with each morbidity (Tables 3.6-3.9), VAT area was most 
consistently and strongly associated with four morbidity traits of T2D, HT, cIMT and 
ALT. 
 
For T2D, while the univariate ORs for the 3 adiposity measures were all associated 
(Table 3.6A), visceral fat and age provided the best-fit multiple regression model 
(pseudo-R2 = 0.08, Table 3.6B and LRT, Supplementary Table 3.2), with an adjusted 
OR of 2.08 (95% CI 1.76 – 2.47) per standard deviation increment in VAT area 
including age. Removing VAT area from the full model resulted in a significant 
decline in model fit (LRT χ21 = 14.4, p-value = 1x10-4), while the removal of DXA 
total abdominal fat and BMI, either individually or together (χ22 = 1.9, p-value = 0.39) 
did not reduce the model fit (Supplementary Table 3.2). Residuals analysis, to assess 
model co-linearity, indicated VAT area mediated the association between T2D and 
adiposity (Supplementary Table 3.3). No residual association between T2D and DXA 
and BMI were observed when the residuals for VAT area and age were used (p-value 
= 0.38), while strong evidence for association between T2D and VAT area remained, 













VAT area 2.17 0.18 9.5 <2x10-16 1.85 2.54 0.07 
DXA 
abdominal fat 
1.86 0.13 8.6 <2x10-16 1.61 2.14 0.05 
BMI 1.66 0.12 7.2 2x10-13 1.45 1.91 0.04 
Age 1.05 0.01 4.3 8x10-6 1.03 1.07 0.02 
B 
VAT area 2.08 0.18 8.5 <2x10-16 1.76 2.47 
0.08 
Age 1.02 0.01 2.0 0.05 1.00 1.05 
 
Table 3.6. Type 2 diabetes and adiposity. 
The study sample prevalence (females > 40 years) estimate for T2D of 5%. (A) 
Logistic regression (n = 2,964) presenting unadjusted OR for each adiposity measure 
and (B) best-fit multiple regression model. For evidence of the presented best-fit 
model and an analysis of residuals to account for co-linearity between adiposity 
variables, see Supplementary Tables 3.1 and 3.2, respectively. Explanatory variables 
VAT area, DXA and BMI are all standardised, implying a change in odds ratio per 
unit SD change. Abbreviations: BMI - body mass index, CI - confidence interval, 
DXA - dual-energy X-ray absorptiometry, OR - odds ratio, SE - standard error, VAT - 





Hypertension was equally strongly associated with VAT area, DXA abdominal fat 
and BMI for univariate analyses (Table 3.7A), but visceral fat and age provided the 
best-fit multiple regression model (pseudo-R2 = 0.10, Table 3.7B), with an adjusted 
OR of 1.90 (95% CI 1.60 – 2.25) per standard deviation increment in VAT area 
including age. Removing VAT area from the full model resulted in a nominal decline 
in model fit (LRT χ21 = 7.1, p-value = 0.01), whilst the removal of DXA total 
abdominal fat and BMI, either individually or together (χ22 = 1.99, p-value = 0.37) did 
not reduce the model fit. Residuals analysis indicated VAT area mediated the 
association with HT, with no residual association between HT and DXA and BMI 
observed when the residuals for VAT area and age were used (p-value = 0.23), while 
strong evidence for association between T2D and VAT area remained, when residuals 














VAT area 2.08 0.16 9.5 <2x10-16 1.79 2.42 0.08 
DXA 
abdominal fat 
1.77 0.14 7.4 6 x10-14 1.53 2.07 0.05 
BMI 1.77 0.13 7.7 6 x10-15 1.53 2.05 0.06 
Age 1.07 0.01 6.4 6 x10-11 1.05 1.09 0.05 
B 
VAT area 1.90 0.17 7.4 9 x10-14 1.60 2.25 
0.10 
Age 1.04 0.01 4.0 4 x10-5 1.02 1.07 
 
Table 3.7. Hypertension and adiposity. 
The study sample prevalence estimate (females > 40 years) for hypertension of 8%. 
(A) Logistic regressions (n = 2,032) showing unadjusted OR for each adiposity 
measure and (B) best fit multiple regression model. For evidence of the presented 
best-fit model and an analysis of residuals to account for co-linearity between 
adiposity variables, see Supplementary Tables 3.3 and 3.4, respectively. Explanatory 
variables VAT area, DXA and BMI are all standardised, implying a change in odds 
ratio per unit SD change. Year of visit was categorised as quintiles and included in all 
HT analyses as a categorical confounding variable. Abbreviations: BMI - body mass 
index, CI - confidence interval, DXA - dual-energy X-ray absorptiometry, OR - odds 





The prospective analysis of subclinical atherosclerosis had a median follow up time of 
9.7 years, during which a total of 221 (27%) individuals were classified as sub-
clinically atherosclerotic. Univariate Cox proportional hazard models showed all three 
measures of adiposity and age at baseline to be associated with incident cIMT (Table 
3.8A), with VAT area (χ21 = 43.8) and age (χ21 = 40) providing the best-fit 
parsimonious model (Table 3.8B). DXA and BMI could be dropped from the full 
model with no nominal (χ22 = 5.7, p-value = 0.06) deterioration in model fit. 
Residuals analysis indicated VAT area mediated the association with cIMT, with no 
residual association between cIMT and DXA and BMI observed when the residuals 
for VAT area and age were used (p-value = 0.19), while strong evidence for 
association between cIMT and VAT area remains, when residuals for DXA and BMI 
were used (p-value < 5x10-4). Both VAT area and BMI better predicted cIMT than 














Model Fit (Wald) 
χ2 df  p-value 
A 
VAT area 1.50 0.09 6.6 2x10-11 1.33 1.69 43.8 1 4x10-11 
DXA abdominal fat 1.29 0.07 4.5 4x10-6 1.16 1.45 20.0 1 8x10-6 
BMI 1.39 0.08 5.5 2x10-8 1.23 1.55 30.5 1 3x10-8 
Age 1.08 0.01 6.3 1x10-10 1.05 1.10 40.0 1 3x10-10 
B 
VAT area 1.36 0.095 4.4 5x10-6 1.19 1.56 
59.6 2 1x10-13 
Age 1.06 0.013 5.0 3x10-7 1.04 1.09 
 
Table 3.8. Sub-clinical atherosclerosis and adiposity. 
(A) Cox proportional hazards regression (n = 801) showing unadjusted HR for each adiposity measure and (B) best fit multiple regression 
model. The study sample prevalence estimate (females > 40 years) for sub-clinical atherosclerosis at follow-up was 0.27 (average time from 
baseline to follow-up was 9.95 years, range 5 - 16 years). Explanatory variables VAT area, DXA and BMI are all standardised, implying a 
change in hazard ratio per unit standard deviation change. For Cox proportional hazards, the Wald model-fit statistic is presented to indicate the 
best model fit (StataCorp, Texas) that predicts onset of sub-clinical atherosclerosis (carotid intima-media thickness, cIMT). Abbreviations: BMI 






All LFT protein serum levels were positively associated with measures of adiposity 
(Table 3.9), except for bilirubin, which was negatively associated. VAT area 
remained associated with alanine aminotransferase (ALT) when conditioned upon 
DXA total abdominal fat and BMI, while VAT area and DXA were still associated 
with ALK, BIL and GGT conditional upon BMI (Table 3.9). Removing VAT area 
from the full model for ALT resulted in a significant decline in model fit (LRT χ21 = 
19.6, p-value = 1x10-5), while the removal of DXA total abdominal fat and BMI, 
either individually or together (χ 22 = 1.56, p-value = 0.46) did not. Residuals analysis 
indicated that VAT linearly mediates the associations between other adiposity traits 
and ALT, with no residual association between ALT and DXA and BMI observed 
when the residuals for VAT area and age were used (p-value = 0.90). Strong evidence 
for association between ALT and VAT area remained, when residuals for DXA, BMI 
and age were used (p-value = 1x10-4). 
 
The estimated variance inflation factor between VAT area and DXA abdominal fat, 
BMI and age was 8.84. Analyses repeated using subgroups of data and analyses using 
underlying quantitative traits for HT, ALT, ALK, BIL and GGT all provided 







Best Fit Model OR SE z  p-value Lower 95% CI Upper 95% CI Model Pseudo-R2 
ALT (0.22) 
VAT area 1.75 0.09 10.9 <2x10-16 1.58 1.93 
0.09 
Age 1.02 0.01 2.9 0.004 1.01 1.03 
ALK (0.27) 
VAT area 1.28 0.14 2.4 0.02 1.05 1.58 0.09 
DXA abdominal fat 1.26 0.13 2.3 0.02 1.03 1.54  
Age 1.06 0.01 9.8 <2x10-16 1.05 1.07  
BIL (0.02) VAT area 0.62 0.10 -3.0 0.003 0.46 0.85 0.054 
BIL (0.02) DXA abdominal fat 0.67 0.10 -2.7 0.01 0.50 0.90 0.049 
GGT (0.20) 
VAT area 1.25 0.14 1.9 0.05 1.00 1.56 
0.06 DXA abdominal fat 1.36 0.15 2.8 0.01 1.10 1.70 
Age 1.02 0.01 2.7 0.007 1.00 1.03 
 
Table 3.9. Liver function tests and adiposity. 
Best-fit multiple regression models are presented for the logistic regression models (n = 3,014) including potential explanatory variables VAT 
area, DXA total abdominal fat, BMI and age. Prevalence for upper limit of normal threshold for each assay is indicated in brackets (Chapter 2: 
TwinsUK sample). Explanatory variables VAT area, DXA and BMI are all standardised, implying a change in odds ratio per unit standard 
deviation change. Year of visit was categorised as quintiles and included in all LFT analyses as a categorical confounding variable. Note that 
two multiple regression models are presented for BIL, since both DXA and VAT area predict BIL equally well. Including both measures in this 
model provides uninterpretable ORs due to co-linearity between the variables (see Supplementary Table 3.1). Abbreviations: ALT – alanine 
aminotransaminase, ALK - alkaline phosphatase, BIL – bilirubin, BMI - body mass index, CI - confidence interval, DXA - dual-energy X-ray 






This study provides evidence that a validated DXA-based measure of visceral fat is a 
strong risk factor for common metabolic and cardiovascular diseases. Validation 
sample explanatory models were able to explain >80% of the variance in CT-
measured visceral fat. A combination of DXA and anthropometric measures (R2 = 
0.91) or including only anthropometric measures (R2 = 0.86), both provided equally 
good estimates of visceral fat. We obtain a heritability of 58% for visceral fat, which 
is consistent with familial studies that report within the region of 48-57% (Perusse et 
al., 1996, Rice et al., 1997, Hong et al., 1998, Fox et al., 2007) and using a twin 
design, confirms for the first time that the observed familial component is also partly 
due to shared familial environment (24%).  
 
Our results confirm that visceral fat is the single most important measure of adiposity 
for risk of T2D. In large DXA resources, such as the one used by Leslie (2010), it 
would be interesting to ascertain whether the risk of developing diabetes is better 
predicted if a DXA-based estimate of visceral fat was used rather than using DXA 
total abdominal fat. 
 
The prevalence of hypertension in the study sample is 8%, which is consistent with 
the range reported for this demographic by the Health Survey for England (2008). 
Visceral fat mediates all associations between hypertension and adiposity variables 
for these cross sectional data. Similarly, in a longitudinal study, Hayashi et al. (2004) 
showed visceral is significantly associated with hypertension and when visceral fat is 
adjusted for other adiposity measures (e.g. BMI, waist circumference or abdominal 
subcutaneous fat). Visceral and subcutaneous adiposity both contribute to the 
prevalence of hypertension, but when adjusted for BMI or waist circumference, 
subcutaneous fat is no longer associated with hypertension (Fox et al., 2007).
 This 
further illustrates that it is the distribution between these two fat depots that 
determines the risk of morbidity. 
 
The LFT protein results suggest that liver function deteriorates with increasing 
abdominal obesity with VAT area positively associated with ALT, ALK and GGT. 




with the inverse association between bilirubin, insulin resistance (Lin et al., 2009) and 
GGT activity (Giral et al., 2010). In particular, of the four tests, the linear association 
between ALT and adiposity is specifically mediated via visceral fat, while for ALK, 
BIL and GGT there is only evidence to suggest this is the case for abdominal fat per 
se (i.e. residuals analysis for ALK, BIL, and GGT demonstrates that the association 
between LFT and visceral fat and DXA total abdominal fat remains, conditional upon 
BMI, but not for association between LFT and visceral fat conditional upon BMI and 
DXA total abdominal fat). The visceral adipose depot is thought to be the major 
source of elevated fatty acid delivered to the liver via the portal vein and it is possible 
that visceral fat acts as a marker of hepatic fat content (Fabbrini et al., 2009). Hepatic 
fat accumulation is known to impair insulin signalling in hepatocytes (Samuel et al., 
2010, Samuel et al., 2004) and "pathway selective insulin resistance"(Brown and 
Goldstein, 2008) maybe pivotal in the transition from normal to impaired fasting 
glucose states. It has been hypothesised that NALFD may play a mediatory role in the 
pathology of CVD (Targher et al., 2010). 
 
The analysis of incident subclinical atherosclerosis is consistent with cross-sectional 
studies that show association between atherosclerosis, total abdominal fat (Kramer et 
al., 2009) and visceral fat (Lear et al., 2007, Kim et al., 2009). Here we provide 
additional evidence that total abdominal and visceral fat accumulation precedes 
atherosclerosis. 
 
The limitations of this study include that adiposity inferences are restricted to middle-
aged Caucasian women. Not having sagittal depth for the study sample limited the 
ability to estimate visceral fat more accurately. This is indicated by the best 
anthropometric validation sample estimate (Model 2) predicting VAT area as well or 
better than a combination of DXA total abdominal fat, waist circumference and age 
(Model 1). As shown in the results, sagittal depth is an extremely useful yet simple 
anthropometric measurement to estimate the body cavity area, when used in 
combination with the subcutaneous fat width, gives a very good approximation of 
visceral fat (R2 ≈ 90%). Where DXA is not available, sagittal depth, waist 
circumference and subcutaneous fat width could be measured to quickly and 





Although the prediction of visceral fat was valid (O'Brien, 2007), co-linearity between 
model explanatory variables – in particular VAT area and DXA total abdominal fat – 
meant that adjusted odds ratios for risk factors were not interpretable. Instead, 
conditional independence structures were assessed using residuals analysis. This 
allowed us to eliminate the possibility of causal relationships between adiposity 
variables and morbidity, except those mediated by visceral fat. 
 
The twin-based heritability estimate presented is likely to be an under-estimate, since 
random measurement error is included in the denominator of the heritability ratio 
estimate and the study sample estimate of visceral fat is known to account for 
approximately only 83% of CT-measured VAT area. 
 
The study design for incident subclinical atherosclerosis was not strictly prospective, 
since no baseline measure of cIMT was taken to facilitate the exclusion of potential 
baseline cases. Where undetected baseline cases exist, the study design is cross 
sectional. 
 
Although not measured the same day, time between DXA and CT scans visits (2 year 
maximum) was included in analyses as a confounding variable and Bland-Altman 
plots revealed no bias in the relationship between predicted and CT-measured visceral 
fat values.  
 
Where a direct measure of visceral fat is unavailable, using an indirect estimate of 
visceral fat (even without a measure of subcutaneous fat) is more predictive of 
morbidity than total abdominal fat. This study suggests that both DXA body fat 
composition and anthropometric measures of body cavity volume alone can provide 
reliable estimates of abdominal visceral fat.  
 
In conclusion, this study in middle-aged women demonstrates that a DXA-based 
measure of visceral fat is associated with T2D, hypertension, subclinical 
atherosclerosis and liver function. It is the predominant measure of adiposity risk for 
T2D, hypertension and alanine aminotransaminase serum level. This is consistent 
with hypotheses that suggest excess visceral fat accumulation is causally related to 




Chapter 4: A Candidate Gene Study for the PARL/ABCC5 Gene 






A candidate polymorphism and candidate gene study of a linkage disequilibria 
genomic region including PARL and ABCC5 was conducted for European and African 
American samples, in relation to the phenotypes of fasting plasma insulin and glucose 
levels, visceral fat accumulation and T2D. Previous functional studies, animal models 
of T2D and human observational data have implicated PARL, with the latter including 
a report that a non-synonymous SNP in exon 7 of PARL (Val262Leu, rs3732581) may 
be a causal functional variant that confers disease risk. 
 
No evidence of phenotypic association with PARL was found using commercial and 
fine map genomic data (European and African American samples). By contrast, 
strong evidence of phenotypic association within intron 26 of the ABCC5 gene was 
observed for European and African American samples, which is located adjacent 
(35Kb) and in LD with PARL. The genomic location estimate for the ABCC5 disease 
susceptibility variant associated with T2D-related phenotypes and expression data 
was the same for all samples (185,136Kb), with the location restricted to ABCC5 
(95% CI 185,108-185,235Kb). The expression data strongly suggests the identified 
genomic variant regulates ABCC5 mRNA expression levels with ABCC5 expression 
also associated with T2D-related phenotypes, including T2D. 
 
Previous observations of human genomic association with PARL may be due to LD 
confounding with neighbouring ABCC5. The ABCC5 variant is associated with 
ABCC5 expression, fasting insulin, glucose and T2D, while ABCC5 expression is 
itself an intermediate phenotype for T2D. Given the ABCC5 risk variant is 
cosmopolitan, common and observed in populations of disparate ancestry, this 
indicates the polymorphism is old and that the transporter gene is likely to play an 






The long arm of chromosome 3, specifically 3q26-29, has been gained interest in T2D 
research due to repeated evidence of linkage to this locus for glycaemic traits 
(Francke et al., 2001) and T2D (Guan et al., 2008, Mori et al., 2002, Vionnet et al., 
2000, Hegele et al., 1999, Walder et al., 2005, Civitarese et al., 2010). GWA studies 
have identified two genes (ADIPOQ and IGF2BP2) in this ~37Mb region that are 
associated with T2D, but given the replicated linkage for T2D and T2D-related traits, 
there are likely to be many additional disease susceptibility genes to be found at this 
locus with a more common allelic spectra. 
 
As part of a gene expression study designed to identify NEM genes associated with 
T2D, Walder et al. (2005) screened differentially expressed genes across the genome 
using skeletal muscle from hyper- and normo-glycaemic Israeli sand rats 
(Psammomys obesus). The list of differentially expressed genes were then filtered by 
retaining only genes that were thought to have mitochondrial roles and located in 
regions thought to harbour obesity and T2D susceptibility loci, only one gene met this 
criteria, PARL, located in 3q27. The authors go on to demonstrate that the expression 
of this NEM gene is reduced in insulin resistant and T2D-induced sand rats, but can 
be restored with an exercise regime of the diabetic rats. 
 
In humans, a positive linear correlation was detected between PARL expression 
skeletal muscle and insulin sensitivity (as assessed by glucose disposal during a 
euglycaemic clamp). PARL expression and mtDNA copy number are reduced in T2D 
individuals compared to controls and both measures decline with age (Civitarese et 
al., 2010). Similarly, insulin plasma levels are raised in rats fed a high fat diet 
compared to those fed a standard diet leading to a reduction in PARL expression and 
mitochondrial function (Tang et al., 2009). Genetic polymorphisms in PARL are 
associated with mitochondrial content (Curran et al., 2010) and it is plausible that 
variation in mitochondrial function may predispose individuals to develop overt T2D 
(Liesa et al., 2009, Newsholme et al., 2012, Patti and Corvera, 2010, Szendroedi et 
al., 2012). 
 
Based upon a dominant model, Walder et al. (2005) also observed a non-synonymous 




fasting insulin in 1,031 human subjects with the variant interacting strongly with age, 
in which fasting insulin levels for GG homozygotes were greater than GC/CC carriers 
with increasing age. While there is suggestive evidence of earlier age of T2D onset 
for GG carriers (Hatunic et al., 2009), the SNP-insulin association has not 
subsequently been replicated (Hatunic et al., 2009, Fawcett et al., 2006, Powell et al., 
2008). Proteins that regulate the dynamic process of mitochondrial turnover 
(mitochondrial fusion and fission) are believed to play an essential role in quality 
control, disposing of dysfunctional mitochondria and maintaining collective 
functioning of mitochondria as a healthy “super-organelle” (Poole et al., 2010, Suen 
et al., 2008, Chan, 2006, Scorrano, 2007). 
 
It is therefore of great interest that PARL, one of the mitochondrial proteases that is 
involved in the degradation of the key mitochondrial fusion protein OPA1 (Pellegrini 
and Scorrano, 2007), may also be a genetic risk factor for insulin resistance and T2D. 
Although the relationship is not understood, there is evidence to suggest that 
mitochondrial fusion activity is a defective process under insulin-resistant states 
(Liesa et al., 2009). 
 
The aims of this study are: 1) to confirm if the PARL missense Val262Leu 
polymorphism is associated with fasting plasma insulin levels and 2) to conduct a 
comprehensive candidate gene study of the PARL/ABCC5 gene region within an 
extended LD block covering the approximate physical distance of 185,000-
185,250Kb (build 36), to test for evidence of genetic of association with disease and 
glycaemic traits.  
 
Given the strong functional evidence implicating PARL and the fact that the 
Val262Leu polymorphism is predicted to be benign (Adzhubei et al., 2010), this study 
examines the hypothesis that the contradictory human genetic association results 
observed for Val262Leu may be due to confounding LD between this polymorphism 
and the true functional variant(s) located elsewhere within the gene or gene region. 
 
To address these aims, two T2D case control samples with available genomic data 
(WTCCC1 European and NIDDK African American samples, see Chapter 2) and a 




also measured for fasting insulin and glucose plasma levels, commercial array 
genomic data, additional fine mapped genotypes (including Val262Leu) and mRNA 





Materials and Methods 
Glycaemic Traits 
Insulin and glucose values were available for 5,605 TwinsUK subjects. Residuals for 
fasting glucose were taken by regression upon year of visit (categorical variable), age 
and sex (R2 = 0.18); residuals for fasting insulin were carefully taken separately for 
each the three assays, by regressing each assay upon year of visit (categorical 
variable), age and sex (R2 = 0.07, 0.07 and 0.06, respectively) and then residuals 
combined. Outliers for glucose residuals regressed upon insulin residuals were 
identified and removed (n = 103) using leverage and residual diagnostics. Visual 
inspection and statistical assessment of insulin residuals by year of collection showed 
no evidence of residual mean differences or heteroscedascity. The fasting plasma IGR 
was calculated for the remaining residuals and then quantile normalised. IGR was 
used for analysis to be consistent with Kissebah et al. (2000) and to have one 
summary glucose homeostasis variable for analysis. T2D status was ascertained via 
an online questionnaire asking if a physician had ever diagnosed the individual with 
the condition. These individuals (n = 338) were removed for analyses of healthy 
variation, leaving 5,164 individuals with valid fasting plasma insulin and glucose 
measures. HOMA2 values were calculated (Wallace et al., 2004) for beta cell 
function (HOMA2-%B) and insulin sensitivity (HOMA2-%S). 
  
Fine-Mapping 
The Val262Leu (rs3732581) SNP was not present on either the HumanHap300 or 
Human610-Quad commercial arrays and was therefore genotyped for a total of 3,087 
individuals by KBioscience (http://www.kbioscience.co.uk). For TwinsUK sample 
with HumanHap300 data, the coverage within the PARL/ABCC5 gene region was 
poor so an additional 23 SNPs were genotyped to provide extra coverage and 
improved resolution of the LDU steps in this region. For TwinsUK sample with 
Human610-Quad data, an additional 26 fine-map SNPs were genotyped across the 
analytical window (184,743-185,548Kb, build 36) with a wide range of minor allele 
frequencies (MAF > 0.05) to further improve coverage for the PARL and ABCC5 






Statistical Genetic Methods 
 
Biometric Model 
For the candidate marker Val262Leu test of association, the quantitative traits of 
fasting insulin, glucose and IGR were regressed upon the SNP using a biometric 
additive model (Chapter 2: Biometric model). For the biometric additive model, the 
three genotypes for the SNP rs3732581 were coded G/G (0), G/C (1) and C/C (2) and 
utilised as an ordinal variable with the regression coefficient interpreted in a minor 
allele, dose-dependent manner. For example, an additive SNP model for fasting 
insulin plasma levels (if significant) would be interpreted as pmol/l decrease per copy 
of minor allele. Similarly, to construct the intermediate file of summary results to 
implement the Malécot test of association, the phenotype was regressed upon each 
SNP using an additive biometric model. 
 
An interaction model testing for association between fasting insulin levels and age 
stratified by Val262Leu genotypes was implemented using a nested interaction 
design. A mixed linear regression model was implemented to regress fasting plasma 
insulin upon two age terms, one for GG individuals (ageGG) and another age variable 
for GC/CC individuals (ageGC/CC). Fixed effects were included in the regression for a 
dummy intercept term to identify the two genotype strata, year of visit (categorical 
variable) and a random effects intercept term using family identifier. Familial 
relatedness, i.e. non-independence between individuals, was incorporated into the 
analysis by clustering individual observations by family identifier. 
 
eQTL Regression Analyses 
Gene expression data in three tissues (subcutaneous adipose tissue, skin, and LCL) for 
PARL and ABCC5 were available for a subset of the TwinsUK sample (n = 821); the 
generation of this data is described in Chapter 2. There were three probes per gene, 
each probe tagging a mixture of mRNA transcripts; the location and the associated 
transcripts for each probe are provided in Supplementary Table 4.1 
 
To control for observed systematic experimental protocol effects (different means and 
variances for the three batch groups), mixed linear regression methods were used to 




tissues). Each log2 normalised expression probe was regressed upon SNP plus fixed 
effect confounder variables of age at sample collection and sample batch (a 3-level 
factor). While the regression slope terms were fixed, the intercept included an 
additional random effects term for the twin family identifier to estimate variance 
between families in order to be able to make more reliable population inferences. 
 
Drs Winston Lau and Nikolas Maniatis generated summary statistics from the SNP 
regression models for the entire genomic region (184,743-185,548Kb, build 36) and 
fitted a Malécot model to test for evidence of regulatory eQTLs in the region for each 
gene probe. 
 
Multiple Testing and Significance Threshold 
For the Malécot test of association, which is a single test, the significance threshold is 
an alpha of 5%. For the eQTL analyses, in which a total of 18 tests were performed 
(two genes, three probes per gene across three tissues), a Bonferroni corrected alpha 
threshold of 3x10-3 (0.05/18) was used. 
 
Linkage Disequilibrium Maps and Genetic Association 
There are three major strengths to a genetic map-based test of association. The first is 
that this elegant model is highly interpretable in terms of the ancestry and age of the 
susceptibility variant. The second is that the model does not assume that the disease 
susceptibility variant has been genotyped, nor that it is in high or complete LD with 
one of the genotyped markers, which is a major assumption in standard GWA scans. 
By utilising genetic maps, the model is sensitive to detecting disease susceptibility 
variants that are potentially associated with a constellation of neighbouring genotyped 
markers, but not necessarily in high LD with any one individual genotyped marker. 
For the commercial SNP arrays that are currently available and where the assumption 
of high allelic identity (i.e. a single disease-susceptibility allele at a locus) begins to 
breakdown (Pritchard et al., 2000), this is a much more realistic scenario than the 
current practice of assuming a variant is in high LD with one of the genotyped 
markers. Direct estimation of the disease susceptibility variant location also provides 
a degree of commensurability between different commercial genotyping platforms 
that other methods do not provide. Thirdly, gene mapping is far more efficient using 





Drs Winston Lau and Nikolas Maniatis generated all LDU maps and applied the muli-
marker Malécot test of association. They provided me with their summary results that 






A description for each of the three samples (TwinsUK, WTCCC1, and African 
American) is provided in Chapter 2. Summary statistics of the three study samples are 
provided in Table 4.1. European and African American data sets each contained over 
1,000 cases of T2D with approximately equal (African American) or greater numbers 
of controls (European) and equal numbers of men and women in both groups. While 
the European and African American case-control samples for T2D provided a test of 
genetic association with overt disease, the TwinsUK sample, for which T2D cases 
were excluded from the analysis of glycaemic traits, provided a test of association 
with healthy variation in fasting insulin and glucose plasma levels. All samples were 
middle-aged ranging from approximately 40-70 (WTCCC1 and NIDDK) and 20-80 

















Mean IGR - - - - 11.2 11.1 
Mean age 58.3 45.4 61.5 49.0 50.7 50.6 
Female % 42 51 57.3 61.2 99.9 88.0 
n subjects 
(array) 
1,924 2,938 1,033 971 1,750 2,300 
n subjects 
(fine-map) 
- - - - 801 2,300 
 
Table 4.1. Summary statistics for the three study samples used for the 
PARL/ABCC5 candidate gene study. 
Array refers to the number of individual with genome-wide SNP data generated on 
commercial arrays. Where there was poor coverage for the TwinsUK sample relative 
to European and African American, additional SNPs were genotyped in TwinsUK 
sample with genome-wide SNP data (fine map). Abbreviations: IGR - insulin:glucose 





Val262Leu (rs3732581, PARL) as a Candidate Marker for Insulin Resistance and 
T2D 
The rs3732581 non-synonymous polymorphism in PARL was not included in the 
genotyping platforms (Table 4.1). Therefore this marker was genotyped for a total of 
3,087 individuals from the TwinsUK sample, providing complete genotype and 
phenotype fasting insulin data for 2,358 healthy non-T2D individuals and 2,895 T2D 
case-control data (ncases = 132). The observed minor allele frequency (MAF) was 
0.489 (allele C), which is similar to in documented European, African and Asian 
populations (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3732581). 
 
A previously suggested dominant mode of inheritance for Val262Leu implies that GC 
and CC carriers are likely to witness smaller increases in fasting insulin with age 
compared to individuals with the GG genotype at this locus (Walder et al., 2005). 
Attempting to replicate this age by genotype interaction model for Val262Leu, both 
for fasting insulin and T2D, phenotypes were regressed upon two age terms in the 
same model, in order to test whether the strength of association with age for GG 
individuals (ageGG) was stronger than those carrying GC/CC Val262Leu genotypes 
(ageGC/CC, Chapter 4: Materials and Methods).  
 
Mixed linear regression models showed no evidence of association (unadjusted or 
adjusted for age) for fasting plasma insulin levels (p-value = 0.95) or self-reported 
T2D (p-value = 0.10) with the Val262Leu polymorphism parameterised using a 
simple additive biometric model (Chapter 4: Materials and Methods). By contrast, the 
same regression models showed strong statistical evidence that fasting insulin levels 
(0.12pmol/L per year) and risk of T2D (OR = 1.04 per year) increased with age 
(Table 4.2A). 
 
Although both phenotypes were positively associated with age, GG individuals 
showed no evidence of stronger association between phenotype and age compared to 
CC/GC individuals (Table 4.2B), with age regression coefficients bGG = bGC/CC for 
insulin (Wald 21 = 0.14, p-value = 0.71) and bGG = bGC/CC for T2D (21 = 0.74, p-






Fasting Insulin Type 2 Diabetes 
β SE  p-value OR SE  p-value 
(A) 
 
rs3732581 -0.17 0.56 0.95 0.82 0.10 0.10 
Age 0.12 3x10-2 1x10-4 1.04 0.01 3x10-8 
(B) 
 
AgeG/G 0.13 0.06 0.03 1.03 0.01 0.01 
AgeG/C&C/C 0.12 0.04 1x10
-3 1.05 0.01 3x10-9 
 
Table 4.2. Non-synonymous SNP rs3732581 (Val262Leu) association with fasting 
plasma insulin levels and type 2 diabetes for TwinsUK sample. 
(A) Main effect model: association between phenotype and SNP adjusted for age, 
with rs3732581 coded 0, 1, 2 copies of the C allele for an additive biometric model. 
(B) Interaction model association between phenotype and age stratified by SNP using 
a nested interaction model adapted from Walder et al. (2005), in which age is 
stratified into two genotype groups with the C allele completely dominant over G. 
Fasting plasma insulin levels measured in pmol/L. Year of blood sample collection 
was included as a categorical confounding variable for both fasting insulin analyses. 





LD in the PARL/ABCC5 Gene Region 
Figures 4.1 and 4.2 illustrate the high degree of LD as measured by D’ (see Chapter 2 
for details on LD measures) within and moderate LD between the PARL and ABCC5 
genes, with Figure 4.1 plotting pair wise LD and Figure 4.2 plotting the informative 
fine scale genetic maps for HapMap European (CEU) and African (ASW) populations 
in the form of cumulative LDU. Note that while there is breakdown in LD between 
the two genes, there still remains some extended LD between the two. The mapping 
approach used in this study uses genetic locations derived from LD maps with 
distances in LDU inferred using population-specific HapMap genomic data (Maniatis 
et al., 2002). The maps can be visualised by plotting marker location in LDU against 
the marker physical distances in kilobases (Kb). By plotting these LDU maps against 
physical distance, the non-linear relationship is revealed as a “Block-Step” structure 
(Figure 4.2). “Blocks” of LD represent areas of low haplotype diversity, while “steps” 
define LD breakdown, mainly caused by recombination. The high-resolution genetic 
maps (based upon HapMap markers) provide detailed local LD structure and can be 
used for mapping potential functional variants associated with fasting insulin and 
glucose plasma levels in healthy Europeans (TwinsUK) and T2D for European and 
African American samples. 
 
Given the lack of association between Val262Leu with fasting insulin and T2D, the 
investigation was extended to a more comprehensive candidate gene study of the 
region using genomic data for three samples (Table 4.1). Additional SNPs were 
genotyped for the TwinsUK HumanHap300 samples to make the markers for these 
samples more compatible with the Human610-Quad coverage in the PARL/ABCC5 
region (Chapter 4: Materials and Methods). For the candidate gene association study 
the phenotypes used were fasting IGR (TwinsUK) and T2D status (WTCCC1, 























Figure 4.1. Haploview LD plot illustrating extended linkage disequilibrium in the PARL/ABCC5 region. 








































Figure 4.2. African American and European genetic maps and scatter plot for 
WTCCC1 association between type 2 diabetes and single nucleotide 
polymorphisms. 
The graph presents a line plot for African American (red) and European (blue) 
cumulative LDU genetic maps (y1-axis) and scatter plot for WTCCC1 T2D 
association with SNPs in the PARL/ABCC5 gene region (y2-axis, -log10 p-value). The 
genetic maps for HapMap Africans (ASW, Phase III) and Europeans (CEU, Phase II) 
are plotted, with horizontal regions reflecting "blocks" or extended local LD, while 
vertical steps, reflect breakdown in LD. Each dot on these lines represents a SNP 
location for the high-resolution HapMap samples from which these population-
specific genetic maps are inferred. The arrowed vertical line labelled Ŝ represents the 
functional variant location estimate and the dotted lines the 95% CI for the variant 
location. The total genetic distance (y1-axis) for the same physical genomic region (x-
axis) is greater for the African population compared to the European, reflecting older 
ancestry and larger number of historical recombination events for this population. 
Note that while none of the individual SNP p-values for WTCCC1 are smaller than 
0.001 (-log10[0.001] = 3), collectively they provide strong evidence of association 
with T2D (Malécot model p-value = 3x10-6). The nearest SNP to the Ŝ location 





The PARL/ABCC5 Gene Region as a Candidate for Insulin Resistance and T2D 
Under the supposition that there is at least one detectable common functional 
polymorphism (the “common disease, common variant” or CDCV hypothesis 
(Pritchard, 2001, Reich and Lander, 2001) associated with both insulin sensitivity and 
T2D and that there is minimal allelic heterogeneity in the gene region (Bodmer and 
Bonilla, 2008, Pritchard and Cox, 2002), we examined the PARL/ABCC5 region in 
depth by employing a powerful multi-marker test of association (see Chapter 4 
Materials and Methods). This approach uses information from all SNPs within a 
genomic region (analytical window) and utilises the genetic distances between 
markers from fine scale, population-specific LDU maps. The method provides a 
location estimate, Ŝ, (and 95% CI or location support interval) for the putative 
functional common variant, if there is significant evidence of phenotypic association 















Genomic T2D WTCCC1 T2D 4,864 83 3x10-6 185,136 185,107 185,241 Intron 26 ABCC5 (-) 








801 72 0.50 - - - - 









202 1x10-11 185,136 185,109 185,235 Intron 26 ABCC5 (-) 
 
Table 4. 3. Phenotype-genotype association for PARL/ABCC5 gene region in Europeans and African Americans. 
WTCCC1 showed significant evidence of association between T2D and ABCC5 with a causal variant (Ŝ) estimated to be located in intron 26. 
This is replicated for healthy Europeans measured for fasting insulin and glucose (TwinsUK Human610-Quad, p-value = 0.04) and African 
American samples (p-value = 0.01) with three data sets providing the same variant location at or close to 185,136Kb (95% CI: 185,108-
185,235Kb). Meta-analysis of the four genomic sample data sets including both T2D and IGR showed evidence for an intragenic functional 
variant in ABCC5 with a p-value of 1x10-6. Subcutaneous adipose expression of transcripts tagged by the Ilmn_1706531 probe showed strong 
evidence (p-value = 1x10-11) that the intron 26 variant is an eQTL that regulates ABCC5 expression levels. Analytical window co-ordinates used 
for phenotype and transcript analyses were: 184,743-185,548Kb (build 36). *TwinsUK sample size for individuals with both expression and 
SNP data ranged from 276 to 700 for a total of 202 SNPs in the PARL/ABCC5 gene region, with samples genotyped for SNPs on both the 
Human610-Quad and HumanHap300 arrays (72 SNPs, n = 700), the Human610-Quad only (104 SNPs, n = 276) and 26 additional fine map 
SNPs for the PARL/ABCC5 genes (n = 276). Sample size for each SNP was taken into account for all analyses. Abbreviations: IGR - fasting 
insulin: glucose serum ratio levels, NIDDK – National Institute for Diabetes, Digestive and Kidney disease, T2D - type 2 diabetes, WTCCC1 - 





Table 4.3 presents evidence for phenotypic association with genomic polymorphism 
data centred on the PARL/ABCC5 gene region (analytical window: 184,743-
185,548Kb, build 36) for European and African American populations. The analytical 
window size is approximately 10 LDU in genetic distance (for European populations), 
which is an arbitrarily chosen size, but empirically large enough to be informative 
(Chapter 2: Linkage Disequilibrium). The WTCCC1 T2D sample had a total of 83 
SNPs genotyped in this region (Affymetrix 500K) for a total of 4,864 individuals, 
with significant evidence of association (p-value = 3x10-6) observed for a location 
estimate at 185,136Kb (95% CI 185,108-185,215Kb). Note that while the best 
evidence for the location of the common functional variant is intron 26 of ABCC5, the 
confidence interval for the location estimate includes the entire ABCC5 gene. 
 
Interestingly, an essentially identical location estimate, 185,137Kb (95% CI: 185,114-
185,218Kb), was obtained for African American T2D case-control sample with 
nominal significance (p-value = 0.01). The result is also replicated for healthy 
Europeans (TwinsUK Human610-Quad) measured for IGR, the analysis yielded a p-
value of 0.04 for the same location estimate as T2D and within ABCC5 intron 26 
(185,136Kb; 95% CI 185,110-185,235Kb). The lack of association for the TwinsUK 
HumanHap300 sample maybe due to poorer marker coverage in the gene region (a 
total of 72 SNPs) compared to the other commercial SNP arrays. Meta-analysis of the 
p-values from the four genomic results (Table 4.3; WTCCC1 p-value = 3x10-4, 
NIDDK p-value = 0.01, TwinsUK Human610-Quad p-value = 0.04 and TwinsUK 
HumanHap300 p-value = 0.50) using Fisher’s method (Fisher, 1925), nevertheless 
provided overall significant evidence of association (p-value = 1x10-6) for a common 
functional variant located at 185,136Kb. The 95% confidence intervals for this 
location range from 185,108-185,235Kb, which includes the ABCC5 gene, promoter 
and 3’ region (ABCC5 gene co-ordinates: 185,120-185,215Kb). 
 
Using expression data for PARL and ABCC5, an expression quantitative trait locus 
(eQTL) analysis was performed and the summary p-values were fitted to the Malécot 
model in order to obtain location estimates across multiple tissues. Table 4.3 shows 
the association results for one of the ABCC5 subcutaneous adipose expression probes 
(Ilmn_1706531) measured for the TwinsUK sample, the expression of its transcripts 




the genomic tests (185,136Kb; 95% CI: 185,109-185,235Kb). This result strongly 
suggests that the associated functional variant in ABCC5 is an eQTL that regulates 





Tissue  Gene Probe p-value  Ŝ Kb (B36) 
Lower 95%  
CI (Kb) 
Upper 95%  


















e PARL Ilmn_2341467 4x10
-1 - - - - 
PARL Ilmn_1731354 2x10-1 - - - - 
PARL Ilmn_2257665 2x10-1 - - - - 
ABCC5  Ilmn_1706531 1x10-11 185,136 185,109 185,235 ABCC5 intragenic 
ABCC5  Ilmn_1651964 9x10-2 - - - - 





PARL Ilmn_2341467 4x10-13 185,111 185,108  185,192  - 
PARL Ilmn_1731354 2x10-8 185,109 185,104  185,118  3' ABCC5 intra/intergenic 
PARL Ilmn_2257665 4x10-5 185,302 185,301  185,307  3' ABCC5 intergenic 
ABCC5  Ilmn_1706531 9x10-22 185,179 185,117  185,235  HTR3E intragenic 
ABCC5  Ilmn_1651964 2x10-54 185,193 185,118  185,235  ABCC5 intragenic 





PARL Ilmn_2341467 4x10-5 185,076 184,928  185,117  - 
PARL Ilmn_1731354 1x10-12 185,109 185,104 185,117  - 
PARL Ilmn_2257665 3x10-2 - - - PARL intragenic 
ABCC5  Ilmn_1706531 9x10-22 185,170  185,116  185,235  5' PARL intergenic 
ABCC5  Ilmn_1651964 1x10-6 185,179 185,110  185,235  - 





Table 4.4. Expression quantitative trait locus (eQTL) association analysis for 
TwinsUK data across three tissues. 
The eQTL location estimate (Ŝ) for PARL and ABCC5 expression values in 
subcutaneous adipose, LCL and skin tissues are presented (n = 821). Each analysis is 
based upon the same analytical window co-ordinates used for the genomic analysis 
(184,743-185,548Kb, see Table 4.3). The p-value from the Malécot association model 
represents the statistical evidence for the observed probe-SNP data being consistent 
with the null hypothesis of no association for the entire gene region. Only one of the 
six probes for subcutaneous adipose tissue (Ilmn_1706531) showed evidence for an 
eQTL - located in intron 26 of ABCC5 (185,136Kb, 95% CI 185,109-185,235Kb) - 
that regulates ABCC5 expression levels. By contrast, most of the expression probes 
for LCL and skin tissues showed evidence of eQTL regulation in the same or 
neighbouring gene to which the probe was located. In LCL tissue, distal cis-acting 
eQTLs located in ABCC5 and HTR3E appears to regulate PARL expression and in 
skin, an eQTL located in PARL regulates ABCC5 expression levels. A conservative 
Bonferroni correction threshold of χ21 = 10 (p-value = 0.002) was used to control the 





Gene Expression Quantitative Trait Locus (eQTL) Analysis 
The results from the subcutaneous adipose expression data in Table 4.3 were based on 
the ABCC5 subcutaneous adipose expression probe (Ilmn_1706531), since this was 
the only adipose probe that showed evidence of genetic association. Table 4.4 lists the 
results for the eQTL analysis of all PARL and ABCC5 mRNA probes, measured in 
subcutaneous adipose, LCL and skin tissues for a subset of the TwinsUK sample 
(Chapter 2: TwinsUK Sample). Eighteen expression probes were tested using mixed 
linear regression methods (Chapter 4: Materials and Methods) – three probes in each 
gene measured for three tissues. Of the three tissues most relevant to T2D, 
subcutaneous adipose tissue showed evidence (p-value = 1x10-11) for genetic 
association with only one probe (Ilmn_1706531, ABCC5), with the eQTL having 
exactly the same ABCC5 (intron 26) location estimate as the functional variant 
location estimates for the two associated phenotypes, T2D and IGR. None of the other 
five subcutaneous adipose tissue transcript probes showed evidence of cis- genetic 
association (Table 4.4). 
 
As noted, the location estimates for genomic and subcutaneous adipose expression 
data allude to the same functional variant in ABCC5. Although the ABCC5 variant has 
not been genotyped, by way of illustration, the nearest genotyped SNP to the 
functional variant location estimate is rs4912515 (Figures 4.1 and 4.2). The regression 
coefficient for subcutaneous adipose probe Ilmn_1706531 regressed upon rs4912515 
using an additive model is -0.07 (p-value = 0.003), which is equivalent to 
approximately 0.1 of a standard deviation decrease in ABCC5 expression levels for 
each G allele inherited at this locus (MAF = 0.40). Except for adipose probe 
Ilmn_1706531, SNP rs4912515 is not associated with any of the other transcript 
probes (for all three tissues) or phenotypes (data not shown). SNPs in immediate 
proximity to the variant location estimate in ABCC5 intron 26 showed evidence of 
long range LD. For example, pair wise LD between Val262Leu and rs4912515 
(185,136.7Kb) is D’ = 0.7 and r2 = 0.31 (Figure 4.1). The MAF for Val262Leu 
(rs3732581) and rs4912515 SNPs are similar and common in Europeans (0.49 and 





In addition to the Val262Leu SNP in PARL, another SNP in PARL (rs3792588) has 
been reported to be associated with mitochondrial DNA content (Curran et al., 2010); 
this SNP (TwinsUK, MAF = 0.14) is in LD with Val262Leu (D’ = 1 and r2 = 0.13, 
Figure 4.1). This raised the possibility of a link between the Val262Leu SNP-insulin 
association and mitochondrial abundance, however, rs3792588 showed no evidence 
of association with IGR or T2D (data not shown). 
 
The expression results for LCL and skin tissues were more numerous than 
subcutaneous adipose and the pattern of association more complicated. ABCC5 
expression levels appeared to be mainly regulated by intragenic eQTLs. PARL 
expression levels were either regulated by eQTLs in neighbouring genes (ABCC5 and 
HTR3E for LCL tissue) or by eQTLs upstream proximal to PARL (skin). In short, 
ABCC5 transcripts showed evidence of “self” regulation for all three tissues, while for 
PARL there was (tissue specific) evidence of co-expression between genes. Table 4.5 
presents a correlation matrix for all probes across the three tissues and Supplementary 
Table 4.1 lists the different splice variant transcripts for PARL and ABCC5 that are 
targeted by the three probes in each gene. 
 
The ABCC5 Ilmn_1706531 probe is perhaps the most interesting because despite only 
tagging two transcripts, it is the only probe to be correlated with the all three PARL 
probes across the three tissues. Excluding correlations with the Ilmn_1706531 probe, 
the only PARL probe correlated with ABCC5 is the Ilmn_2257665 probe, which is 
negatively correlated (r = -0.21) with Ilmn_1651964 in both subcutaneous adipose 































































































e PARL Ilmn_2341467 1      
PARL Ilmn_1731354 0.81 1     
PARL Ilmn_2257665 -0.45 -0.36 1    
ABCC5 Ilmn_1706531 0.28 0.23 -0.38 1   
ABCC5 Ilmn_1651964 - - -0.21 0.54 1  





PARL Ilmn_2341467 1      
PARL Ilmn_1731354 0.88 1     
PARL Ilmn_2257665 -0.26 -0.23 1    
ABCC5 Ilmn_1706531 0.11 0.08 -0.33 1   
ABCC5 Ilmn_1651964 - - - 0.51 1  





PARL Ilmn_2341467 1      
PARL Ilmn_1731354 0.85 1     
PARL Ilmn_2257665 -0.42 -0.33 1    
ABCC5 Ilmn_1706531 0.33 0.24 -0.49 1   
ABCC5 Ilmn_1651964 - - -0.21 0.56 1  
ABCC5 Ilmn_2302358 - - - - - 1 
 
Table 4.5. TwinsUK transcript expression correlation structure for PARL and 
ABCC5. 
The Pearson product-moment correlation is presented between six mRNA expression 
probes for PARL and ABCC5 measured in adipose, LCL and skin tissue samples. The 
transcript correlations are for probes within the same gene, while highlighted areas 
refer to between-gene correlations (for the same tissue). The residuals for batch 
effects were first taken for each probe before the correlation coefficients were 
estimated to provide a partial correlation coefficient controlling for batch effect. 





Subcutaneous Adipose ABCC5 Expression as an Intermediate Phenotype for 
Fasting Insulin, Visceral Fat Accumulation and T2D 
To assess if subcutaneous adipose PARL and ABCC5 transcripts may be related to 
T2D and related phenotypes, a series of analyses were performed regressing each 
phenotype upon each of the six subcutaneous adipose probes in turn, using a mixed 
linear regression model to control for batch and age effects (Chapter 4: Materials and 
Methods). Visceral fat was included as a T2D-related phenotype as this phenotype has 
previously been shown to be strongly associated with T2D and arguably may play a 
causal role in T2D disease onset (Chapter 3). In particular, we were interested in 
adipose probe Ilmn_1706531 as this probe already showed evidence of eQTL genetic 
association with ABCC5 (Table 4.3). 
 
The univariate regression results presented in Table 4.6A indicates that only ABCC5 
subcutaneous adipose probe Ilmn_1706531 was significantly associated with fasting 
insulin, visceral fat accumulation and T2D. To control for correlation between 
expression probes, we also performed a multiple regression (Table 4.6B) in which 
phenotype was regressed upon Ilmn_1706531, age, batch effects and the two probes 
(Ilmn_2257665, Ilmn_1651964) that showed marginal evidence of phenotypic 
association in univariate analyses. This confirmed that only subcutaneous adipose 
probe Ilmn_1706531 was significantly (and strongly) associated with fasting insulin, 
visceral fat and T2D. The strength of association for this ABCC5 probe (Table 4.6B) 
was estimated to have a correlation coefficient of 0.37 with IGR (95% CI 0.13 - 0.61), 
a regression coefficient of 30cm2 visceral fat per SD increase in expression (95% CI 
13.2 - 47.4) and for T2D, an OR of 3.8 per SD increase in probe expression (95% CI: 
1.25 - 11.6). 
 
The association between IGR and subcutaneous adipose probe Ilmn_1706531 appears 
to be primarily driven by fasting insulin (p-value = 1x10-4) rather than glucose levels 
(p-value = 0.02) with raised subcutaneous adipose ABCC5 transcript levels positively 
associated with beta cell function (homa2b, p-value = 1x10-3) and negatively with 
peripheral insulin sensitivity (homa2s, p-value = 5x10-5). Significantly, none of the 
expression probes for LCL and skin tissues – including ABCC5 probe Ilmn_1706531 





 Gene Probe 




β SE  p-value β SE  p-value 
A 
PARL Ilmn_2341467 -0.01 0.18 0.96 -1.8 12.1 0.88 -0.71 1.02 0.48 
PARL Ilmn_1731354 0.06 0.18 0.73 -13.9 12.8 0.28 -0.52 1.13 0.65 
PARL Ilmn_2257665 -0.04 0.10 0.67 -15.1 7.5 0.04 -0.57 0.55 0.30 
ABCC5 Ilmn_1706531 0.38 0.10 1x10-4 33.8 6.9 1x10-6 1.67 0.44 2x10-4 
ABCC5 Ilmn_1651964 0.30 0.14 0.03 30.7 9.7 1x10-3 1.82 0.73 0.01 
ABCC5 Ilmn_2302358 0.25 0.31 0.40 -5.9 20.1 0.77 2.25 1.67 0.18 
            
B 
PARL Ilmn_2257665 - - - -1.3 8.0 0.88 - - - 
ABCC5 Ilmn_1706531 0.37 0.12 2x10-3 30.3 8.7 5x10-4 1.34 0.57 0.02 
ABCC5 Ilmn_1651964 0.03 0.16 0.84 7.8 11.4 0.50 0.46 0.91 0.61 
 
Table 4.6. Phenotypic association with subcutaneous adipose PARL/ABCC5 gene expression. 
Three phenotypes, fasting IGR, visceral fat and T2D, regressed upon PARL and ABCC5 transcript levels for the TwinsUK sample. Mixed linear 
models were used including a family identifier random effects intercept term and fixed effect terms for confounding variables age and 
experiment batch effects (3 level factor). Only subcutaneous adipose probe Ilmn_1706531 was associated with fasting IGR, visceral fat and T2D 
in univariate (A) and multiple regression analyses (B). Transcript analysis sample sizes for IGR, visceral fat and T2D were 680, 619 and 820 
respectively. Fasting IGR is quantile normalised with the β regression interpretable as standard deviation units. Visceral fat units are cm2, while 






In this study, the non-synonymous PARL SNP rs3732581 (exon 7) and the PARL gene 
itself, showed no evidence of association with fasting plasma insulin and glucose 
levels or T2D for one African American and two European samples. By contrast 
however, the neighbouring ABCC5 gene shows replicated evidence of genetic 
association with T2D and glycaemic traits for the same genetic location in multiple 
human populations, with the putative common functional variant in ABCC5 playing a 
regulatory role in controlling ABCC5 expression levels. These results are consistent 
with the idea that elevated ABCC5 expression levels increase risk of insulin 
resistance, dyslipidemia and T2D (see Figure 4.3), since the same functional variant 
appears to be associated with not only ABCC5 transcription levels, but also fasting 
IGR, visceral fat accumulation and T2D. In turn, ABCC5 transcript levels are strongly 
associated with fasting plasma IGR, Homeostasis Model Assessment beta cell 
function and insulin peripheral sensitivity, visceral fat accumulation and T2D, which 
suggests that ABCC5 expression is a causal risk factor for onset of T2D. 
 
The ABCC5 genetic variant association with T2D-related phenotypes may also 
explain previous contradictory human association results observed for Val262Leu, if 
observed association with PARL is in fact due to confounding LD with functional 
variants in ABCC5. For example, SNPs such as rs4912515 in immediate proximity to 
the ABCC5 variant Ŝ location estimate show evidence of long range LD with 
Val262Leu in PARL. 
 
Given the overwhelming evidence from animal model and functional studies for 
reduced PARL expression associated with observed and induced T2D (Civitarese et 
al., 2010, Tang et al., 2009, Walder et al., 2005), how is this reconcilable with the 
results presented here for ABCC5 and PARL? It seems that there is evidence for both 
genes to be to be implicated in T2D, but the key question for future research is to 
understand whether (and how) PARL and ABCC5 are functionally related. At this 
point, the most likely explanation for these observations – due to the existence of a 
functional genetic variant associated with T2D in multiple human populations that 
regulates ABCC5 expression – is that ABCC5 has a causal (if modest) role in T2D 




insulin resistance and disease state. This is illustrated by Psammmomys obesus 
experimental studies (Walder et al., 2005) - induction of T2D in these rats by high-fat 
diet and inactivity is associated with a reduction in PARL (skeletal muscle) 
expression, which can restored to normal levels by exercise training (running 
1km/day in 1 hour for 3 weeks). 
 
Empirically, PARL and ABCC5 transcripts are correlated, suggesting co-regulation of 
the two genes due to shared transcription factors and/or cis-acting regulatory 
elements. It is also possible, but perhaps less likely, that ABCC5 more directly 
regulates PARL. Based upon TwinsUK data, there is some indirect evidence of cis- 
co-regulation between the two genes with two PARL transcripts (in LCL) regulated by 
upstream eQTLs (located in ABCC5 and HTR3E) and one ABCC5 transcript (in skin) 
regulated by an eQTL located in PARL (or PARL promoter region). However, these 
observations are for tissues that are unlikely to be functionally relevant to T2D and 
therefore require verification. The results for adipose, which is the most relevant of 
the three tissues, only shows evidence for one ABCC5 probe (Ilmn_1706531) 
regulated by an intragenic cis-eQTL. 
 
ABCC5 is a member of the ATP-binding cassette transporter super-family (Dean and 
Allikmets, 2001), transporting cyclic nucleotides such as cGMP, which is a common 
regulator of ion channel conductance, glycogenolysis, and cellular apoptosis, making 
ABCC5 a potential candidate for T2D. Glycogenolysis takes place in the cells of the 
muscle and liver tissues and is regulated by epinephrine, glucagon and insulin in 
response to blood sugar levels with hormone effects mediated by cAMP or cGMP 
(Lehninger, 1979). In myocytes, glycogen degradation serves to provide an immediate 
source of glucose-6-phosphate for glycolysis, to provide energy for muscle 
contraction; in hepatocytes, the main purpose of the breakdown of glycogen is for the 
release of glucose into the bloodstream for uptake by other cells.  
 
Although ABC transporter genes including ABCC5 have been well studied in relation 
to cancer treatment and drug resistance (Tamaki et al., 2011), little is known about 
ABCC5 in relation to T2D. One exception to this is an ABC transporter expression 
study (Nowicki et al., 2008) of uptake and efflux transporters in the liver and kidney 




quantity (Western blot) of Abcc5 (Mrp5) protein in the liver of SID rats fed a high fat 
diet is reduced to approximately 4% of the level in the control. In contrast, Abcc5 
protein level in SID rats fed a normal diet were not significantly reduced compared to 
the controls. These observations indicate that the almost complete loss of the Abcc5 
protein is in response to the combined effects of induced pancreatic beta cell failure 
and high lipid levels.  
 
Furthermore, the study by Nowicki et al. (2008) adds support to further investigating 
the transporter gene family in relation to common T2D, with the sub-families of 
ABCC and ABCG already implicated in different ways (Matsuo, 2010). Mutations in 
the sulfonylurea receptor (SUR) 1 encoded by ABCC8 have previously been shown to 
cause neonatal diabetes (Greeley et al., 2011), MODY (Bowman et al., 2012) and 
adult T2D (Tarasov et al., 2008). The sulfonylurea receptor is a subunit of the ATP-
sensitive potassium channels, which regulate insulin secretion from pancreatic beta 
cells by sensing cellular metabolic levels. In addition, the ABCG transporter genes 
have also been implicated in cholesterol transport in animal models of T2D (Levy et 
al., 2010). 
 
In summary, this study demonstrates that a common ABCC5 functional variant 
observed in Europeans and African Americans is a risk factor for T2D. The 
mechanism for this association is likely to be that the genetic variant is a regulatory 
eQTL for ABCC5 that confers risk of disease by altered ABCC5 transcript expression 
levels. Increased ABCC5 subcutaneous adipose expression levels are positively 
associated with fasting insulin levels, visceral fat accumulation and T2D. The 
association with intermediate phenotypes for T2D suggests that elevated ABCC5 
expression is a causal risk factor for T2D and not a consequence of disease onset. By 
contrast, PARL genetic variants and gene expression are not associated with 
intermediate phenotypes or T2D for human observational data, suggesting that 
previously observed and experimental evidence for association between PARL 
dysfunction and T2D is likely to be a consequence of disease onset. Given the ABCC5 
risk variant is cosmopolitan, common and observed in disparate populations of 
European and African ancestry, this indicates the polymorphism is very old and that 







Figure 4.3. ABCC5 genetic and mRNA association with intermediate phenotypes 
and T2D. 
An eQTL in ABCC5 (intron 26) regulates expression levels and is associated with 
fasting plasma insulin and glucose levels, visceral fat accumulation and T2D for 
TwinsUK data. ABCC5 transcript Ilmn_1706531 is also strongly associated with 
intermediate phenotypes and T2D (Table 4.6). Consistent with the central dogma 
theory, this suggests the association between the ABCC5 genetic variant is causally 
mediated via expression levels that are tissue and transcript specific. Double-headed 













Changes to mitochondrial structure, function and quantity are routinely observed in 
tissues from type 2 diabetic subjects. Nuclear genes encode the vast majority of 
mitochondrial proteins yet just a handful of common variants within these genes are 
associated with T2D or related traits in GWA studies. Far more nuclear-encoded 
mitochondrial (NEM) genes may contribute to T2D but their effects may be too small 
to detect by testing each SNP individually. An alternative approach is to analyse 
groups of functionally related genes that form biological pathways. Pathway analyses 
have shown oxidative phosphorylation, which takes place within the mitochondrion, 
is down-regulated in T2D, however, several SNP-based pathway analyses failed to 
detect any association between mitochondrial pathways and T2D. 
 
The study presented here attempts to identify NEM biological pathways associated 
with T2D. A total of 38 manually curated NEM gene sets were identified from public 
databases. Summary results from multi-marker, GWA scans for T2D in European and 
African American samples were then used to test for association with these gene sets. 
Five of the 38 gene sets tested show potential evidence of association with T2D in 
both European and African American data sets. T2D-associated NEM gene sets 
include those that represent pyruvate metabolism, the tricarboxylic acid cycle, and 
mitochondrial protein translation, collectively emphasising the role of ATP 







In this Chapter I present a pathway analysis of NEM genes to test for potential 
association with T2D. The rationale for a pathway analysis is that by simultaneously 
analysing a set of genes that represent a well-defined biological pathway, it may be 
possible to detect individually weak, but functionally coordinated changes in the 
biological processes that underlie complex traits. Several pathway-based studies in 
relation to T2D have been conducted (Perry et al., 2009, Segre et al., 2010, Mootha et 
al., 2003). Here I present a modified pathway analysis based upon summary results 
from a powerful genome-wide analysis of European and African American samples 
using a multi-marker test of association. 
 
Identification of NEM Genes 
The first stages of the analysis are to define what constitutes a NEM gene and 
comprehensively identify them all. Multiple strategies have been employed to 
catalogue all NEM genes in the genome, these strategies can be broadly split into 
three types of information: sequence-based, mass spectrometry, and microscopy; for 
an excellent review of current methods, see Calvo and Mootha (2010). In this section 
I will provide an overview of these methods as it is important to understand for this 
Chapter. 
 
One mechanism of importing proteins encoded by NEM genes from the cytoplasm 
into the mitochondrion is through a cleavable targeting amino acid sequence at the N 
terminal of the protein (Figure 5.1). These “post codes” are less than 100 amino acids 
(Neupert and Herrmann, 2007, Calvo and Mootha, 2010), and are read by 
transmembrane mitochondrial proteins that mediate the translocation; once within 
their pre-determined location the targeting sequence is cleaved from the protein. 
 
Conservation of the targeting sequence in mitochondrial proteins allows identification 
of these proteins using bioinformatic tools, e.g. Target P (Emanuelsson et al., 2000), 
MitoPred (Guda et al., 2004), and MitoProt2 (Claros and Vincens, 1996) that 
interrogate amino acids sequence of nuclear proteins for conserved motifs. However, 
not all proteins are imported into the mitochondrion in this way and many non-




reasons, algorithms based purely on target sequence alignment, i.e. without prior 
experimental evidence of mitochondrial localisation can suffer from high false 
positive and negative rates. 
 
Mass spectrometry is another extremely fruitful technique to identify proteins. The 
first stage of this approach applied to the mitochondrial proteome is the isolation and 
purification of mitochondria, and then the population of proteins within this 
mitochondria-enriched fraction are analysed. Depending on the type of mass 
spectrometry being performed the proteins may or may not be digested with trypsin. 
Computational analysis of the resulting mass-charge ratio spectra can then be used to 
identify the proteins. 
 
One of important analytical challenge for cataloguing the mitochondrial proteome 
through mass spectrometry is the lack of sensitivity (i.e. the probability of correctly 
detecting a mitochondrial protein, if it is present in the sample). Pagliarini et al. 
(2008) present data on the sensitivity of different analytical techniques based solely 
mass spectrometry in comparison to an integrative approach. Average sensitivity 
amongst the single methods compared was approximately 30%, which is interpretable 
as these methods detecting only 30% of mitochondrial proteome. Tissue specific 
expression of NEM gene and detection bias of the most abundant proteins in the 
sample may explain why this figure is so low. 
 
A third approach to identify proteins localised in the mitochondrion is 
immunofluorescence microscopy, whereby proteins are visualised by the attachment 
of an immunoflorescent antibody. For large-scale purposes, such as at the proteome 
level, this method is laborious and results are potentially influenced by the antibody 
used. Hence, this method is more suited to relatively small-scale, focused studies. 
 
In view of the technical and analytical challenges of any single method to catalogue 
the mitochondrial proteome, Calvo et al. (2006) have developed a whole-genome 
integrative approach to predict human mitochondrial protein localisation. The 
principle of this method is the creation of an aggregate score, termed “Maestro”, 
designed to reflect the probability that a protein localises to mitochondria. The score 




evidence: presence of target sequences, protein domains, regulatory elements, yeast 
homology, ancestry, co-expression, PGC1 alpha-biogenesis induction, and mass 
spectrometry. Proteins with a Maestro score greater than a predefined threshold are 
considered to localise to the mitochondrion, with the threshold selected to maximise 
both sensitivity and specificity. 
 
Pagliarini et al. (2008) extended the work of Calvo et al. (2006) by integrating mass-
spectrometry and GFP tagging of the mitochondria proteome from 14 mouse tissues 
with the other prediction methods of mitochondrial localisation listed above 
(excluding biogenesis induction) to calculate Maestro scores. In total this 
compendium of mitochondrially-localised proteins, named MitoCarta, currently lists 
1,098 mouse genes and their 1,013 human orthologs 
(http://www.broadinstitute.org/pubs/MitoCarta). 
 
The data made available by Pagliarini et al. (2008), in addition to providing a 
comprehensive list of mammalian mitochondrial proteins, present fascinating insights 
into the differential expression of these proteins across various tissues. Of particular 
interest are that a third of genes encoding mitochondrial proteins are ubiquitously 
expressed, the number of mitochondrial proteins per tissue detected by tandem mass 
spectrometry range from 554 to 797, and mitochondrial content, as assessed by 







Figure 5.1. Proteins are targeted to locations within the mitochondrion through 








Figure 5.2. MitoCarta protein expression and mitochondrial quantity across 14 
tissues (Pagliarini et al., 2008). 
Images A - D show potential tissue specificity by the nuclear-encoded mitochondrial 
genes (NEM genes) of MitoCarta. Approximately a third of all proteins encoded by 
NEM genes are ubiquitously expressed as detected by tandem mass spectrometry, 
whilst a quarter of the proteins encoded NEM genes could not be detected using this 
method (A-B). From the correlation matrix (C) it appears some of the tissues relevant 
to glucose homeostasis (adipose, liver, and skeletal muscle) show partial but not 
complete correlation of expressed NEM genes. The heart is by far the most 







The use of single marker association tests is widespread in dissecting the genetic 
architecture of complex diseases. With a few exceptions, the actual susceptibility 
variant(s) and their contribution to the trait, remain unidentified. Interaction between 
susceptibility variants within the same gene or between genes in biological pathways 
further adds to the difficulty in elucidating the biological impact of these variants. 
Therefore, many have adopted a more holistic approach of knowledge-based 
biological pathways to search for novel susceptibility loci. The set of genes that 
comprise a biological pathway can be used as framework to test for enrichment of 
association signal.  
 
The basic scheme for pathway-based analyses of GWA data consists of five stages 
(Wang et al., 2011). In the first stage, SNPs are mapped to genes by their 
transcriptional start and end coordinates. The start coordinate can be extended to the 
promoter region of the gene, the size of this region varies widely but a generic 1 Kb 
upstream of the transcriptional start site of the gene can be used to cover proximal and 
core elements of the promoter (Maston et al., 2006). Regulatory motifs, such as 
enhancer, silencer, and insulator elements can be located much further away and at 
either end of the gene. Therefore deciding where a gene start and end depends on the 
context of the study, usually 5-10 Kb both upstream and downstream of the coding 
region is defined as a gene unit, but can be up to 500 Kb in both directions for 
regulatory regions of very large genes. 
 
Each gene unit contains numerous SNPs each with a single association test statistic; 
pathway analyses require every gene to be represented by a single test statistic. 
Therefore, the multiple SNP associations for each gene must be collapsed into a 
single measure of association; the most frequently used method in the literature is to 
assign the most significant SNP p-value to the gene. 
 
Once SNPs are mapped to genes and a suitable summary gene-level statistic is 
chosen, the second stage in a pathway analysis is the assignment of genes into 
molecular pathways. A plethora of public pathway annotation databases are available 




Selecting the most appropriate database depends on the research question and the 
available data, e.g. SNP, expression data, or methylation probe identifiers. Most, if 
not all, databases have cross-platform utility to convert standard commercial 
identifiers into a unique, unambiguous, internal identifier. Choice of internal identifier 
used in the database has implications for the conversion. For example, if multiple 
transcript probe identifiers can only be mapped to a single Ensembl or UCSC gene 
identifier, important information is lost through this form of reductionism. The 
transcript probes may discriminate alternative splice variants of the gene, some of 
which may have distinct or opposing roles. 
 
Curation of biological pathways in these databases is of paramount importance in 
pathway analyses; curation can either be manual or automated. The latter far 
outnumbers the former in number of pathways deposited in databases and the 
automated pipeline has the potential for rapid incorporation of new data as it appears 
in the literature. However, this dependence on text mining algorithms may give rise to 
inaccurate pathways with a lack of human review and it is for this reason manually 
curated pathways are usually preferred where possible. Manual pathway curation is 
the result of human review of experimental work and thus regarded as the more 
reliable of the two. 
 
Obtaining large-scale data is no longer a challenge in the field; the constraint lies in 
how the results are interpreted and only a proportion of biological pathways have 
been fully described (i.e. all components of the pathway characterised by functional 
work). This is the ultimate goal of pathway annotation. Many more pathways are 
understood to be incomplete and only more experimental work will allow their 
annotation to fully emulate the biological pathway. Until then this limitation is 





Name  Curation Major features URL 
Biocarta  M Driven by user input with expert review of some pathways  http://www.biocarta.com/  
DAVID  M/E Augments and integrates annotations from other databases  http://david.abcc.ncifcrf.gov/  
GO  M/E 
Largest database; hierarchical structure; can filter data by evidence 
codes  
http://www.geneontology.org/  
Ingenuity  M/E Large collection of canonical pathways; high-quality pathway maps  http://www.ingenuity.com/  
Kyoto Encyclopedia 
of Genes and 
Genomes (KEGG)  
M 
Reference pathways (mosaics from several organisms) and 
organism-specific annotations; pathway maps link to closely related 
genes  
http://www.genome.jp/kegg/  
MetaCore  M Extensive disease pathways; can edit pathway maps for publication  http://www.genego.com/  





Can download pathways from several other databases as a 
collection for input to analytical software; novel groupings (e.g. 
motif gene sets)  
http://www.broadinstitute.org/gsea/ 
msigdb/index.jsp/  
PANTHER  M Can predict protein functions from sequence and evolutionary data  http://www.pantherdb.org/  
Pathway Interaction 
Database (PID)  
M/E 
Broad range of cellular pathways with special focus on cancer 
signaling; can generate interaction maps from a list of genes  
http://pid.nci.nih.gov/  
Reactome  M 
Pathways are extensively cross-referenced to PubMed, HapMap 
and other resources; can overlay expression or other data onto 
pathway maps  
http://www.reactome.org/ReactomeGWT/ 
entrypoint.html/  
ResNet Series  M/E 
Regular updates through web server; optional user editing or text 
scanning of user documents; links to reference articles  
http://www.ariadnegenomics.com/  
 
Table 5.1. Public databases for listing molecular pathways and providing pathway analysis algorithms (Ramanan et al., 2012) 






Allocation of genes to pathways in the databases is, in some aspects, an artefact of the 
studies and analyses performed and therefore may not recapitulate actual biological 
complexity. Each member of a pathway in database is given equal importance, which 
may not be true for all pathways; moreover there may be complementary mechanisms 
that rescue a pathway under certain conditions. In spite of this, manually curated 
pathways, as units of analysis, are our best attempt to reflect the biology. 
 
Some of the pathway resources listed in Table 5.1 are briefly described here to 
provide an overview and background to the following section on statistical analysis of 
pathways. 
 
Consistent gene descriptors across multiple databases are vital to study any biological 
pathway. The Gene Ontology (GO) project (Gene Ontology, 2013) is a major 
resource cataloguing standardised vocabulary to describe gene products. Gene 
products are described by annotation terms across three ontology domains: cellular 
component, molecular function, and biological process. 
 
The hierarchical system of GO allows the user to define the level of information 
required. For example, if one were interested in glucose metabolism (GO:0006006) in 
humans there are currently 390 gene products under that GO term. Refining the 
search specifically to gluconeogenesis reduces the number of gene products to 85; 
further refinement of the GO search term to regulation of gluconeogenesis 
(GO:0006111) contains 24 genes. With more general GO terms, the number of gene 
products increases, as does the difficulty in determining the biological significance of 
the pathway analysis. 
 
The quality of the annotation of a gene product can be assessed by its evidence code, 
which expresses how the annotation information was acquired, i.e. through 
experimental or computational methods, or in a very small proportion of annotations 
such information is not available (Rhee et al., 2008). As of November 2012, the 
number of human gene products annotated was 44,914. A number of GO-based tools 






Biocarta is an example of an exclusively manual curated database, where users can 
add new pathways or amend existing pathways after review. It is ultimately a 
database of biological pathways with no facilities to perform statistical analysis; 
therefore, its primary use is the retrieval of pathway information. Biocarta pathways 
are displayed as an interactive image whereby individual elements of the pathway are 
linked to additional information and other bioinformatics repositories. The list of 
genes in a pathway can also be viewed as text presented as full gene names with 
NCBI gene identifier, which is useful for gene set analysis. 
 
The Kyoto Encyclopedia of Genes and Genomes, KEGG (Kanehisa and Goto, 2000), 
resource aims to provide a representation of biological systems (at time of writing, n = 
272,804; http://www.kegg.jp/kegg/docs/statistics.html) across a range of organisms, 
despite its manual curation. KEGG presents this information across 15 databases 
spread across 3 broad categories of systems, genomic, and chemical information. Like 
BioCarta, KEGG also uses interactive pathway diagrams and provides additional 
pathway information. 
 
The Molecular Signature Database (MSigDB) was developed as a resource for use in 
the gene-set enrichment analysis (GSEA), such as notable studies by Mootha et al 
(2003) and later by Subramanian et al. (2005). It is currently in its third major release 
(v3.1; October 2012) listing 8,513 gene sets across six collections reflecting their 
source – chromosomal location, manually curated, shared regulatory motifs, 
computational, gene ontological, and oncogenic signatures. Distribution of gene sets 
by collection in v3.1 is presented in Figure 5.3. The investigative gene set feature of 
MSigDB can be used to integrate a user’s list of genes with biological pathways, 
where those genes appear most frequently and provide an informative summary of the 













Gene identifiers from a variety of platforms can be ambiguous, resulting in multiple 
identifiers for the same gene or the same identifier corresponding to multiple genes. 
Like many gene set databases, MSigDB efficiently handles this potential ambiguity 
by mapping input gene identifiers to a common identifier. Alternatively gene 
identifiers can be converted prior to searching for gene sets using freely available 
tools such as BioMart ID converter, DAVID Gene ID Conversion Tool (Huang da et 
al., 2008), and IDconverter (Alibes et al., 2007) to name but a few.  
 
Internal identifiers need to possess certain properties that facilitate their use, for 
example, they need to be unique, unambiguous - i.e. provide a 1:1 correspondence 
between identifier and gene, stable, and well integrated within many biological 
databases. The MSigDB uses the Entrez gene identifier as the internal identifier 
because it fulfills all these requirements. 
 
MSigDB was chosen for this study for a number of reasons. The first being it is freely 
available to the public, secondly because it allows the user to batch query a list of 
genes and automatically search for overlap with gene sets within the database. 
Thirdly, the MSigDB contains the largest number of manually curated gene sets (at 
the time of writing, 4,850 gene sets), which is considered the most reliable form of 
curation. The latter point is also related to the high-level of integration with other 




The third stage of a pathway analysis is to decide on what hypothesis is being tested. 
Goeman and Buhlmann (2007) describe two types of pathway analysis - competitive 
and self-contained tests, differing in their definition of the null hypothesis and 
interpretation. In a competitive test, the null hypothesis is that the association of genes 
of a particular pathway are no different from the association of genes selected at 
random from the genome (matched for size). 
 
A self-contained test simply asks whether there is an association between a pathway 




constructed by combining the p-values for all genes in the pathway, for example by 
Fisher’s method, and the pathway p-value is then compared to a standard probability 
distribution. The test is described as self-contained as the input data is only from 
genes of a single pathway; association information from genes outside that pathway is 
not required. 
 
Statistical Analysis of Pathways 
Stage four of a pathway analysis is the statistical test. Traditionally pathway analyses 
were designed to be applied to genome-wide expression microarray experiments. For 
example, translating a list of differential expressed genes between two conditions (e.g. 
case-control, exposure to a drug, etc.) into appropriate biological pathways. These 
pathway methods have been adapted to analyse data GWA scans. 
 
The simplest form of pathway analysis compares a list of genes deemed significant 
with known pathways. The null hypothesis being tested is that the list of genes of 
interest (e.g. significant SNPs from a GWA scan) is not significantly overrepresented 
in the pathways tested. In practice it is a count of genes on the significant list in a 
pathway compared with a count of the list not on the pathway that are formally 
compared using a 2 by 2 table contingency table (Table 5.2) and a p value can be 














a b a+b 
Genes not in 
pathway 
c d c+d 
 a+c b+d N 
 
Table 5.2. Two by two contingency table - statistical measures that can be used to 
test for association between phenotypic and molecular pathways. 
 
The test statistic, χ2, is given by: 
 
2 = n(ad – bc)2 / (a+b)(c+d)(a+c)(b+d) 
 
Which is equivalent to the Pearson’s χ2 but avoids calculating expected values: 
 
2 = n(ad – bc)2 / (a+b)(c+d)(a+c)(b+d)  
= (Oi - Ei)2 / Ei2 
 
As the proportion overlap between a pathway and the list of significant genes (cell a, 
Table 5.2) is small under the null, the Fisher exact test is more appropriate. The 
probability of the obtaining the observed values under the null is calculated as 
follows: 
 
Fisher’s exact test: 
 







An obvious question for a competitive test is, what list of genes is the pathway genes 
compared to? The comparison list of genes could be all genes of the genome or 
restricted to those that were actually tested for association. The latter option is the 
more rational approach as it avoids any possibility of introducing genes that were not 
included in the analysis. For example, if SNP data is used, the comparison list of 
genes should be confined to genes with SNPs that have passed quality control (QC), 
which is a preliminary step in all genome-wide studies, but is important to remember 
for these purposes. Genes without any SNPs that have passed the QC filter are should 
not be represented in the analysis. 
 
A number of groups have explored gene-set based overrepresentation approaches with 
a variety of gene scores and test statistics, some of examples are listed in Table 5.3. 
 
 
Table 5.3. Defining features of selected overrepresentation approaches (Wang et 
al., 2011). 
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Gene Set Enrichment 
Alternative to having to specify a significance threshold, enrichment methods rank all 
genes in order of significance, and then test for differences between ranks of genes in 
a pathway compared to non-pathway genes. Mootha et al. (2003) introduced GSEA as 
part of a gene expression microarray study of T2D; the approach starts by ranking 
genes (one expression probe per gene) according to difference in gene expression 
between normal and disease states. A schematic diagram of this non-parametric 
statistical test is presented in Figure 5.4. The gene ranking is used to construct a 
running sum statistic for each gene set, from the first ranked gene, the test statistic 
increases or decreases by a value depending on whether the gene is a member of the 
gene set (S) being considered. The maximum enrichment score (MES) for each gene 
set is defined as the largest positive deviation of the running sum. Significance of the 
MES is assessed by permutation of phenotype labels and recalculation of the MES; 
the p-value is calculated as the fraction of MES from the permutated data sets that are 
greater than the observed MES. The process is repeated for all gene sets being 
considered. 
 
Through GSEA, Mootha et al. (2003) identified the oxidative phosphorylation gene 
set as being down regulated in T2D. Further examination of the gene set revealed a 
subset that accounted for the majority of the MES for the oxidative phosphorylation 
gene set and that the expression of this subset was reduced in individuals with 
impaired glucose tolerance but not normoglycaemic. This study demonstrates the 
effectiveness of gene set methods over single gene methods in that conventional 
microarray analysis were unable to detect any genes that showed significant 
differential expression between normal and disease states, whereas GSEA identified 








Figure 5.4. Gene set enrichment analysis (Subramanian et al., 2005). 
This figure outlines the method of gene set enrichment analysis (GSEA). The procedure 
begins with genome-wide, case-control microarray expression data; genes are ranked in 
accordance with the differential expression between the two phenotype classes (A). For a 
particular gene set, S, the aim is to determine if genes of S appear predominantly at the top or 
bottom of the ranked list, or are uniformly distributed. The enrichment score of the gene set, 
ES(S) is calculated by walking down the ranked list and increasing the running score 
whenever a gene from S is encountered and conversely it decreases when genes from S do not 
appear. The score is weighted by phenotypic correlation/association meaning that the score 
increases/decreases more largely for genes of S at the top and bottom of the ranked than those 







There are potential sources of bias in each of the five stages of a gene set analysis, 
some can go unnoticed, without any effect on the final results, whereas others have 
effects that cloud any putative signal. The allocation of SNPs to genes is relatively 
straightforward; one minor consideration is that of nested genes, that is the spatial 
arrangement of one gene within another gene. A gene nested within another maybe 
fully contained within an intron or spread across introns and exons of the larger gene. 
Based on a 2004 build of the human genome, Yu et al. (2005) estimated there were 
373 nested genes in the human genome. A simple one gene nested with a larger host 
gene is considered here for simplicity, but other possibilities such as multiple nested 
genes with the same gene or more complicated scenario of two physically overlapping 
genes (Kumar, 2009). 
 
If a SNP is assigned to both genes and both are biologically related, i.e. act in the 
same pathway; this will give rise to false evidence of enrichment for that particular 
pathway. A preliminary check in the analysis can reveal overlapping gene boundaries 
within each pathway under analysis. As nested genes makeup a very small proportion 
of all genes in the genome, they are the least important source of bias. 
 
A second SNP-related bias is the variability of SNPs between genes. Genome-wide 
arrays are design to maximise coverage of SNPs with the minimum number of SNPs 
through LD. Because LD represents lack of recombination and recombination rates 
vary across the genome, genes of the same physical size will vary on a genetic scale 
and the number of SNPs required for adequate coverage. Genes with many SNPs will 
be expected to show a greater number of significant associations than genes with 
fewer SNPs – a correlation confirmed by Hong et al. (2009).  
 
Local clusters of genotyped SNPs, such as those within a gene, may show a 
correlation structure, that is, they are not completely independent of each other. 
Genotyped SNPs in high LD between two or more genotyped SNPs is a form of 
redundancy and can be reduced by removing SNPs that are above a certain LD 
threshold. An alternative is to correct the gene test statistic for the number of non-





In GWA studies it is unlikely that a casual susceptibility locus will be represented on 
the array. Instead, it is more likely that a marker SNP is in LD with the putative 
susceptibility locus. The same logic applies to and is extended in gene-based analyses 
- in addition to the one or more genotyped SNPs tagging an non-genotyped variant, a 
variant driving the association signal may not necessarily reside within the gene, but 
could be located some distance away and be in LD with one more SNPs within that 
region. 
 
Non-independence in gene set analyses also occurs within and between gene sets; 
members of the same gene set are likely to be non-independent in terms of expression. 
And when testing more multiple gene sets, some gene sets maybe more related to 
others through shared members. Non-independence between genes in a pathway being 
tested violates an assumption of most standard statistical tests, which usually assume 
identical, independent distributions (IID) for each data point. This includes 
hypergeometric tests and Fisher’s exact test. A positive correlation between the genes 
of a pathway can artificially inflate the apparent association with a trait. Under the 
null hypothesis, the probability distribution is no longer hypergeometric (Goeman and 
Buhlmann, 2007) for correlated genes and the test produces an inflated p-value. 
Goeman and Buhlmann (2007) simulate how intra-pathway gene dependencies affect 
the p-value of a pathway; the proportion of pathways rejected under the null increases 
for correlations of 0.2 through to 1. For example, at a correlation (r) of 0.2 and alpha 
threshold of 0.05, the increase in proportion of pathways rejected under the Null 
compared to r = 0 is 1.9 fold; for the same r of 0.2 but an alpha of 0.0001, the 
increase in proportion rejected is 2.24 fold greater. The trend exhibits greatest effect 
for tests with smaller alpha threshold and large correlations. 
 
Gatti et al. (2010) investigated the issue of intra pathway dependency using 202 data 
sets from the NCBI Gene Expression Omnibus data repository. They confirm the 
ubiquitous presence of inter-gene/intra-pathway correlation and find that violation of 
the independence assumption can increase the false positive rate up to 80%. The 
authors argue that in a expression microarray context, permutation of the gene labels 
handles intra-pathway correlation and the significance of the observed pathway test 
statistic is determined through comparison with an empirical null distribution of 





One final important source of bias is size variation for genes and gene sets. The size 
of a gene can vary on both genetic and physical scales; for example, genes of similar 
physical length may vary widely on a genetic distance, which is related to the 
underlying rate of recombination in the regions where the genes are located. If an 
additive genetic map is available, gene sets can be compared in terms of total genetic 
and physical lengths. The total length of a gene set is a combination of the length of 





Materials and Methods 
Subjects and Data 
This study analysed the GWA results from European (WTCCC1) and African 
American (National Institute for Diabetes and Digestive and Kidney disease) LD 
mapping studies for T2D (Lau et al., in preparation). LD mapping has been described 
in detail elsewhere (Maniatis et al., 2002, Zhang et al., 2002, Maniatis et al., 2004). 
The main advantages of this approach are (1) it does not assume that the susceptibility 
variant is genotyped nor in high LD with a genotyped marker; and (2) facilitates 
informative multi-marker tests of genetic association with a phenotype. This approach 
has recently been applied to Crohn’s disease and identified more than 200 
susceptibility loci (Elding et al., 2011, Elding et al., 2013), far surpassing the number 
from conventional GWA studies for Crohn’s disease. 
 
Definition of NEM Genes 
The entire list of 1,024 human NEM genes was downloaded from MitoCarta 
(Pagliarini et al., 2008), http://www.broadinstitute.org/pubs/MitoCarta/). Entries with 
duplicate Human Entrez identifiers were removed (n = 11), as were entries located on 
the mitochondrial genome (n = 13), X chromosome (n = 30) and Y chromosome (n = 
1). This filter returned 968 unique Entrez identifiers. Gene coordinates provided by 
MitoCarta were UCSC human assembly March 2006 (hg18) and were converted to 
UCSC human assembly May 2004 (hg17) to be compatible the genomic data used. 
Build conversion was performed using the LiftOver tool (http://genome.ucsc.edu/cgi-
bin/hgLiftOver); all 968 gene coordinates were successfully mapped to hg17. 
 
NEM Gene Sets 
Pathway membership for each NEM gene was identified through the MSigDB 
(http://www.broadinstitute.org/gsea/msigdb). Symbols for each known NEM gene 
were uploaded to the MSigDB: 955/968 submitted gene identifiers were recognised 
by the database and the top 100 overlapping gene sets with the manually curated 
collection (C2) were obtained. From this list of 100 gene sets, any gene set with less 
than 50% of NEM gene members were filtered out, resulting in 37 gene sets taken for 




made up the majority of the biological pathway. In addition, the full MitoCarta NEM 
gene list was also included as a separate gene set, in total 38 gene sets were analysed. 
All genes of NEM gene sets were included in the analysis including non-NEM genes. 
 
NEM Gene Set Tissue Specificity 
There is evidence of tissue specific expression of NEM genes at the protein level 
(Pagliarini et al., 2008). To potentially identify tissue-specific NEM gene sets related 
to T2D – namely, adipose, liver, and skeletal muscle – pathway gene memberships 
were obtained for each list of expressed NEM genes by using MSigDB as described 
above. As the tissue specific lists are subsets of the original NEM gene list, the 
majority of tissue specific NEM gene set memberships were the same as obtained for 
the full list of NEM genes; however, a novel gene set that met the definition of a 
NEM gene set (i.e. >= 50% of genes are NEM genes) in the liver sample of NEM 
genes was identified. 
 
Genomic Regions 
Using the location estimate for each analytical window, an additional 2 LDUs were 
added to each side of the functional variant estimate to create the genomic region of 
interest; the value of 2 LDU was chosen as values greater than 3 reflect large genetic 
distances with substantial breakdown in LD. LDU locations were interpolated onto a 
physical map so that genes could be allocated to genomic regions by overlapping start 
and end physical coordinates. Build 35 was used for the European data set and build 
36 for the African American. 
 
Gene Set Size 
Gene set size is the number of genes of a gene set; not all genes of a gene set fall 
within the genomic regions as defined above, reducing the gene set size. 
Supplementary Tables 5.1 – 5.4 list all 38 NEM gene sets considered for analysis 
along with the gene set size, number of mapped genes and genes within genomic 
regions for the European and African American data sets.  
 
The average percentage of genes from NEM gene sets that could be mapped to the 




which is due to Ensembl returning multiple start and end coordinates for a single gene 
and likely to reflect the presence of more than one viable transcriptional start and stop 
site. As the differences between the alternative sites were very small, both sets of 
coordinates were kept. 
 
Rather than number of genes of a NEM gene set, of greater importance for this 
analysis is the number of genomic regions that contain genes from a particular NEM 
gene set. I refer to this as the effective gene set size, because genes located outside the 
defined location estimate genomic region (but still within the analytical window) are 
unlikely to be responsible for any observed association with T2D. The Ringo package 
(Toedling et al., 2007) was used in R (R Development Core Team, 2011) to compute 
overlap between genomic regions and gene coordinates. For each NEM gene set, a 
binary label was assigned to each genomic region to indicate the presence (1) or 
absence (0) of genes from the NEM gene set.  
 
Where a gene overlaps neighbouring genomic regions, the gene is assigned to both 
genomic regions. There is an approximate 1:1 correspondence between the number of 
genomic regions with genes of a NEM gene set (effective gene set size) and the 
number of genes within the genomic regions (Supplementary Table 5.3). The average 
percentage of genes from NEM gene sets within genomic regions for the European 
and African American data sets were 34% and 25% respectively. 
 
Extent of NEM Gene Set Overlap 
To correctly address the issue of multiple testing using a Bonferroni correction, it is 
important to quantify how many independent tests are performed. Overlap between 
two NEM gene sets was calculated by combining the unique genes into one list and 
expressing the proportion of that list shared by both gene sets. The overlap results 
(Figure 5.5) were plotted using the Lattice package (Sarkar, 2008) in R. As the figure 
illustrates, there is very little overlap between the 38 NEM gene sets, which means the 
tests are essentially independent and therefore a Bonferroni correction is valid. The 
Bonferroni corrected alpha threshold at 5% for 36-38 independent tests is 
















Figure 5.5. NEM gene set overlap for European and African American data sets. 
Plots A and B illustrate the extent of overlap between all 38 NEM gene sets. The 
overlap is expressed as the proportion of genes shared between any two NEM gene 
sets, 0 indicates that no genes are shared, whilst 1 indicates all genes are shared. The 






For each of the 38 NEM gene sets, a two-sample t-test was used to test if the mean 2 
association statistic for T2D was greater for genomic regions that contained genes of 
the NEM gene set against those that did not. An empirical p-value was obtained for 
each NEM gene set by permuting gene-membership status 100,000 times, the 
empirical p-value is given by the proportion of permuted test statistics that are equal 
to or more extreme than the observed test statistic: ∑(tn..N>t0)/ N. Where, tn..N 
represents the test statistic (t) from each permutation, t0 is the observed test statistic, 
and N is the total number of permutations. 
 
Over-Representation Analysis 
For comparison with the quantitative analysis above, which compared the distribution 
of chi-square statistics for NEM gene set versus non-NEM gene set genomic regions, 
a more qualitative test was conducted using a 2x2 contingency classification. Four 
counts were observed in this table: (1) genomic regions that were nominally 
associated (p-value < 0.05) with T2D and contained genes of the NEM gene set, (2) 
genomic regions that were nominally associated with T2D and did not contain genes 
of the NEM gene set, (3) genomic regions that were not associated with T2D and 
contained genes of the NEM gene set, and (4) genomic regions that were not 
associated with T2D and did not contain genes of the NEM gene set. Fisher’s exact 
test as implemented in R was used to test for association between presence of NEM 
gene set members and T2D. Fisher’s exact test as opposed to the contingency χ2 test 
was used because it was anticipated that some cell counts would be small (expected 







Descriptive statistics of the 38 NEM gene sets outlined in the Materials and Methods 
section of Chapter 5 can be found in Supplementary Tables 5.1 – 5.4. The Mean, 
median, and inter-quartile range of the effective gene set sizes for the European data 
set were 33, 13, and 21 genes respectively. For the same gene sets, the African 
American data set had a smaller effective gene set sizes due to the relationship 
between physical and genetic maps. This is observation is explained by the African 
population having shorter stretches of LD due to being much older with more 
historical recombination than the European population, which is the primary cause for 
breakdown in LD. As a result, when genetic distances are interpolated onto a physical 
map they are usually shorter for the African American population. Mean, median, and 
inter-quartile range for the African American data set were 36, 10, and 17 genes 
respectively. Two gene sets were removed from the African American data set due to 
mapped gene set size being less than or equal two genes, thus, only 36 of the 38 
defined NEM gene sets were analysed for this data set. 
 
Over half of the gene sets analysed (n = 21) showed association with T2D-implicated 
loci at an alpha threshold of < 0.10 in the European data set. Replication of these 
results was sought in an independent data set using African American T2D results; 
analysis in this data set produced 19 out of 36 nominally significant gene sets. A gene 
set was considered to be potentially replicated if it is present in both European and 
African American data sets with a p-value less than or equal to 0.10 or replicated, if 
the meta-analysed p-value < 1x10-3. A threshold p-value of 0.10 was used at this stage 
to reduce the probability of over-looking potential association between a gene set and 
T2D. There were 12 gene sets that satisfied this criterion. Analysing the same data 
using overrepresentation analysis in the form of Fisher’s exact test on a 2x2 
contingency table produced just three replicated gene sets below the same 
significance threshold. 
 
To quantify the relationship between effective gene set size and p-value for these data 
(i.e. inflated association due to large gene set size), all manually curated gene sets 
deposited in the MSigDB (4,850 gene sets as of release 3.84, October 2012) were 




for effective gene set size explained approximately 37% of the variance in gene set –
log10 p-value. A simpler linear model omitting the quadratic term had an adjusted R
2 
of 35% (Table 5.4). Figure 5.6 illustrates that the regression line from the full model 
including a quadratic term fits the data only slightly better than the linear model gene 
set sizes greater than 300. 
 
Model Term  
Standard 
Error 
t statistic  p-value Adj. R2 
A 
Intercept 4.81x10-3 8.81x10-3 54.64 <2x10-16 
35.13 
Set size 5.97x10-3 1.17x10-4 50.81 <2x10-16 
 
B 
Intercept 0.42 9.92x10-3 42.20 <2x10-16 
37.32 Set size 8.77x10-3 2.46x10-4 35.69 <2x10-16 
(Set size)2 -8.25x10-6 6.38x10-7 -12.94 <2x10-16 
 
Table 5.4. Linear and quadratic regression models for the effect of gene set size 
on gene set p-value. 
In both the simple linear regression (A) and the quadratic model (B), effective gene 
set size has a highly significant effect on the p-value of the gene set and explained to 
35-37% of the variance in the gene set p-values. These regression coefficients were 
applied to the 38 NEM gene sets and gave identical results in terms of NEM gene sets 








Figure 5.6. A plot of all manually curated MSigDB gene sets (n = 4,850) 
association with T2D (-log10 p-value, y axis) on effective gene set size (x axis). 
The dashed regression line represents the linear regression model omitting the 
quadratic term for effective set size, whereas the solid line represents the regression 





On the basis of model-fit statistics, the quadratic regression model was a marginally 
better fit than the linear model. Alternative effective gene set size correction factors 
were calculated based on the both linear and quadratic models and compared. The 
effective set size corrected p-value was calculated by subtracting the fitted -log10 p-
value from the model from the observed -log10 p-value. The two correction factors 
gave identical results in terms of NEM gene sets considered significantly associated 
with T2D in the individual data sets and replication. For the European data set, 15 
NEM gene sets were significantly associated with T2D after correcting for effective 
set size; a similar result was found in the African American data set, whereby 12 
NEM gene sets were significantly associated with T2D. Five NEM gene sets 
corrected for effective set size were significantly associated at an alpha of 0.10 in both 
data sets (Table 5.5). 
 
Fisher’s method (Fisher, 1925) was used to meta-analyse p-values from these five 
NEM gene sets and these are presented in Table 5.5. As 36-38 independent NEM 
gene set tests were performed, the appropriate significance threshold is an alpha of 
1x10-3, at which only one NEM gene set (NEMG988) is considered significantly 











t statistic  p-value Adj. p-value 
Effective  
Set size 
t statistic  p-value Adj. p-value 
NEMG988 324 3.29 1.00x10-5 2.49x10-3 248 2.85 2.50x10-4 3.06x10-2 0.0008 
Wong Mitochondria Gene Module 91 2.57 5.00x10-4 7.04x10-3 56 1.84 1.00x10-2 7.67x10-2 0.005 
Reactome Pyruvate Metabolism and 
Citric Acid TCA Cycle 
17 1.95 3.08x10-3 1.13x10-2 12 1.40 2.88x10-2 9.61x10-2 0.008 
KEGG Citrate Cycle TCA Cycle 10 1.64 9.22x10-3 2.95x10-2 10 1.39 2.94x10-2 9.41x10-2 0.02 
MIPS 28S Ribosomal Subunit 
Mitochondrial 
13 1.66 8.89x10-3 3.02x10-2 10 1.77 7.33x10-3 2.35x10-2 0.006 
 
Table 5.5. Replicated gene set associations between European and African American data sets. 
Gene sets listed in this table have an effective set size adjusted p-value at less than or equal to 0.10 in both European and African American data 






The potential tissue specific expression of NEM gene sets was explored using NEM 
gene expression data from Pagliarini et al. (2008). Tissues of particular interest in this 
study were adipose, liver and skeletal muscle as they are major sites of insulin action. 
The number of NEM gene sets shared between these three tissues is presented in 
Table 5.6. A large proportion of all NEM gene are expressed in adipose tissue, which 
means for the purpose of identifying NEM gene sets, the full list and adipose-
expressed list of NEM gene are for practical purposes the same. By contrast, using 
NEM gene expressed in skeletal muscle identified only 68% of the known NEM gene 
sets. The list of NEM genes expressed in the liver produced a unique NEM gene set 
not identified using the full NEM gene list, which was tested in the same way as the 





Adipose Liver Muscle 
Complete 
MitoCarta 
37 - - - 
Adipose 37 37 - - 
Liver 31 31 32 - 
Muscle 25 25 24 25 
 
Table 5.6. Overlap between gene sets identified through the MSigDB using lists 
of expressed NEM genes. 
Values in the table represent the total number of gene sets identified for each tissue 
(diagonal) and the number of NEM gene sets shared between the three tissues. The 
majority of gene sets identified from the NEM genes expressed in each of three 






With the exception of the NEMG988 and Wong mitochondrial gene sets due to their 
large sizes (Supplementary Table 5.1, 5.2, and 5.4), the results for other replicated 
NEM gene sets (Reactome pyruvate metabolism and citric acid TCA cycle, KEGG 
citrate cycle TCA cycle, and MIPS 28S ribosomal subunit mitochondrial) are 
presented in much greater detail in Tables 5.7-5.12. The tables provide the location 
estimate (Ŝ) of the disease-susceptibility variant(s), its confidence interval, the size of 
the genomic region and the association statistic for the analytical window. The final 
two columns indicate whether the location estimate is within the gene coordinates and 
if the gene is located with the confidence interval for the analytical window. 
 
A comparison between the European and African American results for any of the 
three replicated NEM gene sets reveal that gene set membership and size is not 
identical between the two samples. For example, the Reactome pyruvate and TCA 
cycle gene set has 17 genes (Supplementary Tables 5.1 and 5.2), all 17 are located 
within the genomic regions for the European sample (Supplementary Table 5.4) but 
only 12 are located within the genomic regions for the African American sample 
(Supplementary Table 5.4). The largest discrepancy in gene set membership and size 
between the European and African American samples is the Reactome pyruvate and 
TCA cycle gene set, in which there are four more genomic regions (Supplementary 
Table 5.4) in the European sample to which the genes of this gene set could be 
mapped to. This is a feature of mapping genes using a genetic rather than physical 
location and as explained previously, a genetic distance interpolated into a physical 
distance is usually shorter in the African American sample, resulting in a smaller 
genomic region to map genes into. 
 
It can be seen from the 2 test statistics presented in Tables 5.7-5.12 that no NEM 
gene set contains unduly influential analytical windows. Taken as a whole, 68% of the 
analytical windows for the three replicated NEM gene sets have a significant (2 > 
3.84) association statistic; individually, no NEM gene set has less than 50% of 
analytical window deemed significant. This demonstrates the mean 2 for each NEM 





The general NEM gene sets as defined by MitoCarta and Wong et al. (2008) both 
contain genes located in genomic regions with very large 2 test statistics but these 
occurrences are infrequent. To illustrate this, the largest gene set, the MitoCarta list of 
approximately 1,000 NEM genes (378 genes in genomic regions, Supplementary 
Table 5.4), maps to 324 genomic regions in the European sample, with 317 of the 324 
genomic regions below the 99th percentile for 2 test statistic distribution in this data 
set. The same gene set for the African American data sets maps to 248 genomic 
regions (277 genes in genomic regions, Supplementary Table 5.4), 241 of the 248 



























SDHC 158.097-158.146 1q 158.292 158.129 158.405 158.088 158.375 0.27 6.07x10-1 N Y 
SUCLG1 84.562-84.599 2p 84.880 84.816 84.919 84.301 85.052 13.68 2.17x10-4 N N 
PDK1 173.246-173.315 2q 173.358 173.304 173.407 173.120 173.473 7.45 6.3510-3 N Y 
SUCLG2 67.494-67.788 3p 67.831 67.800 67.865 67.576 67.867 7.83 5.15x10-3 N N 
NNT 43.639-43.743 5p 43.273 43.273 43.301 42.897 43.650 21.78 3.06x10-6 N N 
MDH2 75.322-75.341 7q 75.218 75.182 75.232 75.123 75.492 0.04 8.52x10-1 N N 
DLD 107.125-107.166 7q 107.181 107.078 107.183 107.070 107.198 5.33 2.09x10-2 N Y 
ADHFE1 67.505-67.546 8q 67.589 67.583 67.717 67.409 68.602 0.92 3.38x10-1 N N 
PDHX 34.894-34.999 11p 34.815 34.814 34.815 34.631 34.992 6.90 8.61x10-3 N N 





11q 110.984 110.854 111.290 110.800 111.489 21.07 4.43x10-6 N N 
LDHB 21.680-21.802 12p 21.710 21.706 21.868 21.636 21.909 6.34 1.18x10-2 Y Y 
CS 54.952-54.980 12q 54.906 54.902 54.910 54.683 55.140 1.97 1.61x10-1 N N 
L2HGDH 49.774-49.849 14 49.586 49.586 49.593 49.579 49.877 1.08 2.98x10-1 N N 
IDH2 88.427-88.447 15 88.432 88.429 88.432 88.379 88.507 1.77 1.84x10-1 Y Y 
BSG 0.522-0.534 19p 0.549 0.537 0.556 0.518 0.565 5.91 1.51x10-2 N N 
ACO2 40.190-40.249 22 40.648 40.605 40.908 39.742 41.019 16.51 4.83x10-5 N N 
 
Table 5.7. European results for the Reactome pyruvate metabolism and TCA cycle gene set. 
Genomic coordinates (Mb) are human genome build 35/hg17. χ2 and p-value represent the association of the analytical window with T2D. 
Abbreviations: Chr - Chromosome, CI - confidence interval, CI Gene - gene located with CI of analytical window, Ŝ - location estimate, Ŝ Gene 


























SDHB 17.218-17.253 1p 17.183 17.177 17.231 17.078 17.278 0.47 4.93x10-1 N Y 
FH 239.728-239.750 1q 239.775 239.771 239.778 239.745 239.828 18.82 1.44x10-5 N N 
PDK1 173.128-173.198 2q 173.123 173.070 173.128 173.006 173.284 26.78 2.28x10-7 N Y 
IDH1 208.809-208.839 2q 208.826 208.803 208.849 208.760 209.034 1.47 2.25x10-1 Y Y 
SUCLG2 67.494-67.788 3p 67.768 67.767 67.817 67.697 67.845 51.82 6.08x10-13 Y Y 
PDK4 95.051-95.064 7q 95.019 94.997 95.038 94.963 95.088 5.53 1.87x10-2 N N 
DLD 107.319-107.359 7q 107.282 107.258 107.384 107.249 107.391 0.28 5.97x10-1 N Y 





11q 111.314 111.289 111.457 110.871 111.501 0.79 3.74x10-1 N Y 
CS 54.952-54.980 12q 55.080 55.064 55.099 54.768 55.134 18.29 1.90x10-5 N N 
L2HGDH 49.774-49.849 14q 49.740 49.607 49.797 49.593 49.912 9.84 1.71x10-3 N Y 
SLC16A3 77.780-77.812 17q 77.758 77.631 77.783 77.627 77.783 1.99 1.58x10-1 N Y 
 
Table 5.8. African American results for the Reactome pyruvate metabolism and TCA cycle gene set. 
Genomic coordinates (Mb) are human genome build 36/hg18. χ2 and p-value represent the association of the analytical window with T2D. 
Abbreviations: Chr - Chromosome, CI - confidence interval, CI Gene - gene located with CI of analytical window, Ŝ - location estimate, Ŝ Gene 


























SDHC 158.097-158.146 1q 158.292 158.129 158.405 158.088 158.375 0.27 6.07x10-1 N Y 
MDH1 63.727-63.746 2p 62.798 62.732 62.822 62.636 63.855 27.42 1.64x10-7 N Y 
SUCLG1 84.562-84.599 2p 84.880 84.816 84.919 84.301 85.052 13.68 2.17x10-4 N N 
SUCLG2 67.494-67.788 3p 67.831 67.800 67.865 67.576 67.867 7.83 5.15x10-3 N N 
MDH2 75.322-75.341 7q 75.218 75.182 75.232 75.123 75.492 0.04 8.52x10-1 N N 





11q 110.984 110.854 111.290 110.800 111.489 21.07 4.43x10-6 N N 
CS 54.952-54.980 12q 54.906 54.902 54.910 54.683 55.140 1.97 1.61x10-1 N N 
IDH2 88.427-88.447 15 88.432 88.429 88.432 88.379 88.507 1.77 1.84x10-1 Y Y 
ACO2 40.190-40.249 22 40.648 40.605 40.908 39.742 41.019 16.51 4.83x10-5 N N 
 
Table 5.9. European results for the KEGG citrate cycle TCA cycle gene set. 
Genomic coordinates (Mb) are human genome build 35/hg17. χ2 and p-value represent the association of the analytical window with T2D. 
Abbreviations: Chr - Chromosome, CI - confidence interval, CI Gene - gene located with CI of analytical window, Ŝ - location estimate, Ŝ Gene 


























SDHB 17.218-17.253 1p 17.183 17.177 17.231 17.078 17.278 0.47 4.93x10-1 N Y 
FH 239.728-239.750 1q 239.775 239.771 239.778 239.745 239.828 18.82 1.44x10-5 N N 
MDH1 63.669-63.688 2p 63.712 63.494 63.759 63.062 63.922 48.81 2.82x10-12 N Y 
IDH1 208.809-208.839 2q 208.826 208.803 208.849 208.760 209.034 1.47 2.25x10-1 Y Y 
SUCLG2 67.494-67.788 3p 67.768 67.767 67.817 67.697 67.845 51.82 6.08x10-13 Y Y 
DLD 107.319-107.359 7q 107.282 107.258 107.384 107.249 107.391 0.28 5.97x10-1 N Y 





11q 111.314 111.289 111.457 110.871 111.501 0.79 3.74x10-1 N Y 
CS 54.952-54.980 12q 55.080 55.064 55.099 54.768 55.134 18.29 1.90x10-5 N N 
PCK1 55.570-55.575 20q 55.596 55.595 55.598 55.574 55.604 0.1 7.52x10-1 N N 
 
Table 5.10. African American results for the KEGG citrate cycle TCA cycle gene set. 
Genomic coordinates (Mb) are human genome build 36/hg18. χ2 and p-value represent the association of the analytical window with T2D. 
Abbreviations: Chr - Chromosome, CI - confidence interval, CI Gene - gene located with CI of analytical window, Ŝ - location estimate, Ŝ Gene 


























MRPS21 147.079-147.094 1q 146.809 146.626 146.814 146.528 147.330 3.04 8.13x10-2 N N 
DAP3 152.471-152.522 1q 152.856 152.833 152.893 151.973 152.975 14.80 1.19x10-4 N N 
MRPS23 140.207-140.559 3q 140.522 140.511 140.541 140.332 140.829 32.82 1.01x10-8 Y Y 
MRPS27 71.551-71.652 5q 71.511 71.487 71.517 71.456 71.697 0.29 5.88x10-1 N N 
MRPS33 140.159-140.168 7q 139.790 139.691 139.832 139.669 140.206 4.04 4.44x10-2 N N 
MRPS28 80.994-81.105 8q 81.226 81.004 81.252 80.936 81.253 2.96 8.54x10-2 N Y 
MRPS16 74.677-74.682 10q 74.125 73.724 74.380 73.402 75.367 45.00 1.97x10-11 N N 
MRPS35 27.755-27.800 12p 27.810 27.744 27.857 27.695 27.917 1.76 1.85x10-1 N Y 
MRPS31 40.201-40.243 13 40.038 40.031 40.159 39.968 40.590 22.40 2.21x10-6 N N 
MRPS11 86.812-86.23 15 86.837 86.836 86.838 86.731 86.912 10.92 9.50x10-4 N N 
MRPS34 1.762-1.763 16p 1.716 1.584 1.748 1.455 1.931 4.20 4.05x10-2 N N 
MRPS23 53.272-53.282 17q 53.257 53.222 53.290 53.204 53.295 2.05 1.53x10-1 N Y 
 
Table 5.11. European results for the MIPS 28S ribosomal subunit gene set. 
Genomic coordinates (Mb) are human genome build 35/hg17. χ2 and p-value represent the association of the analytical window with T2D. 
Abbreviations: Chr - Chromosome, CI - confidence interval, CI Gene - gene located with CI of analytical window, Ŝ - location estimate, Ŝ Gene 


























MRPS15 36.694-36.703 1p 36.630 36.630 36.634 36.580 36.705 17.01 3.72x10-5 N N 
MRPS21 148.533-148.548 1q 148.478 148.432 148.484 148.405 148.755 0.84 3.59x10-1 N N 
MRPS23 140.207-140.559 3q 140.477 140.468 140.482 140.344 140.525 6.6 1.02x10-2 Y Y 
MRPS33 140.352-140.361 7q 140.171 140.000 140.293 139.927 140.454 32.41 1.25x10-8 N N 
MRPS2 137.532-137.536 9q 137.523 137.510 137.529 137.510 137.564 0.06 8.06x10-1 N N 
MRPS2 137.532-137.536 9q 137.564 137.529 137.587 137.523 137.569 0.46 4.98x10-1 N Y 
MRPS16 74.677-74.682 10q 75.031 74.399 75.074 74.323 75.077 44.48 2.57x10-11 N Y 
MRPS11 86.812-86.823 15q 86.837 86.836 86.839 86.747 86.942 5.55 1.85x10-2 N N 
MRPS34 1.762-1.763 16p 1.782 1.761 1.865 1.541 1.936 42.42 7.36x10-11 N Y 
MRPS7 70.769-70.774 17q 70.656 70.622 70.815 70.606 70.928 6.540 1.05x10-2 N Y 
 
Table 5.12. African American results for the MIPS 28S ribosomal subunit gene set. 
Genomic coordinates (Mb) are human genome build 36/hg18. χ2 and p-value represent the association of the analytical window with T2D. 
Abbreviations: Chr - Chromosome, CI - confidence interval, CI Gene - gene located with CI of analytical window, Ŝ - location estimate, Ŝ Gene 






This Chapter has presented evidence for the identification of five mitochondrial gene 
sets associated with T2D in European and African American populations. The 
approach employed in this study is unique for two reasons; the first is the use of 
multi-marker test of association as opposed to the single-marker test. Secondly, due to 
the nature of data that is generated from this type of genetic analysis based upon 
analytical windows across the genome, it is possible to map entire gene sets onto the 
genome to perform the gene set analysis. Publically available gene set analysis tools 
such as GSEA (Subramanian et al., 2005), MAGENTA (Segre et al., 2010), DAVID 
(Huang da et al., 2009) are designed with gene expression microarray or single SNP 
data in mind and therefore are unsuitable for this mapping procedure. 
 
Of the five NEM gene sets potentially identified, two are lists of NEM genes (Wong 
mitochondria gene module and NEMG988), whilst the remaining three all relate to 
specific biological processes involved in ATP production - pyruvate metabolism, the 
TCA cycle, and mitochondrial protein translation. These connected biological 
pathways encompass all cellular ATP production, which is a key determinant of 
glucose-stimulated insulin secretion (Chapter 1: Insulin and Glucose Action). The 
pyruvate metabolism and the TCA cycle pathways have been identified in a metabolic 
approach to characterise the amplifying pathway of glucose-stimulated insulin 
secretion in glucose-responsive and unresponsive pancreatic beta cells (Spegel et al., 
2011). The authors were able to demonstrate glucose unresponsiveness was due to the 
decoupling of glycolysis and the TCA cycle, which could be circumvented by 
stimulating the TCA directly, resulting in increased oxygen consumption and insulin 
secretion of the glucose unresponsive cell line. 
 
In extreme diabetic conditions (>25 mM glucose), as is seen in diabetic ketoacidosis 
and the hyperglycaemic hyperosmolar state, the pancreatic beta cells might be 
expected to maximise secretion of insulin in an attempt to restore normoglycaemia. 
However, the opposite is true – insulin secretion is reduced and this reduction is in 





As for the mitochondrial translation gene set, it could be proposed that alterations in 
the mitochondrial ribosomal subunit affect the translation of mitochondrial mRNA 
into the polypeptide sequence, which leads to compromised or inefficient 
mitochondrial protein synthesis. Mutations in the transfer RNA units of mitochondrial 
can lead to certain type of diabetes as discussed in Chapter 1. Thus, some (Jacobs and 
Turnbull, 2005, Scheper et al., 2007, Smits et al., 2010) have suggested the 
mitochondrial ribosomal is not impervious to similar deleterious mutations, and draw 
attention to an example documented in Drosophila (Toivonen et al., 2001). In this 
example, the mutation in the MRPS12 gene that encodes one of proteins that form the 
small mitochondrial subunit disrupts the stability of the subunit and results in 
complete loss of oxidative phosphorylation activity of the mitochondria. 
 
The 13 protein-encoding genes in the mitochondrial genome encode critical 
components of the oxidative phosphorylation complexes. What is the significance of 
this allocation of genes within the mitochondrial genome? One theory (Allen, 2003), 
the co-location for redox regulation (CORR), suggests mitochondria must have the 
ability to swiftly regulate the production of damaging reactive oxygen species (ROS) 
as a consequence of oxidative phosphorylation. It is thought that the electron carriers 
of this pathway sense the redox state of the mitochondrion and can down regulate 
turnover through mitochondrial protein synthesis restriction (Escobar Galvis et al., 
1998).  
 
If the CORR hypothesis is correct, the reason why these genes have not transferred to 
the nucleus is because of a need for an immediate fail-safe switch at the site of ROS 
production to limit the damage inflicted upon the cell by these molecules. 
Alternatively, the presence of a small number of oxidative phosphorylation genes in 
the mitochondrial genome may simply reflect the fact that the transfer of organelle 
genes to the nucleus takes a very long time (Keeling and Palmer, 2008, Leister, 2005). 
The latter explanation is negated by the fact that nearly all organisms that rely on 
aerobic respiration retain a mitochondrial genome, which indicates a shared 
evolutionary constraint and not merely that there has not yet been enough insufficient 





Previous studies (Mootha et al., 2003, Segre et al., 2010, Perry et al., 2009) have used 
gene set methods in relation to T2D. Differential expression of nuclear genes that 
encode members of the oxidative phosphorylation pathway were shown by Mootha et 
al. (2003) to be associated with T2D; we were unable to replicate this finding using 
our data in that the Mootha OXPHOS gene set (Supplementary Table 5.1) did not 
reach nominal significance in either European or African American populations. It is 
likely our analysis for this particular gene set was underpowered since approximately 
two-thirds of the genes from this gene set were discarded, as they were not located 
within the defined genomic regions. 
 
Segre et al. (2010) could not find evidence of association for genetic variants in the 
oxidative phosphorylation gene set for T2D and related phenotypes; their explanation 
for the result is that down regulation of the oxidative phosphorylation gene set is a 
consequence of T2D rather than contributory. This is certainly reasonable, as studies 
on the expression of oxidative phosphorylation genes have been cross-sectional in 
design, so causality cannot be unambiguously inferred. In addition, expression of this 
gene set in T2D appears to be coordinated across different tissues; it is down 
regulated in skeletal muscle (Mootha et al., 2003, Skov et al., 2007) and pancreatic 
beta cells (Olsson et al., 2011b), whereas it is up regulated in the liver (Buchner et al., 
2011). 
 
With this in mind, a more likely explanation for why Segre et al. (2010) did not 
observe an association between oxidative phosphorylation genes and T2D, where as 
the gene expression studies persuasively show a relationship does exist, is the 
distinction between SNP data and gene expression data. Assuming the effect of 
somatic mutation is negligible, the genotype at a locus does not change over an 
individual’s lifetime nor does it vary between cells of different tissues. On the other 
hand, the expression of a gene at the level of mRNA transcript abundance can vary by 
orders of magnitude between cells of different tissues and over time. Tissue specific 
changes in gene expression are not going to be observed with SNP data. 
 
Perry et al. (2009) offers slightly more commensurability with the study presented 
here in that both use data from the WTCCC1 T2D study (Wellcome Trust Case 




presented in Perry et al. (2009), only one (KEGG pyruvate metabolism) also appears 
in this study. A significant association for this gene set is observed in the European 
data set after adjusting for effective gene set size but was not replicated in our African 
American sample. 
 
Elbers et al. (2009) have expressed concerns regarding gene set analysis and its 
interpretation. Pertinent to this study are the influence of large genes, large gene sets, 
and representativeness of gene sets from publically available databases. They suggest 
permutation of gene set membership would lessen the bias caused by large genes 
within gene sets, which is one of the reasons why we incorporated permutation into 
our analyses.  
 
The tendency of large gene sets to produce large test statistics under the null has been 
observed in this study, which is the same relationship observed by both Elbers et al. 
(2009) and Perry et al. (2009). As explained above, this has been addressed by some 
means such as down-weighting the p-value for a gene set by its effective gene set size. 
Thirdly, interpretation of the results of a gene set analysis needs to be approached 
with caution as the interpretation is only as good as the quality of the data being used 
- in particular gene set definition. For this reason, inclusion of MSigDB gene sets for 
analysis was restricted to those that had been manually curated. While these gene sets 
are of high quality based upon well-documented evidence, the limitation of curated 
gene sets is that, by definition, these are restricted to well-characterised gene 
pathways.  
 
Gene sets are seldom defined in an identical manner between different sources and 
where they are, these are likely to be small gene sets that represent extensively studied 
biology pathways. It is far more likely that a gene-set from two independent databases 
or defined under different experimental conditions within the same database will 
share some proportion of genes, but will also will contain genes unique to each 
source/condition. The hope is enough genes are common to both in order to give 
consistent results when analysed. 
 
Many of the 38 gene sets that were analysed in this study are ostensibly based on 




Table 5.1) attempt to single out the tricarboxylic acid (TCA) cycle, a core biological 
pathway for aerobic respiration of glucose. These four definitions of the TCA cycle, 
each from a different source (Biocarta, KEGG, Reactome, and Mootha et al. (2003)), 
vary in the number of genes from 8 to 32. If we also include gene sets that represent a 
combination of the TCA cycle and another biological pathway, then there are six 
TCA cycle gene sets, varying in size from 8 to 141 genes. Figure 5.5 illustrate that 
despite the inclusion of multiple gene sets for the same biological pathway, the gene 
sets are independent entities, in other words, the proportion of genes shared between 
any two gene sets is small. 
 
The nominally replicated gene sets are considered to be of most interest are because 
they represent specific biological pathways (pyruvate metabolism and the TCA cycle) 
or function (subcomponent of mitochondrial translation). In total, these three mapped 
gene sets contain 31 unique genes (Supplementary Tables 5.5 – 5.8). None of the 
mapped genes in these mitochondrial gene sets have been implicated in T2D or 
related phenotypes through GWA studies according to the NHGRI catalogue 
(Hindorff et al., 2009), accessed 08/04/13. 
 
A search of the Expression Atlas and the Mouse Genome Informatics (MGI) 
resources was undertaken to find any evidence that would connect these genes with 
T2D. Twelve of the 31 genes show expression evidence (Supplementary Table 5.5 – 
5.8) that potentially relates them to T2D; insulin secretion (PDK1, IDH2, NNT), 
impaired glucose tolerance (NNT), coupling electron transport and oxidative 
phosphorylation (MRPS22), adipogenesis (MDH1, ADHFE1), hyperglycaemia-
induced inflammatory response (BSG), hepatic response to high fat diet (ACO2, 
MRPS22), lipid-storage (MRPS35) and gestational diabetes (MRPS21, MRPS27). 
 
The results of Table 5.5 are strictly limited to gene sets that have an adjusted p-value 
of less than 0.10 in both European and African American data sets. If each population 
is considered separately, then using the same alpha threshold there are 13 observed 
gene sets for the European sample and coincidentally, 13 gene sets for the African 





As a subsidiary research-method question relating to gene set analysis, the data was 
also analysed using an overrepresentation method (Fisher’s exact test) in order to be 
compared with results obtained for the set-based (two sample t-test) method. The 
standard two-sample t-test produced a greater number of potentially replicated gene 
sets for two unrelated case/control samples, compared to the Fisher’s exact test. 
However, the only gene sets from the overrepresentation analysis that replicated 
between the two samples (unadjusted p-value  0.10) were the largest (effective gene 
set size) of the 38 gene sets analysed. The t-test provided a much more varied set of 






Study Strengths and Limitations 
As a direct consequence of the gene mapping strategy some gene sets were poorly 
represented at the stage of analysis. The average reduction in gene set size was 
approximately 70%. As explained in the Materials and Methods (Chapter 5), each 
genomic region utilised the location estimate for each analytical window, which can 
be interpreted as the most likely location for a causal T2D susceptibility variant 
within an analytical window. The location estimate for all analytical windows was 
used, irrespective of the association of the window with T2D and extended it into a 
region by adding a constant genetic distance to both sides of the estimate. Genetic 
distance is a function of recombination, thus when interpolated to physical distance, 
the genomic regions will vary in size according to local recombination. 
 
In the European sample, 98.56% (4,242 / 4,304) of the genomic regions are smaller 
than the analytical window they originate from. As a genome-wide average, the 
location estimate regions are 58.70% smaller than their parent analytical window in 
terms of the physical length. The African American data show a similar trend 
whereby 99.56% (4,517 / 4,537) of the genomic regions are smaller than their parent 
analytical windows and the genomic regions are on average 70.26% smaller than the 
analytical windows.  
 
By centring on the location estimate and shortening the region of interest, specific 
statements can be made about the role of nuclear-encoded mitochondrial genes in 
T2D susceptibility. As the location estimate regions are smaller than the analytical 
windows, whenever a nuclear-encoded mitochondrial gene set collectively maps to 
within these regions, then by design, they are within close proximity of the T2D 
association signal if one is present. Had the analytical windows been used for gene set 
mapping, it would be expected that many more genes of mitochondrial gene sets 
could have been successfully mapped, but would ignore information about location of 
the susceptibility variant. For example, a mitochondrial gene and a T2D susceptibility 






A potential limitation may be that our 100,000 permutations of gene set membership 
may not have been sufficient to exhaust all possible combinations of gene set 
membership for each gene set. We chose this figure as a compromise between the 
possibility of a particular gene set appearing with identical members in one of the 
permutations and the computational time required to run the analysis, which is fairly 












In the concluding chapter I provide a brief outline of my main research findings and 
discuss these in relation to the literature, the strengths and weaknesses of my work, 
and finally, building upon this research, I discuss what I think might be worthwhile 
future research questions to pursue. 
 
This thesis begins by evaluating various measures of adiposity and their effect on 
cardiovascular and metabolic co-morbidities associated with T2D; as T2D is the main 
disorder studied in this thesis, it is important to understand how adiposity and body fat 
distribution relate to disease. Almost ubiquitously, BMI is used as the measurement 
for defining obesity. Its inappropriateness is discussed in the introduction of Chapter 
3. Despite its wide usage, the measurement tells the investigator nothing about the 
amount or location of fat an individual carries - the correlation between BMI and 
percentage body fat or between BMI and lean (muscle) mass are similar (Romero-
Corral et al., 2008). 
 
Rather than use generalised measures of adiposity as a height-corrected measurement 
of body mass, a better solution in assessing the risk conferred is to actually measure 
the amount and location of fat directly. Fortunately, the TwinsUK resource has 
multiple adiposity phenotypes on the same individual, including computer-assisted 
and manually measured, for a large number of individuals. This feature allows useful 
comparisons to be made across adiposity phenotypes. 
 
For T2D, abdominal fat and more specifically, intra-abdominal (visceral) fat, has 
received considerable interest as a contributory risk factor for the disease. Partly due 
to the expense, very few individuals of TwinsUK have a direct, computed 
tomography measurement of their visceral fat. Nevertheless, the literature contains a 
wealth of information that consistently indicate that various proxy measures of 
visceral fat can be created by the judicious combination of relevant measurements. 
This study was one of the first to systematically assess the validity and reliability of 
DXA and anthropometry-based measures of visceral fat. This proxy measure for a 
large sample of twins was also used to assess the role of visceral fat in contributing to 





For this study it was possible to assess a number of previously reported visceral fat 
estimation models using TwinsUK data as shown in the results of Chapter 3. A 
heritability study was conducted that showed 57% of the phenotypic variance could 
be attributed to additive genetic variance, which is consistent with other heritability 
studies using the classical twin model, and to my knowledge, this study is the largest 
heritability study of visceral fat conducted. The bivariate analysis between the 
estimate of visceral fat and DXA total abdominal fat, showing a genetic component 
specific to estimated visceral fat and not shared by DXA total abdominal fat, also 
provided additional evidence of measurement validation. 
 
Having a measure of visceral fat made it possible to better address the issue of body 
fat distribution in relation to morbidity. This is important because a number of studies 
demonstrate that not all fat depots behave in the same way – fat appears to be safely 
stored in subcutaneous regions, whilst being particularly detrimental when stored 
close to the internal organs. The message from these studies is that location of fat 
storage is more important that the actual quantity of fat. One of the main findings of 
Chapter 3 was, almost without exception, visceral fat was the biggest independent risk 
factor for the cardiovascular and metabolic morbidities that were investigated. This 
suggests weight loss programs might perhaps be more effective in reducing the 
burden of these conditions on the health service, if they tracked intra-abdominal fat 
rather than waist circumference or BMI. 
 
The focus of Chapter 4 was a candidate locus study for T2D. The starting point of the 
study was to attempt to replicate a previously reported association between a SNP in 
the PARL gene and fasting insulin level. Approximately 3,000 individuals from 
TwinsUK were genotyped for this SNP along with 26 additional SNPs to improve 
coverage in this genomic region. Despite this effort, the SNP-insulin association could 
not be replicated nor were any SNPs in the PARL gene associated with fasting insulin 
or glucose based upon a single SNP test of association. 
 
Analysis of the same genomic region using a fine-scale genetic map and a multi-
marker test of association identified a strong association signal with T2D in the 
neighbouring gene, ABCC5. The strongest association was seen for the WTCCC1 




replicating the statistical association with an identical location estimate. In addition to 
SNP data, a subset of TwinsUK also had gene expression data, which meant an eQTL 
analysis could be performed to assess whether the T2D/IGR association, was perhaps 
in part, driven by the expression of ABCC5. A very strong signal was found for 
ABCC5 gene expression in subcutaneous adipose tissue, both confirming a role for 
ABCC5 and the same genomic location estimate for the functional variant (at 
185,136Kb). This suggests the susceptibility variant is itself an eQTL for ABCC5 and 
confers risk of disease via increased expression levels of ABCC5. 
 
Relative to gene expression in LCL or skin, subcutaneous adipose tissue was the 
primary tissue of interest for T2D in relation to the expression patterns of PARL and 
ABCC5. In subcutaneous adipose tissue, only one eQTL was identified and was 
strongly associated with the expression of ABCC5, whereas the other tissues provided 
a less clear picture with several eQTLs that act both locally and in the neighbouring 
gene. ABCC5 (but not PARL) expression in subcutaneous adipose tissue was 
positively associated with T2D and related traits, including the estimated measure of 
visceral fat from Chapter 3, for which a one standard deviation increase in ABCC5 
expression value is associated with a 30 cm2 increase in visceral fat area. 
 
Collectively the results presented in Chapter 4 provide firm evidence for ABCC5 to be 
involved in the aetiology of T2D. The gene has received little attention from large 
T2D consortia, which primarily advocate ever-larger sample sizes, but still use a 
single SNP test of association incurring a large multiple testing penalty.  
 
In the WTCCC1 T2D study (Wellcome Trust Case Control, 2007), the p-value for the 
most significantly associated SNP in the PARL/ABCC5 region was only 10-3. By 
contrast, for the same region and the same data, the multi-marker test provided a 
model p-value of 10-6 and a functional variant location estimate in intron 26 of 
ABCC5 (185,360Kb). At a conventional genome-wide significance threshold (500K 
SNPs, p-value < 10-7), neither result would be considered to be a significant 
association. However, the multi-locus Malécot model (with a model fit p-value of 10-
6) provides significant evidence of association for a candidate gene study, using an 
alpha threshold of 10-4. Indeed, using a Malécot model approach, a genome-wide 




involved (Elding et al., 2013). The genome-wide significance threshold for the multi-
marker approach (10-5) is larger than the conventional GWAS threshold of 10-7, 
because the multi-marker analysis divides the entire genome into nearly 5,000 
analytical windows of equal genetic distance and tests each window - not each SNP. 
This is equivalent to approximately 5000 independent tests of association (Bonferroni 
corrected p-value = 0.05/ 5000 = 10-5). The impact of this is a genome-wide 
significance threshold of 10-5 – two orders of magnitude larger than genome-wide 
single SNP tests. Taken together, the combined effect of testing SNPs in the aggregate 
and reducing the number of tests being performed explains why an association 
between T2D and ABCC5 is observed in this study, which uses the data from the 
WTCCC1 T2D study, but not in the original WTCCC1 T2D study. 
 
Aside from statistical evidence, there is also intriguing ABCC5 functional evidence 
documented in the literature – Nowicki et al. (2008) showed that destruction of 
pancreatic beta cells in rats combined with a high fat diet reduces protein abundance 
of Abcc5 by almost 100% in hepatocytes. It is interesting to speculate how removing 
insulin on a high fat diet causes this effect. Other than the study cited above, to my 
knowledge there is no literature to explain the relationship between insulin and 
ABCC5 and how a high fat diet modulates their interaction.  
 
Chapter 4 began by looking the PARL gene, which is mitochondrial gene encoded by 
nuclear DNA. As explained in the introduction, mitochondria are an essential 
component in glucose-stimulated insulin secretion. Hence, the fact that very few 
susceptibility variants have been identified near or within mitochondrial or nuclear-
encoded mitochondrial genes is somewhat counter-intuitive, and probably reflects 
inadequate study designs and/or inappropriate statistical methods. 
 
The analysis of biological pathways rather than variants in individual genes is a 
relatively new approach for identifying additional disease susceptibility genes and 
pathways. Pathway analysis first grew in popularity in its application to genome-wide 
expression studies and then was adapted for SNP data analysis. One of the reasons for 
its appeal is that sets of genes are based on prior biological knowledge rather than 
identifying a single gene as part of a hypothesis-free approach. Moreover, it captures 




isolation. The results of the mitochondrial gene set analysis in Chapter 5 show NEM 
pathways appear enriched for signals of T2D association - pyruvate metabolism, the 
TCA cycle, and mitochondrial translation. These pathways all relate to the generation 
of cellular energy, the key determinant of insulin secretion by the pancreatic beta cells 
and therefore of major interest in the treatment of T2D. Currently the only oral anti-
hyperglycaemic that targets the pancreatic beta cells are sulfonylureas, which act by 
closing the ATP-sensitive potassium channel. Increasing the availability of ATP in 
these cells by enhancing ATP generation potentially provides an additional method to 






As discussed in the end of Chapter 3, there is considerable utility for a non-CT 
method of measuring visceral fat in large research data resources such as the UK 
Biobank (Palmer, 2007). In effect, such a resource would be able to acquire both 
DXA-assessed abdominal already being collected and at no additional cost, a DXA-
based visceral fat estimate using routine and inexpensive measures of abdominal 
anthropometry, such as waist circumference or sagittal depth, and age. 
 
Since a large proportion of the TwinsUK individuals that have visceral fat data also 
have genome-wide SNP data available (Chapter 2: TwinsUK Sample), it would be 
possible perform a standard GWA scan for visceral fat in this sample. However, 
considering that the estimate is an inexact proxy with approximately 20% 
measurement error compared to CT, in the context of the multiple testing burden of 
GWA scans, it would be unwise to perform the GWA scan for two main reasons. Any 
significant hits would have to be validated in an independent study (which is true for 
all GWA studies) but more substantially, the fact it is an imperfect proxy 
measurement, will likely result in an inflated Type I error rate compared to most 
GWA studies for common disease. 
 
To date, only one GWA study has been performed for visceral fat (Fox et al., 2007) 
with a large with a sample size of approximately 10,000 participants drawn from three 
population based studies - the Framingham Heart Study (FHS), a subset of this - the 
Family Heart Study, and the Health, Aging, and Body Composition (Health ABC) 
Study. Only one SNP in the THNSL2 gene was identified by Fox et al. (2007) and the 
association was only seen in females, which led the authors to the somewhat anodyne 
conclusion that many more susceptibility loci remain to be identified. The FHS and 
the Health ABC study appear to allow external requests for genotype and phenotypic 
data or at the very least, GWA scan p-values; it would be interesting to re-analyse 
their data to perform a genome-wide multi-marker association test in the hope of 






Functional work is required to understand how ABCC5 is mechanistically implicated 
in the aetiology of T2D and how this gene might provide broader insights into the 
disease process. To date, the ABCC5 protein has largely received attention in its role 
of conferring resistance to thiopurine anticancer drugs. The analysis presented in this 
thesis is certainly consistent with a contributory role of ABCC5 in the development of 
T2D. The fact that ABCC5 encodes a transmembrane protein also opens up the 
possibility of it being a drug target in T2D treatment. The work presented in this 
thesis suggests a potentially direct causal role for ABCC5 in the development of T2D, 
specifically – the association of fasting insulin levels, visceral fat and T2D with 
ABCC5 expression levels. In addition, the destruction of the insulin secreting cells of 
the pancreas combined with a high diet is able to eliminate hepatic ABCC5 expression 
(Nowicki et al., 2008) also illustrates that in more extreme circumstances, the loss of 
ABCC5 function can also be a consequence of T2D. 
 
The gene set analysis (Chapter 5) provides potentially novel insights into the 
aetiology of T2D, implicating biological pathways that relate to the production of 
ATP through cellular respiration (glycolysis, the TCA cycle, and indirectly, oxidative 
phosphorylation through mitochondrial protein synthesis [mitochondrial ribosome 
translational unit, 28S]). For glycolysis and the TCA cycle, a fruitful way to confirm 
these results is to adopt a similar strategy to that used by Spegel et al. (2011). Their 
study showed that glucose unresponsiveness of pancreatic beta cells could be 
explained by the decoupling of products from pyruvate metabolism to the TCA cycle. 
Measuring the individual metabolites of these pathways in relevant tissues might 
reveal differences between normoglycaemic and T2D individuals and potentially 
therapeutic targets.  
 
For the mitochondrial translation gene set, there is a direct connection with glucose-
stimulated insulin secretion. As discussed in Chapter 1, it was noted that the 13 
protein coding genes on the mitochondrial genome are essential components of the 
electron transport system, which performs oxidative phosphorylation and are 
ultimately responsible for the generation of ATP. The increase in ATP/ADP ratio is 
an early and key event in glucose-stimulated insulin secretion from the pancreatic beta 
cells. A systematic deletion or knock down of each nuclear–encoded mitochondrial 




al., 2009, Imamura et al., 2009, Bugger et al., 2009, Chinopoulos et al., 2009). The 
results from this type of study could provide important insights into beta cell function 
in relation to T2D and also, in an evolutionary context, the relative importance and 
role of genes that have been retained in the mitochondrion compared to those that 











  VAT DXA BMI WC 
DXA  0.90       
BMI 0.78 0.77     
WC 0.96 0.83 0.79   
Age 0.42 0.26 0.17 0.19 
 
Supplementary Table 3.1. Correlation and colinearity between measures of 
adiposity for study sample (n = 3,457). 
Pearson product-moment correlation coefficient is presented. Abbreviations: BMI - 
body mass index, DXA - total abdominal fat measured using dual-energy X-ray 






T2D OR SE z p-value 












VAT 2.50 0.62 3.7 2.2x10-4 1.54 4.05    
DXA  1.00 0.17 0.0 9.9x10-1 0.71 1.41       
BMI 0.84 0.13 -1.2 2.3x10-1 0.62 1.13       
Age 1.02 0.01 1.5 1.3x10-1 0.99 1.04       
  






DXA 1.53 0.17 3.8 1.5x10-4 1.23 1.92    
BMI 1.22 0.14 1.8 7x10-2 0.98 1.52    
Age 1.04 0.01 3.4 6.7x10-4 1.02 1.06    
  






VAT 2.51 0.43 5.3 1.2x10-7 1.79 3.52    
BMI 0.84 0.13 -1.2 2.3x10-1 0.62 1.13    
Age 1.02 0.01 1.5 1.3x10-1 1.00 1.04    
  






VAT 2.08 0.40 3.8 1.5x10-4 1.43 3.02    
DXA 1.00 0.18 0.01 9.9x10-1 0.71 1.41       
Age 1.02 0.01 1.91 6x10-2 1.00 1.05       
  





VAT 2.08 0.18 8.5 1.9x10-17 1.76 2.47    
Age 1.02 0.01 2.0 5x10-2 1.00 1.05       
  





DXA 1.81 0.14 7.9 2.8x10-15 1.56 2.10    
Age 1.04 0.01 3.2 1.4x10-3 1.01 1.06       
  





BMI 1.65 0.12 6.9 5.2x10-12 1.43 1.90    
Age 1.04 0.01 3.8 1.5x10-4 1.02 1.06       
 
Supplementary Table 3.2 Type 2 diabetes (T2D) multiple regression analyses. 
The likelihood ratio test (LRT) statistic p-value is presented to assess the decline in 
model fit when one or more measures of adiposity are removed from the full model. 
Note that dropping total abdominal fat (DXA) and/or body mass index (BMI) does 
not diminish the model fit, while dropping visceral adipose tissue (VAT) area does (p-





Type 2 diabetes 
 SE t p-value 




p > F 
 A: Visceral fat residuals         7x10-4  0.38 
 T2D' ~                 
  DXA' 0.00 0.04 0.07 0.95 -0.08 0.09   
  BMI' -0.05 0.04 -1.39 0.17 -0.12 0.02    
  
 B: DXA & BMI residuals        5x10-3  1x10-4 
 T2D''~                 
  VAT'' 0.23 0.06 3.89 2.8x10-4 
 
0.11 0.34   
 
 Where residuals are for:          
A 
T2D' = T2D ~ VAT + Age         
DXA' = DXA ~ VAT+ Age      
BMI' = BMI ~ VAT+ Age     
      
B 
T2D'' = T2D ~ DXA + BMI + Age          
VAT'' = VAT ~ DXA + BMI + Age      
 
Supplementary Table 3.3. Residuals analysis for type 2 diabetes. 
No residual association remains (p-value = 0.38) between T2D and total abdominal 
fat (DXA) and body mass index (BMI), when the residuals for T2D, DXA and BMI 
are taken in relation to visceral adipose tissue (VAT) area (A). The residuals for T2D 
are on the logit scale, while the DXA and BMI residuals use ordinary least squares 
regression. By contrast, a small but statistically significant residual association 
remains between T2D and VAT (B), when the residuals for T2D and VAT are taken 
in relation to DXA, BMI and age. Despite co-linearity between VAT, DXA and BMI 
(see Supplementary Table 3.1), these results strongly indicate that the association 






















































Supplementary Table 4.1. Microarray gene expression probes tag a population 






Index Gene Set 
1 Biocarta ETC pathway 
2 Biocarta Kreb pathway 
3 Galluzzi Prevent Mitochondial Permeabilization 
4 KEGG Beta Alanine Metabolism 
5 KEGG Butanoate Metabolism 
6 KEGG Citrate Cycle TCA Cycle 
7 KEGG Fatty Acid Metabolism 
8 KEGG Glyoxylate and Dicarboxylate Metabolism 
9 KEGG Limonene and Pinene Degradation 
10 KEGG One Carbon Pool by Folate 
11 KEGG Oxidative Phosphorylation 
12 KEGG Parkinsons Disease 
13 KEGG Propanoate Metabolism 
14 KEGG Pyruvate Metabolism 
15 KEGG Valine Leucine and Isoleucine Degradation 
16 MIPS 28S Ribosomal Subunit Mitochondrial 
17 MIPS 39S Ribosomal Subunit Mitochondrial 
18 MIPS 55S Ribosome Mitochondrial 
19 MIPS F1F0 ATP Synthase Mitochondrial 
20 Mootha FFA Oxydation 
21 Mootha Human MitoDB6 2002 
22 Mootha Mitochondria 
23 Mootha TCA 
24 Mootha VOXPHOS 
25 Reactome Branched Chain Amino Acid Catabolism 
26 Reactome Citric Acid Cycle TCA Cycle 
27 Reactome Formation Of ATP by Chemiosmotic Coupling 
28 Reactome Mitochondrial Fatty Acid Beta Oxidation 
29 Reactome Mitochondrial Protein Import 
30 Reactome Mitochondrial tRNA Aminoacylation 
31 Reactome Pyruvate Metabolism 
32 Reactome Pyruvate Metabolism and Citric Acid TCA Cycle 
33 Reactome Regulation of Pyruvate Dehydrogenase PDH Complex 
34 Reactome Respiratory Electron Transport 
35 
Reactome Respiratory Electron Transport ATP Synthesis by Chemiosmotic 
Coupling and Heat Production by Uncoupling Proteins 
36 Reactome TCA Cycle and Respiratory Electron Transport 
37 Wong Mitochondria Gene Module 
38 NEMG988 
 






Index Number of Genes Number of Mapped Genes 
1 12 9 
2 8 8 
3 22 22 
4 22 21 
5 34 33 
6 32 28 
7 42 41 
8 16 16 
9 10 10 
10 17 19 
11 135 115 
12 133 110 
13 33 32 
14 40 39 
15 44 43 
16 30 31 
17 48 49 
18 78 80 
19 16 14 
20 22 21 
21 429 408 
22 447 426 
23 16 15 
24 87 86 
25 17 16 
26 26 18 
27 16 13 
28 14 14 
29 58 48 
30 21 21 
31 19 16 
32 48 37 
33 13 10 
34 79 64 
35 98 80 
36 141 113 
37 217 210 
38 988 968 
 
Supplementary Table 5.2. Number of genes in each gene set and the number that 





Index Genes in Overlap  Proportion Overlap 
1 9 0.75 
2 8 1.00 
3 13 0.59 
4 12 0.55 
5 23 0.68 
6 27 0.84 
7 27 0.64 
8 11 0.69 
9 8 0.80 
10 11 0.65 
11 81 0.60 
12 80 0.60 
13 28 0.85 
14 27 0.68 
15 39 0.89 
16 30 1.00 
17 48 1.00 
18 78 1.00 
19 14 0.88 
20 17 0.77 
21 321 0.75 
22 314 0.70 
23 14 0.88 
24 70 0.80 
25 16 0.94 
26 18 0.69 
27 13 0.81 
28 13 0.93 
29 40 0.67 
30 14 0.67 
31 12 0.63 
32 32 0.67 
33 9 0.69 
34 60 0.76 
35 76 0.78 
36 104 0.74 
37 166 0.76 
38 968 1.00 
 
Supplementary Table 5.3. Gene sets were selected from the MSigDB that showed 






















1 3 3 4 4 
2 4 4 3 3 
3 12 9 12 9 
4 12 10 10 8 
5 13 13 9 11 
6 10 11 10 11 
7 14 13 8 9 
8 9 7 7 6 
9 3 3 1 1 
10 7 5 6 4 
11 44 44 31 30 
12 43 39 34 31 
13 14 14 8 8 
14 23 22 13 13 
15 16 16 8 8 
16 13 13 10 9 
17 19 18 14 13 
18 31 31 23 22 
19 4 4 3 3 
20 9 10 5 4 
21 153 161 113 118 
22 156 176 114 121 
23 7 7 4 4 
24 28 28 23 24 
25 8 8 4 4 
26 10 10 6 6 
27 4 4 3 3 
28 4 4 2 2 
29 18 18 17 17 
30 10 8 7 6 
31 7 6 6 6 
32 17 17 12 13 
33 5 4 5 5 
34 24 24 23 23 
35 29 29 26 26 
36 43 44 36 37 
37 91 92 56 60 
38 324 378 248 277 
 
Supplementary Table 5.4. Distribution of genes for each gene set mapped into 






Supplementary Table 5.5. Differential expression studies in diabetes case-control 







t statistic p-value Study 
Expression Atlas  
Reference 
ADHFE1 3.2 0.03 Kennedy et al. (2010) E-GEOD-22097 
CS 5.8 0.005 Pavlinkova et al. (2009) E-GEOD-41095 
DLAT 3.3 0.036 Pavlinkova et al. (2009) E-GEOD-41095 
DLD 3.9 0.016   
NNT 5 0.017 Pavlinkova et al. (2009) E-MEXP-2559 
IDH2 7 3.4x10-4 Kennedy et al. (2010) E-GEOD-22097 
LDHB - - - - 
MDH2 - - - - 
ACO2 - - - - 
PDK1 8.5 9.1x10-5 Kennedy et al. (2010) E-GEOD-22097 
SDHC 4.2 0.04 
Vukkadapu et al. 
(2005) 
E-GEOD-1623 
SDHD 5.1 0.007 Pavlinkova et al. (2009) E-GEOD-41095 
BSG 4.9 0.02 
Vukkadapu et al. 
(2005) 
E-GEOD-1623 
L2HGDH 3.5 0.029 Pavlinkova et al. (2009) E-GEOD-41095 
PDHX 5.4 0.001 Gerber et al. (2006) E-GEOD-4745 







t statistic p-value Study 
Expression Atlas 
Reference 
CS 5.8 0.005 Pavlinkova et al. (2009) E-GEOD-41095 
DLAT 3.3 0.036 Pavlinkova et al. (2009) E-GEOD-41095 
DLD 3.9 0.016 Mishra et al. (2004) E-GEOD-642 
IDH2 7 3.4x10-4 Kennedy et al. (2010) E-GEOD-22097 
MDH1 3.3 0.029 Kennedy et al. (2010) E-GEOD-22097 
MDH2 2.3 0.704 van Tienen et al. (2011)* E-GEOD-19420 
ACO2 - - - - 
SDHC 4.2 0.04 Vukkadapu et al. (2005) E-GEOD-1623 
SDHD 5.1 0.007 Pavlinkova et al. (2009) E-GEOD-41095 
SUCLG2 4.2 0.015 Pavlinkova et al. (2009) E-GEOD-41095 
SUCLG1 - - - - 
 
Supplementary Table 5.6. Differential expression studies in diabetes case-control 
studies from the Expression Atlas for genes of the KEGG TCA cycle. 













DAP3 4.8 0.004 Kennedy et al. (2010) E-GEOD-22097 
MRPS11 - - - - 
MRPS16 6.6 0.003 Pavlinkova et al. (2009) E-GEOD-41095 
MRPS21 7.4 0.002 Pavlinkova et al. (2009) E-GEOD-41095 
MRPS22 6.3 7.1x10-4 Kennedy et al. (2010) E-GEOD-22097 
MRPS23 3.6 0.026 Pavlinkova et al. (2009) E-GEOD-41095 
MRPS26 3 0.047 Pavlinkova et al. (2009) E-GEOD-41095 
MRPS27 7.1 0.002 Pavlinkova et al. (2009) E-GEOD-41095 
MRPS28 5.6 0.005 Pavlinkova et al. (2009) E-GEOD-41095 
MRPS31 5.9 0.004 Pavlinkova et al. (2009) E-GEOD-41095 
MRPS33 5.1 0.003 Pavlinkova et al. (2009) E-GEOD-22097 
MRPS34 4 0.017 Pavlinkova et al. (2009) E-GEOD-41095 
MRPS35 3.2 0.033 Kennedy et al. (2010) E-GEOD-22097 
 
Supplementary Table 5.7. Differential expression studies in diabetes case-control 
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